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“Knowledge is of two kinds. We know a subject ourselves, or we know 









STRESS      
Stress is one of the buzzwords of modern life, used widely to describe a variety of 
situations, events and emotions (Charlton, 1992). The heterogeneous nature of stress 
is neatly illustrated in the excerpt from Hans Selye’s book “Stress in Health and 
Disease” (Selye, 1976a):  
“Stress is part of our daily human experience, but it is associated with a great 
variety of essentially dissimilar problems, such as surgical trauma, burns, emotional 
arousal, mental or physical effort, fatigue, pain, fear, the need for concentration, the 
humiliation or frustration, the loss of blood, intoxication with drugs or environmental 
pollutants, or even with the kind of unexpected success that requires an individual to 
reformulate his lifestyle. Stress is present in the businessman under constant 
pressure; in the athlete straining to win a race; in the air-traffic controller who bears 
continuous responsibility for hundreds of lives; in the husband helplessly watching 
his wife’s slow, painful death from cancer; in a race horse, its jockey and the spectator 
who bets on them.”  
Hans Selye defined stress as the non-specific response of the body to any 
demand. Furthermore, he regarded it as an alarm process that warns about 
disrupted homeostasis and helps to restore it, by inducing the “fight or flight” 
response (Cannon, 1929; Selye, 1936, 1956). As such, stress accounts for nearly 
everything disturbing the daily routine of an individual and challenging to adapt to 
changes (Selye, 1936). Accordingly, the stress response helps in readjusting to a new 
situation, by inducing multiple changes collectively named as the general adaptation 
syndrome (GAS). While the initial stages of the GAS are beneficial, severe and 
prolonged stress may lead to the stage of exhaustion, in which the acquired 
adaptation is lost (Selye, 1955). Currently, in biomedical sciences and clinical 
practice, the term stress is mainly used to describe this latter situation, when the 
stress response becomes maladaptive and may predispose to pathology. In this 
thesis, I will mainly focus on chronic stress-induced changes in the brain that may 
lead to psychopathology. 
 
THE STRESS RESPONSE 
Stress involves two-way communication between the brain and periphery via neural 
and endocrine mechanisms. Two main physiological pathways are activated in 
response to stress: the autonomic nervous system (ANS), particularly its sympatho-
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adrenomedullary division, and the hypothalamic-pituitary-adrenal (HPA) axis. Both 
of these systems are involved in the physiological support of behavior and respond 
rapidly to stressors.  
Activation of the sympatho-adrenomedullary system triggers noradrenergic 
projections from locus coeruleus in the brain and releases noradrenaline from the 
sympathetic nerves and adrenaline from the adrenal medulla. Adrenaline and 
noradrenaline stimulate the α- and ß-adrenergic receptors in the heart muscle and 
blood vessel walls, thereby increasing heart rate and blood pressure. This, in turn, 
leads to a higher blood flow to the brain and muscles, allowing a fast performance of 
a “fight or flight” reaction.  
This immediate autonomic response is followed by delayed neuroendocrine 
changes, due to activation of the HPA axis (Tsigos and Chrousos, 2002). Stress 
results in the production of corticotropin-releasing hormone (CRH) and arginine-
vasopressin (AVP) in the paraventricular nucleus (PVN) of the hypothalamus. Upon 
stimulation by a stressor, CRH and AVP are released into the hypophyseal portal 
system and act synergistically via specific receptors (CRH-R1 and V1B receptor, 
respectively) in the anterior pituitary to trigger the synthesis of adrenocorticotropic 
hormone (ACTH) from its precursor proopiomelanocortin (POMC). Secreted ACTH is 
transported by the blood stream to the adrenal glands, where it acts on the adrenal 
cortex via type 2 melanocortin receptors (MC2R, ACTH receptors) and induces the 
production of glucocorticoids (cortisol in humans and corticosterone in rodents, 
hereafter abbreviated as CORT). Glucocorticoids, released into the systemic 
circulation, promote many adaptive processes by stimulating energy mobilization, 
gluconeogenesis, lipolysis, and by suppressing growth, reproduction and 
inflammation. Such a broad variety of glucocorticoid-induced effects is due to the 
widespread expression of receptors for CORT throughout the body’s cells 
(Buckingham, 2006). Approximately 90% of CORT in the circulation is bound to a 
carrier protein, corticosteroid-binding globulin, and only unbound CORT readily 
crosses the blood-brain barrier and cell membranes. An important target organ of 
glucocorticoids is the brain, endowed with mineralocorticoid and glucocorticoid 
receptors (MRs and GRs, respectively), which have a widespread distribution and 
are co-expressed abundantly in the neurons of limbic structures, e.g. the 
hippocampus (Reul and de Kloet, 1985; Herman et al., 2003; de Kloet et al., 2005). 
These two receptor types differ in affinity for glucocorticoids, and thereby, in their 
functional role. The higher affinity MRs are predominantly occupied at lower, basal 
glucocorticoid levels, and are implicated in the onset of stress responses. The lower 




the termination of stress reactions, facilitation of recovery, and formation of memory 
related to stressful events (de Kloet et al., 2005).  
Glucocorticoids, the final effectors of the HPA axis, are also responsible for 
neuroendocrine regulation of this system. By exerting negative feedback at several 
sites of the HPA axis, glucocorticoids suppress their own release, and thereby 
terminate the stress response. Feedback inhibition is principally mediated via the 
GRs. At the pituitary level, glucocorticoids suppress POMC gene transcription, and 
also interact with the CRH-R1 receptors, acutely inhibiting the binding of CRH to its 
receptors and chronically decreasing CRH-R1 numbers. At the hypothalamic level, 
glucocorticoids suppress CRH and AVP mRNA synthesis and their secretion. Acute 
and relatively rapid inhibition of CRH release is followed by chronic downregulation 
of CRH and AVP expression in the PVN neurons (Keller-Wood and Dallman, 1984; 
Papadimitriou and Priftis, 2009). Glucocorticoid negative feedback on the HPA axis 
is also exerted centrally, at the level of the hippocampus, amygdala and prefrontal 
cortex. Although these limbic structures are suggested to connect to the PVN only 
indirectly (Hurley et al., 1991; Herman et al., 1996; Floyd et al., 2001; Fernandes et 
al., 2007), a number of structural and functional studies provide evidence for their 
role in regulation of the HPA axis (Dedovic et al., 2009). The hippocampus exerts an 
inhibitory influence on hypothalamic CRH-containing neurons via a polysynaptic 
circuit, however, the amygdala is suggested to exert a direct excitatory influence. 
Other important inputs to the HPA axis structures come from ascending 
monoaminergic pathways. In addition, HPA axis regulation is influenced by 
numerous other hormones, neurotransmitters, cytokines, and growth factors. 
 
THE STRESSED BRAIN 
Since this thesis largely focuses on stress-related changes in the brain that may 
predispose to ill health, a brief overview of brain areas involved in the stress 
response will be presented. 
Within the brain, a distributed neural circuitry determines what is threatening 
and thus potentially stressful to the individual, as well as regulates the physiological 
and behavioral responses which can be either adaptive or damaging (McEwen, 2007; 
McEwen and Gianaros, 2010). This circuitry includes three limbic system areas in 
particular: the hippocampus, amygdala and prefrontal cortex (PFC).  
The hippocampus was the first brain region, besides the hypothalamus, to be 
recognized as a target of stress and glucocorticoids. It plays important roles in 
learning and memory, processing the contextual aspects of emotional events, and 
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regulating visceral functions, including the HPA axis. The hippocampus is enriched 
with receptors for glucocorticoids and other stress mediators that can enhance 
cognitive processes, affect mood and motivation, and promote excitability and 
neuroprotection. Yet, these same molecules can also have deleterious effects on the 
hippocampus under conditions of prolonged stress (McEwen, 2007). Both animal 
models and human studies reveal that stress and its related pathologies are 
associated with structural and functional changes in the hippocampal circuitry. The 
specific alterations will be discussed in the further sections of this thesis.  
The hippocampus is closely linked to the amygdala, both anatomically and 
functionally (Pitkanen et al., 2000; Petrovich et al., 2001). Also, these limbic brain 
structures interconnect with vegetative brain areas, such as the hypothalamus and 
brainstem, and higher cortical areas, particularly with the PFC.  
The amygdala is comprised of distinct nuclei that play important roles in 
detecting and responding to threats in the environment, as well as in formation of 
emotional memories (LeDoux, 2000; Davis and Whalen, 2001; Sah et al., 2003). In 
brief, sensory inputs are relayed through brainstem, thalamic and cortical-thalamic 
pathways to the basolateral complex of amygdalar nuclei: the lateral nucleus (LA), 
the basal or basolateral nucleus (BLA), and the accessory basal or basomedial 
nucleus. From there, sensory signals are relayed to the central nucleus of amygdala 
(CeA), which serves as a primary output system. The CeA has substantial 
projections to the hypothalamus, bed nucleus of stria terminalis (BNST), and several 
nuclei in the brainstem that control the autonomic system and enable the stress 
response. Also, both CeA and BNST project to ascending monoaminergic and 
cholinergic neuron groups, including noradrenergic locus coeruleus, the dopamin-
ergic substantia nigra and ventral tegmental area, the serotonergic raphe, and the 
cholinergic nucleus basalis (Davis and Whalen, 2001). Importantly, the basolateral 
complex of the amygdala is also connected to (sub)cortical areas involved in 
processing of stress-related information, the hippocampus and PFC. Hence, the 
amygdala is in a good position to process sensory inputs, associate them to past 
experiences, and form memories of emotionally laden events (Sah et al., 2003).  
The PFC is involved in higher cognitive functions. One of them is the top-down 
regulation of stress-related responding and coping processes mediated by subcortical 
limbic areas, including the amygdala, hippocampus and hypothalamus (McEwen and 
Gianaros, 2010). The PFC is organized in a topographical manner, such that regions 
regulating emotions are situated ventrally and medially, while regions regulating 
thought and action are located more dorsally and laterally (Arnsten, 2009). Thus, the 
emotional and stress responses are mainly modulated by the medial PFC (mPFC), 




orchestrate the brain’s activity for regulation of behavior, thought and emotion. The 
mPFC has extensive connections with subcortical structures, involved in the stress 
response. Under conditions of stress, the activation of the amygdala and other 
subcortical structures eventually leads to impaired prefrontal regulation. Animal 
studies on the PFC reveal stress-induced changes in neuronal structure and 
connectivity. For instance, the mPFC shows reduced neuronal complexity and loss of 
synaptic connections as a result of chronic stress (Radley et al., 2006; Holmes and 
Wellman, 2009). Also, repeated stress has been shown to disrupt the plastic 
relationship between the PFC and the hippocampus that is needed for flexible 
memory consolidation (Cerqueira et al., 2007).  
In summary, the limbic brain system exerts diverse emotional, cognitive and 
mnemonic functions, involved in adaptive regulation of the stress response. These 
same brain regions, including the hippocampus, amygdala and PFC, show distinct 
changes when adaptation to stress fails. 
 
ALLOSTASIS AND ALLOSTATIC LOAD 
The adaptive processes that underlie the stress response have been collectively 
termed as allostasis (McEwen, 2003). If the stress response is inappropriate, 
excessive or prolonged, the costs of adaptation may become too high, leading to a 
condition of allostatic load. The concept of allostatic load refers to cumulative 
changes that result in a “wear and tear” of the body and brain (McEwen, 2003). The 
inability to adequately cope with stressful events, thus, may promote maladaptation 
and predispose to various stress-related pathologies. It is important to keep in mind, 
however, that since all the facets of the stress response show tremendous individual 
variability, only a part of the subjects (either laboratory animals or humans) exposed 
to stress will eventually succumb to stress-related pathology. Hence, individual 





Many health problems are thought to arise, at least in part, from exposure to 
prolonged stress and inability to adequately cope with it. Among these stress-
influenced conditions are cardiovascular diseases, diverse endocrine and metabolic 
disorders, and psychopathologies. The latter include, but are not limited to, 
depression, post-traumatic stress disorder, and burnout. In this thesis, I will mainly 
refer to depression, when translating preclinical research findings regarding chronic 
stress- and antidepressant treatment-induced changes in the brain. 
 
DEPRESSION 
Depression, also called major depression, major depressive disorder or clinical 
depression, is a heterogeneous disorder with a highly variable course, an 
inconsistent response to treatment, and no established mechanism (Belmaker and 
Agam, 2008). The symptoms of depression encompass mood disturbances, 
characterized by sadness or irritability, as well as a variety of cognitive, motoric, 
autonomic, endocrine, and sleep/wake abnormalities, thought to arise from the 
complex interaction of multiple genetic and environmental factors (Manji et al., 
2001). Diagnosis of depression is based on symptomatic criteria set forth in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 2000), 
summarized in table 1.1. Because of a highly variable set of symptoms, depression is 
often viewed as a heterogeneous syndrome comprised of numerous diseases of 
distinct causes and pathophysiologies (Nestler et al., 2002a). 
Research attempts to elucidate the mechanisms responsible for development and 
treatment of depression have yielded valuable insight, but its puzzling nature 
persists. Diverse theories have been postulated in search for the cause of depression. 
The most prominent hypotheses of depression are briefly reviewed in the following 
text, along with various predisposing factors, such as genetic and environmental 




Table 1.1 The diagnostic criteria for major depression.  
MAJOR DEPRESSION 
Symptoms: 
 Depressed or irritable mood 
 Diminished interest in pleasurable activities (anhedonia) 
 Weight loss or weight gain / decreased or increased appetite 
 Insomnia or hypersomnia 
 Psychomotor agitation or retardation 
 Fatigue or loss of energy 
 Feeling of hopelessness, worthlessness or guilt 
 Diminished ability to concentrate or think / indecisiveness 
 Recurrent thoughts of death or suicide 
Diagnosis: 
Depressive episode is diagnosed when five or more of the above listed symptoms 
have been present during a 2-week period of time, and when they disrupt normal 
social and occupational functioning. Presence of either depressed mood or 
anhedonia is mandatory for diagnosis of depression (DSM-IV-TR, 2000). 
 
Genetics of depression 
The evidence for genetic influences on depression consists primarily of twin studies, 
where monozygotic twins show higher prevalence for depression than dizygotic twins 
(Uher, 2008). Epidemiological studies suggest that major depressive disorder is 
moderately heritable, about 40% in women and 30% in men (Sullivan et al., 2000; 
Kendler et al., 2006). Yet, no specific gene or a series of genes that induce depression 
have been reliably identified to date. Rather, certain variations in genes, called 
polymorphisms, may increase risk for depression (aan het Rot et al., 2009). However, 
most genes in quest are not depressive disorder-specific, but overlap with other 
psychiatric conditions and drug abuse. 
A common functional length polymorphism in the serotonin transporter gene (5-
HTTLPR) has been suggested to predispose to depression as well as to personality 
traits of anxiety and pessimism (Lesch et al., 1996; Belmaker and Agam, 2008). Yet, 
it turned out that this ‘short allele’ 5-HTTLPR polymorphism predicted depression 
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only in association with stressful life events (Caspi et al., 2003). Likewise, other 
depression-associated gene polymorphisms have been shown to interact with 
environmental factors. A single nucleotide polymorphism (SNP) in the gene encoding 
brain-derived neurotrophic factor (BDNF), Val66Met, has been shown to interact 
with the 5-HTTLPR short allele to confer sensitivity to environmental factors 
(Kaufman et al., 2006; Uher, 2008). A corticotropin-releasing hormone type 1 
receptor (CRH-R1) also appears to interact with early life adverse experiences in the 
genesis of adult depression (Bradley et al., 2008). Similarly, various depression-
associated glucocorticoid receptor polymorphisms seem to have a modulating, rather 
than causal, effect in the development of depressive disorder, as reviewed elsewhere 
(El Hage et al., 2009). Recently, specific polymorphisms in genes that affect 
dopamine transmission were also suggested to increase susceptibility to depression 
(Opmeer et al., 2010). Polymorphisms in several genes may combine to produce 
environmentally sensitive dispositions (Uher, 2008). The etiology of depressive 
disorder is thus believed to be under interactive influence of genetics and 
environmental factors (Jabbi et al., 2008). In sum, vulnerability to depression is only 
partly genetic, with non-genetic factors being at least as important. 
  
Hypotheses of depression 
Major depressive disorder is likely to have multiple causes. Here, I will briefly 
review existing hypotheses of depression, in order to depict a variety of mechanisms 
that may be involved in the etiology, pathogenesis and treatment of this complex 
multifactorial disorder. 
 
The monoamine hypothesis 
For half a century, the majority of neurobiological research and classical 
pharmacotherapy regimens have explained depression with the monoamine 
hypothesis, which proposes that low levels of brain monoamines, such as serotonin, 
noradrenaline and/or dopamine, are responsible for the development of depressive 
symptoms. In fact, many currently used antidepressant drugs, such as selective 
serotonin reuptake inhibitors (SSRI), noradrenaline reuptake inhibitors (NRI), 
serotonin and noradrenaline reuptake inhibitors (SNRI), tricyclic antidepressants 
and monoamine oxidase inhibitors potentiate the brain’s monoaminergic system and 
elevate the monoamine levels (Wong and Licinio, 2001). Furthermore, the role of 




in patients with Parkinson’s disease. In line with this, some direct dopamine 
receptor agonists, originally developed for treatment of Parkinson’s disease, display 
antidepressant efficacy (Gershon et al., 2007). 
The monoamine hypothesis provided first clues into chemical changes in the 
brain that might underlie depressive symptoms, and thus advanced the way 
depression was viewed and treated. However, this hypothesis has several important 
limitations. First, experimental monoamine depletion in humans does not decrease 
mood in healthy subjects and only slightly lowers mood in healthy controls with a 
family history of depression and in drug-free patients with remitted depression 
(Ruhe et al., 2007). These studies thus fail to demonstrate a causal relation between 
brain monoamine levels and development of depression, yet presumably clarify a 
vulnerability trait for depression. Similarly, acute elevation of monoamine levels is 
not sufficient to cure depressive symptoms. Although the above mentioned 
antidepressant drugs acutely potentiate brain’s monoaminergic system, however, 
their mood-alleviating properties take at least several weeks to become manifest 
(Berton and Nestler, 2006). Thus, although the monoaminergic transmitters 
serotonin, noradrenaline and dopamine are undoubtedly involved in the mechanism 
and treatment of depression, it is obvious that monoamine deficits are only part of 
the story and are not sufficient on their own to explain the nature of depressive 
disorder.  
It is now thought that antidepressant-induced acute increases in synaptic 
monoamine levels produce secondary neuroplastic changes that last longer and 
involve transcriptional and translational changes, mediating molecular and cellular 
plasticity (Krishnan and Nestler, 2008; Pittenger and Duman, 2008). This view led 
to formulation of the neuroplasticity hypothesis of depression, which will be 
discussed separately in this text. 
 
Glucocorticoid (HPA axis) hypothesis 
There is considerable evidence that abnormal, excessive activation of the HPA axis is 
implicated in depression (Sachar and Baron, 1979; Arborelius et al., 1999; Holsboer, 
2001; Nestler et al., 2002a). A subset of depressed patients exhibit increased CORT 
production, as shown by elevated levels of this hormone in blood plasma and urine 
(Burke et al., 2005). Moreover, many patients have an abnormal response to the 
dexamethasone-suppression test, showing a decreased ability of the potent synthetic 
glucocorticoid, dexamethasone, to suppress plasma levels of CORT and ACTH 
(Nestler et al., 2002a). On the other hand, patients with Cushing’s syndrome, who 
have  extremely  high  concentrations  of  circulating  CORT,  often  show  depressive 
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Figure 1.1 Overview of the multiple players implicated in the pathophysiology of major depressive 
disorder. This figure is based on different hypotheses of depression, which are discussed in the main text. In 
brief, various internal and external factors, such as genetic background and stressful experiences interact to 
shape brain vulnerability to major depression. Specific neurobiological changes include altered 
neurotransmitter balance, decreased BDNF levels and increased HPA axis activity, followed by induction of 
proinflammatory cytokines. In turn, cytokines activate IDO which catabolizes tryptophan to kynurenine, and 
thereby reduces 5-HT levels as well as results in increased accumulation of quinolinic acid, a kynurenine 
metabolite, causing neurotoxicity through NMDA receptors. Decreased availability of tryptophan and 5-HT 
culminates into reduced melatonin production, as well as indirectly to downregulated BDNF levels. Decreased 




symptoms (McEwen, 2007; Krishnan and Nestler, 2008). Also, there is direct and 
indirect evidence for hypersecretion of CRH in some depressed patients (Nemeroff et 
al., 1984; Arborelius et al., 1999; Holsboer, 2001; Kasckow et al., 2001; Merali et al., 
2004). Increased levels of CRH have been found in cerebrospinal fluid (Nemeroff et 
al., 1984). Moreover, intravenously administered CRH has been shown to evoke 
blunted ACTH response, suggesting pituitary CRH receptor downregulation due to 
chronic CRH hypersecretion (Gold et al., 1984). In line with these observations, 
postmortem studies have reported upregulated CRH mRNA and protein levels in 
limbic brain regions, and downregulated CRH receptor numbers, perhaps as a 
response to elevated CRH secretion (Merali et al., 2004). In addition to these 
changes, elevated vasopressin levels have also been found in postmortem brains of 
depressed humans (Purba et al., 1996). 
These correlative data are supported by longitudinal studies with repeatedly-
performed neuroendocrine tests, showing that persistent HPA axis disturbances are 
associated with poor therapeutic response in depressed patients and may predict 
relapse in subjects with remitted depression (Zobel et al., 2001). Apparently, the 
normalization of HPA axis dysregulation is a prerequisite of successful treatment, 
whereas the reappearance of HPA axis disturbances is prognostically unfavorable 
(de Kloet et al., 2005).  
Thus, HPA axis dysregulation represents a risk factor for depression and other 
psychopathologies, which may be predisposed by various conditions that affect this 
stress response system. For instance, the cortisol-awakening response, a measure of 
HPA axis activity, has been shown to be altered in chronically stressed humans, 
victims of bullying, and subjects suffering from burnout (Kudielka and Wust, 2010). 
Additional support for this concept comes from animal studies, showing that stress-
induced behavioral and neuroendocrine disturbances resemble some of the 




a transcription factor, implicated in regulation of neuroplasticity, neurogenesis and cellular resilience. 
Cytokine-activated NF-κB is also suggested to decrease BDNF and 5-HT levels, as well as to increase CRH 
release and to activate the HPA axis. Together, all these players may contribute to impaired brain function in 
major depression.  
Dashed arrows indicate both direct and indirect influences. 
5-HT – serotonin, ACTH – adrenocorticotropic hormone, BDNF – brain-derived neurotrophic factor, CREB – 
cAMP response element binding protein, CORT – cortisol, CRH – corticotropin-releasing hormone, DA – 
dopamine, GABA – γ-aminobutyric acid, IDO – indoleamine 2,3-dioxygenase, MT – melatonin, NE – 
noradrenaline, NF-κB – nuclear factor kappa B, NMDA – N-methyl-D-aspartic acid, NT – neurotransmitter, 
TRP – tryptophan. 
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In animal models, strong HPA axis activation and sustained elevation of 
glucocorticoid levels, seen under conditions of prolonged stress, have been suggested 
to affect hippocampal morphology and function. Chronic stress in laboratory animals 
has been shown to induce dendritic atrophy of hippocampal CA3 pyramidal neurons 
(Magarinos and McEwen, 1995a; Magarinos et al., 1996; Sapolsky, 2000), suppress 
neurogenesis in the dentate gyrus (Fuchs and Flugge, 1998; Gould and Tanapat, 
1999) and lead to reduction in hippocampal volume (Czeh et al., 2001; van der Hart 
et al., 2002). Sustained glucocorticoid exposure is suggested as one of the mediators 
of stress responsible in causing these changes, although the precise mechanism 
remains incompletely understood (de Kloet et al., 2005). Regardless of the nature of 
the damage, it would be expected to reduce inhibitory control of the hippocampus on 
HPA axis, which would further increase circulating glucocorticoid levels and 
subsequent hippocampal damage (Nestler et al., 2002a). Thus, a sustained HPA axis 
hyperactivation and hypercortisolaemia may contribute to depression partly by 
inducing above described changes in hippocampus that might impair its function. 
Based on the normal functions exerted by the hippocampus, its dysfunction might 
lead to some of the cognitive symptoms of depression.  
Moreover, in humans, there are striking parallels between some aspects of the 
stress response, severe depression and the effects of centrally administered CRH 
(Arborelius et al., 1999; Holsboer, 2001), suggesting that a hyperactive HPA axis 
may contribute to depression not only via hypercortisolaemia but also via enhanced 
CRH secretion in the hypothalamus and other brain regions that are innervated by 
these neurons (Nestler et al., 2002a).  
Despite the compelling evidence outlined above, it is still unknown whether HPA 
axis abnormalities are a primary cause of depression or, instead, secondary to 
depressed mood. Thus, a major liability of the HPA axis hypothesis of depression is 
the difficulty of defining the relationship of stress to depression. There is good 
evidence that episodes of depression often occur in the context of some form of stress; 




The term neuroplasticity describes the ability of the adult and differentiated brain to 
adapt functionally and structurally to internal and external stimuli. Altered 
neuroplasticity is considered as a feature of depressive illness (figure 1.1). Brain 
regions, such as the hippocampus, amygdala and PFC are reported to undergo 




emotions, memory and cognitive functions (Sheline, 2003; McEwen et al., 2010). 
Such neuroplastic processes include modulation of adult neurogenesis and 
synaptogenesis, together with alterations in neurotrophic factor expression, 
governed by multiple transcriptional and translational changes. 
 
Neurotrophic factors 
The neuroplasticity hypothesis of depression states that a deficiency in neurotrophic 
support may contribute to structural and functional brain changes during 
development of depression, and that reversal of this deficiency by antidepressant 
treatments may lead to the remission of depressive symptoms (Nestler et al., 2002a). 
Because this theory has focused largely on the role of brain-derived neurotrophic 
factor (BDNF) in regulating plasticity within adult brain, it is often referred as the 
neurotrophic or BDNF hypothesis of depression. 
Support for involvement of neurotrophins in depression and its treatment has 
come from preclinical studies in stressed animals as well as postmortem brain 
analysis of depressed humans. Acute and chronic stress in laboratory animals has 
been shown to reduce BDNF and its mediated signaling in the hippocampus and 
other brain areas (Smith et al., 1995; Duman and Monteggia, 2006; Krishnan and 
Nestler, 2008). This effect is suggested to be mediated partly via stress-induced 
glucocorticoids (Smith et al., 1995), but the precise mechanism is not well understood 
yet. Conversely, chronic (but not acute) treatment with various antidepressants has 
been shown to increase BDNF-mediated signaling in the hippocampus, and prevent 
the stress-induced decrease in BDNF expression (Nibuya et al., 1995; Castren et al., 
2007; Martinowich et al., 2007). Similar changes have been observed in the 
postmortem hippocampus and PFC of depressed humans (Chen et al., 2001; Castren, 
2004b; Karege et al., 2005a; Duman and Monteggia, 2006). Interestingly, several 
studies have found decreased blood levels of BDNF in depressed patients, and their 
normalization after antidepressant therapy; however, the relevance of these findings 
to the action of BDNF in the brain remains to be established (Shimizu et al., 2003; 
Karege et al., 2005b; Castren et al., 2007). Antidepressant induction of BDNF is at 
least partly mediated via the transcription factor cyclic adenosine monophosphate 
(cAMP) responsive element binding protein (CREB) (Carlezon et al., 2005). 
Importantly, BDNF itself might posses antidepressant-like properties as observed in 
the experiments where BDNF was directly infused in the hippocampus of laboratory 
animals (Shirayama et al., 2002). Moreover, BDNF was reported to promote 
hippocampal function by enhancing long-term potentiation (LTP) and other forms of 
synaptic plasticity (Korte et al., 1996; Patterson et al., 1996; Kang et al., 1997; 
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Bramham, 2007). Together, these findings raised the possibility that antidepressant-
induced upregulation of BDNF could help to repair stress-induced damage to 
hippocampal neurons and preserve hippocampal function (Nestler et al., 2002a).  
However, more recent findings have necessitated a revision of this hypothesis 
(Krishnan and Nestler, 2008). Some studies have failed to replicate the patterns of 
changes associated with stress and antidepressant treatment, or have even shown 
opposite effects (Groves, 2007; Martinowich et al., 2007). Another important 
drawback of the BDNF hypothesis is that mice lacking BDNF or its receptor do not 
clearly and consistently show depressive-like behaviors (Zorner et al., 2003; 
Monteggia et al., 2007), which may however partly relate to the limitations of testing 
depression-like syndromes in animal models. Furthermore, the effects of BDNF are 
region-specific: its enhancement is antidepressant in the hippocampus, but 
prodepressant in the ventral tegmental area (VTA) and nucleus accumbens (NAc) 
(Eisch et al., 2003; Berton et al., 2006; Krishnan et al., 2007). Finally, a previously 
mentioned SNP in the gene encoding BDNF, Val66Met, associated with impaired 
release of BDNF and decreased hippocampal volume, does not directly increase the 
risk of depression (Egan et al., 2003; Szeszko et al., 2005; Chen et al., 2006; Gratacos 
et al., 2007).  
Thus, although BDNF-mediated signaling is involved in neuroplastic responses 
to stress and antidepressants, these effects are region-specific and function in the 
background of other potent genetic and environmental modifiers (Krishnan and 
Nestler, 2008). Nevertheless, BDNF as well as other neurotrophins play an 
important role in regulation of hippocampal neurogenesis (Lee et al., 2002b), also 
implicated in the mechanisms of stress, depression and antidepressant therapy. 
 
Adult neurogenesis 
The possibility of postnatal neurogenesis was claimed as early as 1890s but this 
concept was not widely accepted until almost a century later (Altman and Das, 1965; 
Kaplan and Hinds, 1977; Eriksson et al., 1998). For all these years, it was believed 
in the below highlighted dogma that adult brain is not capable to generate new 
neurons: 
“Once the development was ended, the founts of growth and regeneration of the 
axons and dendrites dried up irrevocably. In the adult centers, the nerve paths are 
something fixed, ended and immutable. Everything may die, nothing may be 




Box 1.1  
Regulators of adult neurogenesis 
Adult neurogenesis is an extremely dynamic process. Extensive 
studies have shown that both intrinsic and extrinsic factors regulate 
neurogenesis at different stages, including cell proliferation, fate 
specification, migration, integration, and survival (Ming and Song, 
2005). Regulation of neurogenesis in the olfactory bulb and 
hippocampus overlaps to a certain extent; however, many of the 
regulators have differential influences on these two processes. Since 
the current thesis concerns hippocampal neurogenesis, here I will 
briefly review factors implicated in regulation of new neuron 
generation in the dentate gyrus.  
The intrinsic genetic background influences adult neurogenesis, 
as significant differences in the number of newborn hippocampal 
cells have been found between species and strains (Kempermann 
and Gage, 2002). Age is another important factor in regulating 
neurogenesis. Hippocampal cell proliferation occurs at high rates in 
very young animals and rapidly declines during aging (Kuhn et al., 
1996; Heine et al., 2004b). Other intrinsic regulators of adult 
neurogenesis include various hormones, neurotransmitters and 
growth factors.  
Glucocorticoids are considered as the main mediators of the 
stress-induced suppression of hippocampal neurogenesis. This idea 
originates from experiments in which CORT therapy and 
adrenalectomy have opposing effects on hippocampal cell 
proliferation (Cameron and Gould, 1994; Cameron and McKay, 1999; 
Tanapat et al., 2001). Besides glucocorticoids, other hormones also 
influence adult neurogenesis. For instance, estrogen and 
testosterone are known to differentially regulate the levels of 
newborn neurons in the dentate gyrus (Galea, 2008). 
Several neurotransmitter systems have been implicated in 
regulating adult neurogenesis. Glutamatergic signaling via N-
methyl-D-aspartate (NMDA) receptors has been shown to inhibit 





activation of NMDA receptors appears to play a role in the 
glucocorticoid-mediated effects on progenitor proliferation. For 
instance, blockage of NMDA receptors rescues CORT-induced 
decrease in hippocampal neurogenesis (Cameron et al., 1998). 
Another neurotransmitter, serotonin, has been suggested as a potent 
activator of adult neurogenesis (Djavadian, 2004). Inhibition of 
serotonin synthesis by pharmacological treatment or by lesioning of 
the serotonergic neurons reduces cell proliferation (Brezun and 
Daszuta, 1999). Conversely, stimulation of serotonergic transmission 
by chronic treatment with antidepressants promotes the formation 
of new cells in the dentate gyrus (Malberg et al., 2000). Yet, the net 
influence of serotonin on adult neurogenesis may depend on 
differential activation of its numerous receptors and their possibly 
contradictory actions. Other neurotransmitters have also been 
shown to modulate hippocampal neurogenesis: γ-aminobutyric acid 
(GABA) (Ge et al., 2007), noradrenaline (Kulkarni et al., 2002), 
dopamine (Borta and Hoglinger, 2007), and acetylcholine (Cooper-
Kuhn et al., 2004), to name a few examples.  
Adult neurogenesis is positively influenced by a variety of 
growth factors, including insulin-like growth factor-1 (IGF-1), 
fibroblast growth factor (FGF), vascular endothelial growth factor 
(VEGF), and BDNF; their involvement is reviewed extensively 
(Anderson et al., 2002; Newton and Duman, 2004; Hagg, 2005).  
Among extrinsic factors modulating hippocampal neurogenesis, 
environmental enrichment and physical exercise are the most potent 
activators of hippocampal neurogenesis (Olson et al., 2006). Training 
in hippocampus-dependent learning tasks has also been associated 
with increased neurogenesis in the dentate gyrus, although 
inconsistently (Gould et al., 1999b; Van der Borght et al., 2005a). 
Stress has been repeatedly reported to decrease hippocampal 
neurogenesis, however, contrasting evidence exists (Gould and 
Tanapat, 1999; McEwen, 1999; Thomas et al., 2006; Lucassen et al., 
2010). Complex intrinsic regulatory mechanisms underlie changes in 
neurogenesis elicited by extrinsic factors; thus, the final effect 
achieved is a result of integration of multiple interactions in the 




Currently, there is no doubt that postnatal neurogenesis occurs in at least two 
regions of the brain: the subventricular zone (SVZ) of the olfactory bulb and the 
subgranular zone (SGZ) of the hippocampal dentate gyrus (Abrous et al., 2005; Ming 
and Song, 2005; Lledo et al., 2006). Adult neurogenesis is subject to complex 
regulation with numerous factors involved (box 1.1). Although the function of 
postnatal neurogenesis is not yet completely understood, it has been implicated in 
several neurobiological processes and its dysregulation has been associated with 
multiple brain disorders.  
At the turn of the millennium, it was proposed that the neurogenesis process in 
the adult hippocampus may be oppositely regulated by depression and 
antidepressants (Jacobs et al., 2000). This hypothesis was based on preclinical 
observations that stress, an important regulator of neurogenesis and a significant 
risk factor for major depression, as described above, inhibits proliferative activity in 
the hippocampal dentate gyrus (Gould and Tanapat, 1999; McEwen, 1999). 
Conversely, various antidepressant treatments have been shown to increase the rate 
of hippocampal neurogenesis and/or prevent the effects of stress (Kempermann and 
Kronenberg, 2003), comprising in part their mood-improving actions (Santarelli et 
al., 2003). Accordingly, changes in hippocampal neurogenesis were implicated in the 
etiopathophysiology and treatment of major depressive disorder (Duman et al., 2000; 
Gage, 2000; Jacobs et al., 2000; Kempermann, 2002).  
Nonetheless, although initially promising, this hypothesis has lost some of its 
appeal due to difficulties providing functional mechanism for the etiology of 
depression. So far, no causal link between a decrease in neurogenesis and 
depressive-like behaviors has been identified (Vaidya et al., 2007). Furthermore, 
artificially disrupted hippocampal neurogenesis in laboratory animals has not led to 
the depressive phenotype (Sapolsky, 2004; Eisch et al., 2008). With respect to 
antidepressant drugs, their mood-alleviating effects do not clearly depend on 
hippocampal neurogenesis, however, newly-born neurons may play an important role 
in neuronal remodeling and hippocampal function (Bessa et al., 2009).  
Importantly, literature also reveals contradicting evidence concerning effects of 
stress and antidepressant treatment on adult neurogenesis in the hippocampus. 
Despite a poor documentation of these contrasting results (many of such “negative 
data” do not get easily published), it is becoming clear that the influence of 
stress/antidepressants on neurogenesis is far from unequivocal. 
Yet, the notion that adult hippocampal neurogenesis may be oppositely 
regulated by stress and antidepressant treatment gave rise to the possibility of using 
it as a readout in testing the efficacy of novel treatments for major depressive 
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disorder. In turn, the experimental work described in the following chapters also 
focused on stress-induced effects on hippocampal neurogenesis in animal models, 
and their modulation upon treatment with the novel antidepressant, agomelatine. 
 
Inflammation (cytokine) hypothesis 
The brain is no longer regarded as an immunoprivileged organ, as it became clear 
that many interactions occur between neural and immune systems (Schiepers et al., 
2005). Consequently, changes in the functional activity of the immune system have 
been related to several neuropsychopathologies, including major depression.  
A role for inflammation in depression was first proposed in the early 1990s in 
the form of the macrophage theory of depression (Smith, 1991). It was based on 
clinical observations that depressed patients have increased blood levels of 
inflammatory biomarkers, including cytokines and acute-phase proteins. Later, this 
theory was reformulated to the cytokine hypothesis of depression, suggesting that 
proinflammatory cytokines play the key role in mediation of the behavioral, 
neuroendocrine and neurochemical features of depressive disorder (Schiepers et al., 
2005). Among the most likely players are interleukin (IL)-1, IL-6, and tumor necrosis 
factor (TNF)-α, that are often found to be elevated in the peripheral blood circulation 
and/or the cerebrospinal fluid of depressed patients (Raison et al., 2006; Miller et al., 
2009). Increases in inflammatory mediators have also been correlated to depressive 
symptom severity (Alesci et al., 2005; Thomas et al., 2005; Von Kanel et al., 2009). 
Importantly, administration of cytokines or their inducers, such as lipopoly-
saccharide (LPS) or vaccination, in humans was shown to evoke depressive-like 
symptoms (Reichenberg et al., 2001; Brydon et al., 2008). Long-term exposure to 
cytokines may even lead to development of clinical depression, as observed in a 
subpopulation of patients receiving chronic interferon (IFN)-α therapy for treatment 
of infectious diseases or cancer (Musselman et al., 2001; Capuron et al., 2002). 
Moreover, proinflammatory cytokines can activate indoleamine 2,3-dioxygenase 
(IDO), an enzyme involved in the catabolism of tryptophan, and implicated in the 
relation between chronic inflammation and depressive disorder (Oxenkrug, 2010; 
Raison et al., 2010) (figure 1.1). These findings in humans are consistent with a vast 
literature in laboratory animals showing cytokine involvement in sickness behavior, 
proposed as an immunological model of depression (Dantzer, 2001; Dantzer et al., 
2008; Dobos et al., 2010). 
Since changes in immune system are beyond the scope of this thesis, I will not 
discuss possible mechanisms and mediators of cytokine-induced effects. Interactions 




ongoing research studies. Thus, the future holds promise for better understanding of 
the etiopathogenesis of depression and development of novel treatment approaches. 
 
Other hypotheses of the pathophysiology of depression 
 
Altered neurotransmitter balance 
The section on the monoamine hypothesis briefly described the involvement of 
serotonin, noradrenaline and dopamine in the pathophysiology and treatment of 
depression. Other neurotransmitter systems, however, have also been implicated in 
this disorder. Here, I will give a brief overview on glutamatergic, GABA-ergic and 
cholinergic changes suggested to play a role in depression.  
Glutamate is the major excitatory neurotransmitter of the CNS that controls 
synaptic excitability and plasticity in most brain circuits, including limbic pathways 
(McEwen et al., 2010). The involvement of glutamatergic mechanisms has been 
recognized in many functions perturbed in depressed states (Paul and Skolnick, 
2003; Sanacora et al., 2003; Zarate et al., 2003; Bergink et al., 2004). Current 
evidence suggests that the glutamatergic system is altered in mood disorders and 
contributes to the mechanism of antidepressant action for several treatment 
modalities (Kugaya and Sanacora, 2005). Elevated glutamate levels were observed in 
the peripheral blood of some depressed patients (Kim et al., 1982; Altamura et al., 
1993; Mauri et al., 1998). Moreover, magnetic resonance spectroscopy revealed 
changes in concentrations of cortical glutamate (Auer et al., 2000; Mirza et al., 2004; 
Sanacora et al., 2004). Both increases and decreases in glutamate levels were 
reported; this inconsistency might be due to discrepancies among studies, which 
measured different brain regions in a heterogeneous population of depressed 
subjects (children/adults, on/off medication). So far, these observations only suggest 
that regulation of glutamatergic system might be altered in mood disorders, and 
more controlled studies are needed to elucidate the precise nature of these 
abnormalities. Nevertheless, preclinical studies have shown that medications 
affecting the glutamatergic system, e.g. NMDA receptor antagonists, may have an 
antidepressant effect (Muller and Schwarz, 2007; Sanacora et al., 2008). 
When investigating the contributions of glutamate in the pathophysiology of 
depression, it is also important to consider the role of GABA, since these two systems 
are intricately coupled. GABA is the major inhibitory neurotransmitter of the CNS, 
providing balance against the cortical excitability produced by glutamate (Kugaya 
and Sanacora, 2005). Emerging findings reveal that mood disorders are associated 
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with GABA-ergic abnormalities (Tunnicliff and Malatynska, 2003; Sanacora and 
Saricicek, 2007). Clinical studies report decreased GABA levels in both cerebrospinal 
fluid and blood plasma as well as lower cortical GABA concentrations in patients 
with major depression (Petty, 1995; Sanacora et al., 2004). Thus, GABA-ergic 
activity seems to be lower in the depressed state than in the healthy brain. Future 
studies, however, are needed to confirm the relationship of these changes to the 
pathophysiology of depression.  
The cholinergic changes are also suggested to contribute to depression. This 
notion originated from clinical reports several decades ago, showing that central 
cholinergic activation caused depressant inhibitory effects (Carlton, 1963; Vaillant, 
1967; Domino and Olds, 1968). Based on these observations, the cholinergic 
hypothesis of depression was postulated (Janowsky et al., 1972; Dilsaver, 1986); 
however, its importance diminished over time, due to insufficient evidence linking it 
to the etiology of major depression. Nevertheless, recognizing the role of the 
cholinergic system in depression may shed light upon mechanisms involved in 
certain aspects of this disease. Acetylcholine is largely responsible for a number of 
CNS functions, including arousal, attention, learning and memory (Deutsch, 1971). 
Hence, cholinergic dysfunctions may account for the development of cognitive 
symptoms associated with depression, especially when disease is long-lasting and 
treatment-resistant. The implication of the cholinergic system in major depressive 
disorder, and especially in associated cognitive impairments, is further reviewed in 
chapter 6 of this thesis. 
 
Circadian rhythm abnormalities 
Desynchronization of internal rhythms has been hypothesized to play a role in the 
pathophysiology of major depressive disorder (Wehr and Wirz-Justice, 1982). Indeed, 
several clinical symptoms of depression, such as diurnal mood variation and early 
morning awakening, are characteristic of changes in circadian rhythms (Healy, 1987; 
Germain and Kupfer, 2008; Wirz-Justice, 2008). Clinical findings suggest that many 
internal rhythms can be disrupted in depression, including the 24-hour profiles of 
various hormones, neurotransmitters, body temperature as well as sleep 
architecture and timing (Souetre et al., 1989; Turek, 2007; Lam, 2008). Sleep 
abnormalities represent one of the diagnostic criteria of the major depressive 
disorder. Interestingly, manipulation of the sleep-wake cycle, e.g. by sleep 
deprivation, is known to acutely improve mood in depressed patients (Giedke and 
Schwarzler, 2002). Furthermore, a successful antidepressant treatment is able to 




temperature rhythms (Souetre et al., 1989). These observations suggest a 
relationship between circadian rhythmicity and affective disorders. Yet, it is not 
clear whether changes in circadian processes represent a symptom or a causal factor 
in the pathogenesis of depression.  
Nevertheless, recognition that desynchronization of internal rhythms plays an 
important role in affective disorders has led to the reasoning that resetting normal 
circadian rhythmicity may have a therapeutic effect. Hence, melatonin, a major 




Melatonin is the principal hormone of the pineal gland, the so called “third eye”, 
which transduces the external succession of light and dark into an internal hormonal 
message (Peirson and Foster, Neuron, 2006; Maronde and Stehle, 2006). The neural 
circuitry that transmits information on lighting conditions to the pineal gland is 
remarkably complex and has been reviewed extensively (Moore, 1996; Korf et al., 
1998; Maronde and Stehle, 2007; Reiter et al., 2010). Briefly, environmental light 
information from the retina is carried through the retinohypothalamic tract to the 
circadian clock situated in the hypothalamic suprachiasmatic nucleus (SCN). The 
main efferent output from the SCN goes to the parvocellular autonomic component 
of the PVN, and from there reaches the upper thoracic intermediolateral cell column, 
followed by a projection to the superior cervical ganglion (Luiten et al., 1985; Moore, 
1996; Reiter et al., 2010). Noradrenergic sympathetic nerve fibers originate in this 
ganglion and reach the pinealocytes in the pineal gland. During darkness, the SCN 
sends an electrical signal which causes the release of noradrenaline from 
postganglionic synaptic nerve endings onto the pinealocytes, which initiates and 
sustains, primarily via ß1-adrenergic receptors, melatonin synthesis from its 
precursor tryptophan (Maronde and Stehle, 2007; Reiter et al., 2010). The metabolic 
pathway of tryptophan that culminates in melatonin production is well known and 
has been a topic of numerous reviews (Reiter, 1991; Ackermann and Stehle, 2006; 
Reiter et al., 2010). 
Melatonin influences cellular physiology via membrane receptors as well as via 
cytosolic and nuclear binding sites. The main effects of melatonin are elicited 
through the cell membrane-bound receptors, which will be discussed in more detail. 
These two high-affinity membrane receptors, MT1 and MT2, are members of the G-
protein-coupled receptor family, and account mainly for melatonin action. A third 
melatonin binding site, MT3, shows low affinity and is seemingly identical to the 
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cytosolic enzyme, quinone reductase 2 (QR2) (Boutin et al., 2008); however, its 
actions are beyond the scope of this thesis. Although originally thought to have a 
rather limited distribution, both MT1 and MT2 receptors have now been uncovered in 
virtually every organ of the body (Dubocovich and Markowska, 2005). In the brain, 
they have been localized in many regions, including the SCN, hippocampus, and 
PFC among others (Pandi-Perumal et al., 2008).  
The signaling mechanisms of melatonin via MT1 and MT2 receptors are highly 
complex and vary with cell type and possibly also between species (Reiter et al., 
2010). Although MT1 and MT2 signaling pathways are only partly identical, they are 
often presented collectively, due to complementary action of these two receptor 
subtypes and uncertainties concerning different cell types. In brief, MT1/MT2 
receptor stimulation inhibits adenylate cyclase, reduces cAMP production and 
modulates protein kinase A (PKA) activity (Dubocovich et al., 2003). Moreover, 
dependent on cell type and organ involved, exposure to melatonin leads to activation 
of phospholipase C (PLC), followed by elevated inositol-(1,4,5)-triphosphate (IP3) and 
1,2-diacylglycerol (DAG) (Alarma-Estrany and Pintor, 2007; Hardeland, 2009). These 
effects are followed by activation of the mitogen-activated protein kinase (MAPK) 
and phosphoinositide-3-kinase (PI3K) pathways, and their downstream elements 
(Witt-Enderby et al., 2000; Hardeland, 2009). In addition, various other second 
messenger cascades are triggered upon binding to MT1/MT2 receptors; their 
complexity is reviewed comprehensively (Witt-Enderby et al., 2000; Dubocovich et 
al., 2003; Pandi-Perumal et al., 2008; Hardeland, 2009).  
The actions of melatonin have been most thoroughly studied in the SCN, which 
is proposed as a mediator of melatonin-associated effects on circadian rhythms and 
sleep. Activation of MT1 and MT2 receptors inhibits neuronal firing and phase shifts 
circadian rhythms in the SCN, respectively (Liu et al., 1997). These actions of 
melatonin have been implicated in the regulation of sleep (Dubocovich, 2007). 
Accordingly, exogenous melatonin was shown to promote sleep and phase shift 
circadian rhythms, however, these effects depend critically on the time of 
administration (Arendt, 2005). Thus, melatonin has obvious therapeutic potential in 
treating circadian rhythm sleep disorders, such as delayed sleep phase syndrome, 
non-24-h sleep-wake cycle as well as sleep problems associated with jetlag and shift 
work (Arendt and Rajaratnam, 2008). Furthermore, since melatonin output is 
altered in some depressed patients, it may be beneficial in the treatment of 
depressive disorders, especially if rhythm abnormalities are present (Lewy et al., 
2006; Pandi-Perumal et al., 2006b; Serfaty et al., 2010). Hence, the melatoninergic 





STRUCTURAL CHANGES IN DEPRESSION 
A large body of data suggests that depression is accompanied by neurobiological 
abnormalities, which may persist even during a remission of clinical symptoms. 
Neuroimaging studies indicate that individuals with recurrent major depressive 
episodes may have relatively small hippocampi (Sheline et al., 2003; Videbech and 
Ravnkilde, 2004). Recurring or enduring illness and lack of antidepressant 
treatment are thought to contribute to progressive hippocampal volume reductions 
in some depressed patients (aan het Rot et al., 2009). In turn, these structural 
changes in the hippocampus may explain cognitive as well as several other 
symptoms associated with depression. Patients may also present with volumetric 
abnormalities in other brain regions, including the amygdala, ventral striatum, 
anterior cingulate cortex, orbitofrontal cortex and PFC (Sheline, 2003; Campbell and 
MacQueen, 2006; Konarski et al., 2008).  
Neuropathology in depression has been extensively examined by postmortem 
studies, usually in suicide victims. Such investigations have revealed multiple 
abnormalities, ranging from volume reductions to cellular atrophy and molecular 
changes (Rajkowska, 2003). Postmortem studies of brain tissue of depressed subjects 
have shown hippocampal shrinkage accompanied by increased density of glial and 
neuronal cells and decreased neuropil per cell (i.e. reduction in dendritic branching 
and spine complexity) (Stockmeier et al., 2004). Histopathological evidence has also 
revealed cellular changes in other brain areas. Decreases in cortical thickness, 
neuronal sizes, and neuronal and glial densities in the orbitofrontal and dorsolateral 
PFC were reported (Rajkowska et al., 1999). Also, a reduction in glial density in the 
amygdala was found in depression (Bowley et al., 2002). Thus, alterations in both 
glia and neuron cells appear to participate in the neuropathology of major depression 
(Hercher et al., 2009). Furthermore, postmortem investigations have revealed low 
levels of BDNF in the hippocampus and PFC of depressed subjects (Duman and 
Monteggia, 2006; Martinowich et al., 2007). On the other hand, increases in hippo-
campal BDNF immunoreactivity were observed in patients treated with antidepre-
ssants at time of death, compared with medication-free subjects (Chen et al., 2001).  
Altogether, these findings have provided unique insights into the neurobiology of 
depressive disorder. In order to advance this knowledge even further, postmortem 
investigations should be preceded by and linked to longitudinal clinical studies that 
reveal details of the disease course and treatment. In addition to clinical evidence, 
animal model approach is necessary to unravel the cellular and molecular correlates 




ANIMAL MODELS OF DEPRESSION 
Since depression typically impairs mood and higher cognitive functions, no 
experimental paradigm in animals can fully mimic this disorder. Only particular 
behavioral aspects of depression, such as anhedonia, helplessness or sleep 
abnormalities, are possible to model in animals; yet, clinical implication of effects 
achieved in such paradigms deserves caution. For instance, a rodent which floats 
passively in the forced swim test may start struggling after a single antidepressant 
injection, however, such an experiment is a very far-fetched representation of human 
depression and its effective treatment. Likewise, a stressed rat or mouse which 
consumes less sweet solution than its non-stressed littermate does not adequately 
mimic a depressed individual, with respect to symptoms evoked. Thus, although 
literature often names these and similar paradigms as animal models of depression, 
one should be reluctant to use this term. In the current thesis, I will rather refer to 
animal models of chronic stress, when discussing prolonged stress-induced 
alterations in rodent brain, which may be fundamentally similar to those in affected 
human brain. 
Here, I will briefly review several animal paradigms, used frequently to 
investigate development and treatment of stress-related psychopathologies. Popular 
experimental models of depression include despair paradigms (forced swim, tail 
suspension tests and learned helplessness), olfactory bulbectomy, maternal 
separation and exposure to prolonged stress of various types (chronic mild stress, 
social defeat, footshock and restraint stress). 
The behavioral despair paradigms, such as forced swim and tail suspension 
tests, are based on observation that immobility or decreased struggling of an animal 
in aversive experimental conditions (“despair”) could be reversed by antidepressant 
drugs (Porsolt et al., 1977; Steru et al., 1985). These paradigms are widely used to 
detect potential antidepressant compounds and to measure their effects in animals 
(table 1.3). The common rationale of the above described tests is that animal 
immobility indicates anxiogenic freezing; however, this behavior may have many 
other interpretations, including those of an opposite nature (Kalueff et al., 2007). 
Hence, although such tests contribute to the identification on novel drugs against 
depression, their measured effects should be interpreted with caution. A 
conceptually similar paradigm of learned helplessness induces a condition, in which 
animal learns to behave helplessly by passively accepting aversive stimuli, even 
when the possibility to escape an unpleasant environment is restored (Seligman, 




feeling of hopelessness in clinical depression. Learned helplessness paradigm is 
frequently used to induce depression-like behavior in animals and to test 
antidepressant effects therein (table 1.3).  
The olfactory bulbectomy has been proposed as an experimental model of 
depression, based on observations that bulbectomized rats display a behavioral 
syndrome that reflects a disruption of the limbic-hypothalamic axis (Kelly et al., 
1997). The behavioral changes following olfactory bulbectomy, e.g. motor 
hyperactivity and memory deficits, resemble some of the depression symptoms; 
moreover, they can be attenuated by treatment with antidepressants (table 1.3). The 
olfactory bulbi in the rat form a part of the limbic system in which the amygdala and 
hippocampus contribute to the emotional components of behavior. Thus, bulbectomy 
may cause a dysfunction of the cortical-hippocampal-amygdala circuit that underlies 
the behavioral, endocrine, immune and neurotransmitter changes in depression 
(Song and Leonard, 2005). 
Maternal separation is used to induce early-life stress in rodents, suggested to 
shape various emotional and neuroendocrine parameters in the adulthood (Plotsky 
and Meaney, 1993; Pryce and Feldon, 2003). Disturbed mother-infant relationship is 
hypothesized to increase susceptibility of the offspring to psychopathology later in 
life. Nevertheless, literature demonstrates that effects of maternal separation on 
depression-related behaviors are rather inconsistent, and therefore, do not provide a 
straightforward model of early-life stress (Lehmann and Feldon, 2000; Millstein and 
Holmes, 2007; Hulshof et al., 2010). 
Prolonged stress in the adulthood is frequently applied to laboratory animals in 
order to investigate the impact of stressful events on body and brain. Chronic stress 
can be modeled by exposing rodents to various physical and/or psychosocial 
stressors, e.g. immobilization, footshock, social defeat and chronic mild stress. 
Generally, chronic stress models differ in the degree to which they activate the HPA 
axis as well as in the behavioral and neural responses that they induce. 
Furthermore, animals show ability to habituate, at least partly, to certain stress 
paradigms (Dallman, 1993). Nevertheless, the above mentioned chronic stress 
models have revealed a wide range of stress-induced effects, from changes in gene 
transcription to alterations in neural plasticity, suggested to contribute to one’s 
vulnerability to psychopathology (Krishnan and Nestler, 2008). In addition, they 
have proven to unveil the effects of antidepressant drugs (table 1.3). Hence, animal 
models of chronic stress provide a valuable tool to investigate behavioral, endocrine 
and neurobiological changes underlying stress-related disorders and mechanism of 
antidepressant therapies (Fuchs et al., 2001; Nestler et al., 2002b). The present 
thesis, focused on neurobiological effects of prolonged stress and actions of the 
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antidepressant agomelatine, also employed animal models of chronic stress: repeated 
footshock (chapter 2, 3, and 5) and chronic mild stress (chapter 4). A detailed 
overview of both models and their induced effects will be presented in the separate 
chapters of the current thesis.  
Recognition that inflammation and cytokines play important roles in depression 
gave rise to immunological models of this disorder. The LPS-induced sickness 
behavior in animals was shown to resemble certain symptoms of clinical depression 
(fatigue, reduced appetite, decreased social and physical activity, altered sleep, 
impaired learning and memory), which could be attenuated by antidepressant 
treatment (Dunn et al., 2005; Dantzer et al., 2008).  
Other approaches for modeling depression include the use of selectively bred 
mutant or transgenic animals with altered anxiety- and depression-like phenotypes 
(Gonzalez et al., 1998; El Yacoubi et al., 2003; Thakker et al., 2005; Kalueff et al., 
2007). Such paradigms are also valuable in detecting and testing of potential 
antidepressants drugs (table 1.3). In particular, gene-specific models might enable a 
better dissection of neurobiological mechanisms underlying development and 
treatment of depressive disorder. Given the importance of interaction between 
genetic and environmental factors in vulnerability to depression, these models would 
yield most information when applied in a combination with external risk factors, e.g. 
stress. 
In addition, various anxiety paradigms are frequently employed to test 
behavioral traits that demonstrate marked overlap and co-occurrence with 
depressive disorder. Anxiety tests include exploration-based paradigms (e.g. open 
field, holeboard, elevated plus maze, social interaction tests) and conditioned or 
unconditioned threat responses (e.g. shock-probe defensive burying, ultrasonic 
vocalization, Vogel tests), reviewed extensively elsewhere (Rodgers, 1997; Flint, 
2003; Kalueff et al., 2007). 
Although researchers’ confidence in the above reviewed animal models varies, 
they are indispensible for screening antidepressant drugs, testing neurobiological 
hypotheses and finding candidate genes for human depressive disorder. 
Nevertheless, understanding the potential benefits and weaknesses of the existing 
experimental models is crucial for obtaining valid animal data to parallel and/or 





The first antidepressant treatment emerged in the 1950s after a serendipitous 
discovery of mood-alleviating properties of the monoamine oxidase (MAO) inhibitor, 
iproniazid, originally developed as anti-tuberculosis drug (Lopez-Munoz and Alamo, 
2009). The second generation of compounds, such as the tricyclic antidepressant 
(TCA), imipramine, were originally synthesized as antipsychotic drugs and their 
antidepressant activity was also discovered later in the clinics (Ban, 2001). Shortly 
after, the acute mechanisms of action of these antidepressant medications were 
identified: inhibition of serotonin or noradrenaline reuptake transporters by the 
TCA, and inhibition of MAO, a major catabolic enzyme for monoamine neuro-
transmitters, by MAO inhibitors (Frazer, 1997). 
These discoveries led to the development of numerous more selective 
antidepressant drugs, such as SSRI, NRI and SNRI, which are widely used in the 
clinical practice today (table 1.2). These newer medications display a better side 
effect profile and improved tolerability; however, they have essentially the same 
mechanism of action as the older antidepressant agents. As a result, their efficacy is 
not much better as compared to the older medications. The response rates to the 
current antidepressant drugs range from 60% up to 80%; yet, only approximately 
50% of all treated patients achieve complete remission (Mulrow et al., 2000; Nestler 
et al., 2002a). Moreover, existing options for antidepressant treatment are limited by 
their delayed onset of action and adverse outcomes (aan het Rot et al., 2009). 
Thus, there is a need for novel and more efficient medications with 
fundamentally different mechanisms of action. Search for new targets in treatment 
of depression has led to the development of several novel compounds, reviewed in 
table 1.2. Whereas some of these drugs have already demonstrated antidepressant 
efficacy in clinical trials, others merely represent potential targets for the 
development of novel therapeutics. 
Besides advances in pharmaceuticals, other approaches are also important in 
treatment of depression. For instance, the electroconvulsive therapy has been one of 
the most effective treatment methods so far. Other neurostimulation techniques, 
including deep brain stimulation, transcranial magnetic stimulation and vagus 
nerve stimulation, have been recently proposed in treatment of major depressive 
disorder. Last but not least, social and behavioral interventions, such as cognitive 
psychotherapy, social support and regular physical activity reduce the burden of 
depression and benefit brain and body health and resilience. 
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Table 1.2 Classical and novel pharmacological agents for treatment of depression. The table provides an 
overview of old and new antidepressant drugs as well as potential targets for pharmacotherapy. 
CLASSICAL MECHANISM (MONOAMINERGIC) ANTIDEPRESSANTS: 
Serendipitous discoveries: 
 Monoamine oxidase inhibitors (MAOI) 
 Tricyclic antidepressants (TCA) 
Optimized drugs: 
 Serotonin selective reuptake inhibitors (SSRI) 
 Noradrenaline selective reuptake inhibitors (NRI) 
 Serotonin and noradrenaline reuptake inhibitors (SNRI) 
NOVEL MECHANISM ANTIDEPRESSANTS: 
 Melatonergic  
 Agomelatine 
 HPA-axis targets 
 GR antagonists (e.g. mifepristone) 
 CRH-R1 antagonists 
 V-1B antagonists 
 ß3-adrenoreceptor agonists 
 Other neuropeptide targets 
 Neurokinin (NK) antagonists (e.g. substance P) 
 Amino acid neurotransmitter modulators 
 NMDA antagonists 
 AMPA receptor potentiators 
 Growth factors 
 BDNF 
 Fibroblast growth factor (FGF) 
 Modulators of intracellular signaling cascades 
 CREB activators (phosphodiesterase (PDE4) inhibitors) 
 Glycogen synthase kinase-3 (GSK-3) inhibitors 
 Novel targets 
 Mitochondrial benzodiazepine receptor agonist 
 Neuronal nicotinic receptor antagonist 
 Pentapeptide analog of melanocyte-inhibiting factor (MIF-1) 






A part of this thesis is devoted to the experimental work on the neurobiological 
effects of a novel antidepressant agomelatine. Therefore, here I will briefly introduce 
the pharmaceutical properties of agomelatine as well as its known actions in animal 
and human studies.  
Agomelatine (S-20098; N[2-(7-methoxy-1-naphthyl)ethyl] acetamide; figure 1.2A) 
is the first melatonergic antidepressant (Millan et al., 2003). Besides being a potent 
agonist of the melatonergic MT1 and MT2 receptors, it also acts as a serotonergic 5-
HT2C receptor antagonist (Audinot et al., 2003; Millan et al., 2003). Agomelatine was 
initially investigated as a chronobiotic compound; however, with the discovery of the 
5-HT2C antagonist activity, the emphasis shifted to its anxiolytic and antidepressant 
effects. In the following paragraphs, I will shortly review both preclinical and clinical 
evidence concerning the therapeutic properties of agomelatine as well as proposed 
mechanisms behind them. 
 
Preclinical evidence: animal studies 
The antidepressant activity of agomelatine has been demonstrated in several 
animal models, including the despair test, learned helplessness test, bulbectomy, 
and chronic mild stress (CMS) paradigms (Papp et al., 2003; Bourin et al., 2004; 
Norman et al., 2004; Barden et al., 2005; Bertaina-Anglade et al., 2006) (table 1.3). 
In the learned helplessness test, neither melatonin nor 5-HT2C receptor antagonists 
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Figure 1.2 Molecular structures of agomelatine (A), melatonin (B) and serotonin (C). Agomelatine acts as 




abolished by co-administration of a MT1/MT2 antagonist (Bertaina-Anglade et al., 
2006). Consistent with this notion, a requirement of both melatonin and 5-HT2C 
receptors for therapeutic efficacy of agomelatine was observed in several other 
behavioral studies (Papp et al., 2003; Bourin et al., 2004; de Bodinat et al., 2010). 
Hence, the antidepressant action of agomelatine has been proposed to derive from 
the synergy between melatonin agonism and 5-HT2C antagonism (Popoli, 2009). 
Nevertheless, agomelatine has similar chronobiotic action as melatonin: it is 
able to phase shift free-running rhythms and accelerate re-entrainment after a 
sudden change of the light-dark cycle. This antidepressant has been shown to 
resynchronize circadian rhythms in animal models of jetlag, delayed sleep-phase 
syndrome, blindness (free-running conditions) and aging, both in nocturnal and 
diurnal species (Armstrong et al., 1993; Redman et al., 1995; Martinet et al., 1996; 
Van Reeth et al., 1998; Weibel et al., 2000; Van Reeth et al., 2001). These 
resynchronizing effects of agomelatine are abolished by lesions of the SCN but not 
modified by pinealectomy (Redman and Francis, 1998). The ability of agomelatine to 
re-entrain circadian rhythms is dose- and time-dependent. The window of sensitivity 
to this compound is within a few hours around the light-dark transition; its maximal 
effectiveness coincides with the onset of the elevation in melatonin secretion and 
with the time of maximal melatonin receptor sensitivity (Van Reeth et al., 1997; 
Pandi-Perumal et al., 2006b; de Bodinat et al., 2010). Therefore, a proper timing of 
agomelatine administration is crucial for optimal therapeutic effects.  
In addition, agomelatine also possesses anxiolytic properties, as observed in 
various anxiety models, including Vogel test (conflict-based anxiety test), elevated 
plus maze, social interaction, social defeat, and conditioned ultrasonic vocalization 
(Millan et al., 2005; Tuma et al., 2005; Papp et al., 2006). Anxiolytic actions of 
agomelatine are largely attributed to its antagonism at 5-HT2C receptors (Millan et 
al., 2005). Moreover, anxiolytic effects of agomelatine in the defeated animals have 
been shown to require an intact SCN (Tuma et al., 2005).  
Unlike the classical antidepressants, agomelatine does not modify extracellular 
levels of serotonin (Millan et al., 2003; Millan et al., 2005). Also, chronic treatment 
with agomelatine does not down-regulate presynaptic and postsynaptic 5-HT1A 
receptors, contrary to the effects of SSRI drugs (Hanoun et al., 2004). However, this 
novel antidepressant was reported to increase dopamine and noradrenaline levels in 
the (pre)frontal cortex and hippocampus (Millan et al., 2003; Millan et al., 2005). 
In an attempt to decipher the mechanisms underlying the therapeutic action of 
agomelatine, preclinical studies reported a variety of its mediated changes in the 
















































































enhance adult hippocampal neurogenesis and to increase expression of BDNF 
(Banasr et al., 2006; Soumier et al., 2009). Importantly, these neurobiological effects 
of agomelatine may, at least partly, depend on its synergistic mechanism of action 
through melatonergic and 5-HT2C receptor sites. It was shown that although 5-HT2C 
antagonists mimic the agomelatine-induced increase in hippocampal cell 
proliferation, they do not reproduce its enhancement of cell survival or of levels of 
BDNF, which are only slightly elevated by melatonin (Soumier et al., 2009). 
Moreover, this antidepressant drug was reported to activate several cellular 
signaling proteins, i.e. extracellular signal-regulated kinase 1/2 (ERK1/2), protein 
kinase B (Akt), and glycogen synthase kinase 3ß (GSK3ß), implicated in the 
antidepressant action (Soumier et al., 2009).  
This information considerably advanced understanding of agomelatine’s action 
in the brain. However, since effects of antidepressant drugs might differ in disturbed 
versus intact systems (Berton and Nestler, 2006), the latter findings under basal 
conditions cannot directly be extrapolated to the therapeutic actions of agomelatine 
in depression. This gap may be partially bridged by applying an animal model 
approach. Therefore, in the experiments described in this thesis, agomelatine was 
administered to chronically stressed rats, in order elucidate its effects under 
conditions that might predispose to mood disorders. 
 
Clinical evidence 
Agomelatine proved to be an effective treatment for major depressive disorder in 
several clinical trials (Kennedy and Rizvi, 2010). However, some of the efficacy trials 
against placebo failed due to an excessively high response rate in the placebo group 
(de Bodinat et al., 2010). Nevertheless, when compared to the SNRI venlafaxine and 
with the SSRI sertraline in clinical studies, agomelatine showed an efficacy at least 
equivalent to these established drugs. In fact, it proved superior to both venlafaxine 
and sertraline in improving sleep and anxiety symptoms as well as in its tolerability 
and safety profile (Lemoine et al., 2007; Kennedy et al., 2008; Kasper et al., 2010). 
Interestingly, one placebo-controlled study suggested a more rapid onset of 
agomelatine action as compared to classical antidepressants, showing that its 
therapeutic effects appeared as early as 2 weeks after treatment initiation (Loo et 
al., 2002). Based on the results of all clinical trials, agomelatine was granted a 
marketing authorization in the European Union in 2009, with the approved 




Yet, the antidepressant efficacy of agomelatine (the response rate of 70-80%) is 
not much better as compared to other pharmacotherapies; hence, the advantage of 
this drug mainly lays in its better tolerability and ability to improve co-morbid 
symptoms of depressive disorder. In consequence, the discovery of agomelatine offers 
a benefit for initiation of treatment and long-term adherence; however, it does not 
abate a need for more efficient medications against major depression. 
 
SCOPE OF THE THESIS 
The overall aim of this study is to investigate the neurobiological changes associated 
with stress, depression and agomelatine treatment. 
Chapter 1 of this thesis describes the neurobiology of stress and depression, and 
reviews various factors that may contribute to development of stress-related 
pathologies. It also provides a brief overview of antidepressant therapy in general, 
and introduces the properties of the novel antidepressant, agomelatine.  
In Chapter 2, the effects of acute and chronic footshock stress on brain 
plasticity are examined, using hippocampal neurogenesis as the main readout. The 
aim of this experimental study is to establish the duration of the stress exposure 
(acute versus chronic) needed to evoke specific changes in hippocampal cell 
proliferation, and the persistence of the achieved effect. In addition, the effects of 
chronic footshock stress on HPA axis activity are investigated, as well as their 
relationship to changes in distinct stages of the neurogenesis process (cell 
proliferation, survival and neuronal differentiation).  
The above described chronic footshock stress model is used in Chapter 3, in 
order to test the effects of the antidepressant agomelatine in the stress-compromised 
brain. Specifically, we examine whether chronic treatment with agomelatine 
influences HPA axis reactivity, and whether it induces changes in hippocampal 
neurogenesis (cell proliferation, survival and neuronal differentiation) and neuronal 
activation. 
Another experimental paradigm, the chronic mild stress model, is used in 
Chapter 4, in order to further characterize the effects of agomelatine on 
hippocampal neurogenesis in the stressed brain. In particular, we investigate 
whether this stress paradigm induces differential changes in distinct stages of the 
neurogenesis process (cell proliferation, survival and neuronal differentiation), and 
whether agomelatine treatment reverses them.  
44 
 
In Chapter 5, we ask whether the action mechanism of agomelatine involves 
modulation of synaptic function. Specifically, the chronic footshock stress model is 
used in order to assess the effects of stress and agomelatine treatment on synapsin I 
expression and its phosphorylation pattern in several brain regions.  
Chapter 6 is devoted to the review of literature regarding involvement of the 
cholinergic system in the pathophysiology of major depressive disorder. There, we 
discuss the contribution of cholinergic changes to the development of mood and 
cognitive impairments associated with depression. In view of this, a potential link 
between the cholinergic system, hippocampal neurogenesis and cognitive dysfunction 
in depression is outlined.  
In Chapter 7, the general implication of the findings described in this thesis is 
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Stressful experiences, especially when prolonged and severe, are associated with 
psychopathology and impaired neuronal plasticity. Among other effects on the brain, 
stress has been shown to negatively regulate hippocampal neurogenesis, and this 
effect is considered to be exerted via glucocorticoids. Here, we sought to determine the 
temporal dynamics of changes in hippocampal neurogenesis after acute and chronic 
exposure to footshock stress. Rats subjected to a footshock procedure showed strong 
activation of the HPA axis, even after exposure to daily stress for 3 weeks. Despite a 
robust release of corticosterone, acute footshock stress did not affect the rate of 
hippocampal cell proliferation. In contrast, exposure to footshock stress daily for 3 
weeks led to reduced cell proliferation 2 hours after the stress procedure. Interestingly, 
this stress-induced effect did not persist and was no longer detected 24 hours later. 
Also, while chronic footshock stress had no impact on survival of hippocampal cells 
that were born before the stress procedure, it led to a decreased number of 
doublecortin-positive granule neurons that were born during the chronic stress period. 
Thus, whereas a strong activation of the HPA axis during acute footshock stress is not 
sufficient to reduce hippocampal cell proliferation, repeated exposure to stressful 
stimuli for prolonged period of time ultimately results in dysregulated neurogenesis. 
In sum, this study supports the notion that chronic stress may lead to cumulative 
changes in the brain that are not seen after acute stress. Such changes may indicate 





Stress is a condition commonly experienced upon demand to adapt to the challenges 
of everyday life (Selye, 1976b). It can be regarded as an alarm process that warns 
about disrupted homeostasis and helps to restore it. Therefore, the stress response 
per se is adaptive (Fuchs et al., 2001). However, unpredictable and uncontrollable 
stress, especially when experienced chronically, may become maladaptive and 
increase brain vulnerability to disease (McEwen, 2004; de Kloet et al., 2005). In 
humans, stress might predispose to the development of affective disorders such as 
major depression (Heim and Nemeroff, 1999; Caspi et al., 2003). 
Patients suffering from depression show changes in the expression of various 
neuronal plasticity markers, e.g., decreased levels of cyclic adenosine monophos-
phate responsive element binding protein (CREB) and brain derived neurotrophic 
factor (BDNF), and altered expression of several fibroblast growth factor (FGF) 
family transcripts (Karege et al., 2005a; Blendy, 2006; Turner et al., 2006). They also 
display morphological changes such as reduced volume of hippocampus and 
prefrontal cortex (Drevets et al., 1997; Sapolsky, 2000; Sheline, 2003). Together 
these findings may indicate an impaired adaptive neural response capacity and 
compromised neuronal plasticity (Krishnan and Nestler, 2008). There is yet little 
known about the mechanisms underlying these changes in depression. 
 Animal models of chronic stress represent a valuable approach to increase our 
understanding of human pathology by providing experimental evidence for changes 
in brain vulnerability under conditions of stress (Fuchs et al., 2001). Such models 
have revealed a wide range of stress-induced effects from changes in gene 
transcription to changes in plasticity processes and morphology in several brain 
regions (Krishnan and Nestler, 2008). The hippocampal formation is one of the brain 
areas that appears to be particularly sensitive to stress. Chronic stress has been 
shown to induce dendritic atrophy of hippocampal CA3 pyramidal neurons 
(Magarinos and McEwen, 1995b, a; Magarinos et al., 1996), suppress neurogenesis 
in the dentate gyrus (Fuchs and Flugge, 1998; Gould and Tanapat, 1999) and lead to 
reduction in hippocampal volume (Czeh et al., 2001; van der Hart et al., 2002). 
Furthermore, prolonged stress proved to modulate genes and molecules implicated in 
neuronal plasticity, e.g. reduce the activation of transcription factor CREB and 
impair neurotrophin signaling, such as BDNF (Rasmusson et al., 2002; Gronli et al., 
2006). Sustained glucocorticoid exposure is suggested as one of the mediators of 
stress responsible in causing these changes (de Kloet et al., 2005). 
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It is generally thought that increased brain vulnerability and pathology may 
arise from stress particularly in the case when stress occurs repeatedly or represents 
a chronic condition. However, little is known about the dynamics of gradual changes 
in the brain initiated by stress (Koolhaas et al., 1997). Only few studies directly 
compare effects of acute stress with repeated or chronic stress and examine the 
persistency of stress-induced alterations (Meerlo et al., 1996; Pham et al., 2003; 
Trentani et al., 2003; Heine et al., 2004c). Since acute stress per se is an adaptive 
response, it is important to establish whether and how chronic stress leads to 
gradually accumulating changes that are not seen after acute stress. 
Adult neurogenesis is a commonly used readout of neuroplasticity. The dentate 
gyrus of the hippocampus is one of the brain areas where new neurons are generated 
in adulthood (Abrous et al., 2005; Ming and Song, 2005). Hippocampal neurogenesis 
has been established in several different species (Gould, 2007), including primates 
(Gould et al., 1999c) and humans (Eriksson et al., 1998). The function of adult 
hippocampal neurogenesis is not completely understood, yet, it is proposed to offer 
enlarged plasticity for shaping the existing neuronal circuitry in response to new 
experiences, and thus contribute to adaptation to environmental changes (Lledo et 
al., 2006; Ge et al., 2008). Reduction in neurogenesis has been implicated in cognitive 
and mood disorders (Kempermann et al., 2004a; Doetsch and Hen, 2005). Many 
studies report that stress, especially when experienced chronically, suppresses one 
or more phases of the adult hippocampal neurogenesis process (Gould and Tanapat, 
1999; McEwen, 1999; Joels et al., 2007; Lucassen et al., 2010). This stress effect on 
neurogenesis has been linked to hormones of hypothalamic-pituitary-adrenal (HPA) 
axis, particularly, to glucocorticoids (Cameron and Gould, 1994; Cameron and 
McKay, 1999). However, the effects of stress on neurogenesis are not consistent and 
may depend on study design and nature of the stressor (Lucassen et al., 2010). Many 
studies have measured effects on neurogenesis at one time-point, often shortly after 
exposure to the stressor (Gould et al., 1997; Gould et al., 1998; Westenbroek et al., 
2004; Kuipers et al., 2006), thereby neglecting the temporal dynamics of the stress 
effect. Yet, it is to be expected that changes in such dynamic process as hippocampal 
neurogenesis, and cell proliferation in particular, might be time-dependent and at 
least partially recover when the stressful experience is over. 
In the present study we examined effects of acute and chronic footshock stress 
on brain plasticity using hippocampal cell proliferation and neurogenesis as the 
main readout. The footshock model we applied is a suitable paradigm for studying 
both acute and chronic stress induced changes in the brain (Trentani et al., 2003). 
Previously, chronic footshock stress was shown to promote HPA axis hyperactivity, 




cascade as well as influence hippocampal neurogenesis (Trentani et al., 2002; 
Kuipers et al., 2003; Trentani et al., 2003; Westenbroek et al., 2004; Kuipers et al., 
2006). However, all these studies report on changes immediately after chronic stress 
and do not examine the dynamics and persistence of stress effects on brain plasticity. 
We here investigated both the duration of the stress exposure (acute vs. chronic) 
needed to evoke specific changes in hippocampal cell proliferation as well as the 
persistence of the achieved effect (2 and 24 hours after stress). First, we established 
whether acute footshock stress is sufficient to induce changes in hippocampal cell 
proliferation, and whether these changes persist. Then, we investigated whether 
chronic stress leads to changes in cell proliferation that are not seen after acute 
stress, and how long these changes last. Since glucocorticoids are important 
mediators of stress effects on the brain, we also examined effects of chronic stress on 
HPA axis activity, and how this is related to changes in neurogenesis. 
 
EXPERIMENTAL PROCEDURES 
Animals and housing 
The experiments were performed with adult (10-12 weeks of age) male Wistar rats 
(Harlan, Horst, The Netherlands) weighing 300-350 g at the beginning of the 
experiment. The animals were housed individually in a climate-controlled room with 
constant temperature (21±1ºC) and a 12 h light / 12 h dark cycle (lights on at 06:00 
h). Food and water was available ad libitum. The experiments were approved by the 
ethical committee for the use of experimental animals of the University of Groningen 
and carried out in accordance with the European Communities Council Directive of 
24 November 1986 (86/609/EEC). 
 
Experimental protocol 
In a first experiment, we examined the effects of an acute, single session of footshock 
stress on HPA axis activity and hippocampal cell proliferation. This experiment was 
performed with three groups of rats: one group of home cage control rats and two 
groups of acutely stressed (AS) rats. The first stress group was sacrificed 2 h after 
the footshock session (AS-2h) and the second stress group was sacrificed 24 h after 
the stress exposure (AS-24h). Each group consisted of 8 animals. 
In a second experiment, we assessed the effects of 3-week chronic intermittent 
footshock stress on a variety of behavioral and physiological measures (HPA axis 
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activity, ultrasonic vocalization, food intake and body weight) as well as different 
aspects of hippocampal neurogenesis (cell proliferation, survival and differentiation). 
This experiment consisted of two series, one in which control and chronically 
stressed (CS) animals were sacrificed 2 h after the last footshock session on day 21 
(CS-2h)  and a second series in which control and stressed animals were sacrificed 24 




During a 2-week acclimatization period before the start of the experiments, all rats 
were weighed and handled daily. Footshock stress was applied in a footshock box 
with a grid floor connected to a shock generator and scrambler (Trentani et al., 
2003). Stress group rats were subjected to either a single session in the footshock box 
(acute stress experiment) or a daily session of footshock stress for 21 consecutive 
days (chronic stress experiment). During the session in the footshock box rats 
received 5 uncontrollable and inescapable footshocks (0.8 mA in intensity and 8 s in 
duration). All footshock sessions took place during the light phase. In the acute 
stress experiment, duration of the footshock session was 20 min with a shock 
interval of 5 min. In the chronic stress experiment, to increase unpredictability and 
minimize habituation, both timing as well as duration of footshock sessions and 
intervals between shocks within a session varied randomly (session starting time: 
between 8:00 and 13:00 h; session duration: 15-80 min; shock interval: 1-15 min), 
with the exception of the sessions on day 1, 8, 15 and 21. On the latter days, all 
animals received footshock sessions of 20 min with shock intervals of 5 min to allow 
standardized behavioral and neuroendocrine measurements. Control rats stayed 
undisturbed in their home cages throughout the experiment. 
 
Neuroendocrine measurements 
In order to determine activation of the HPA axis by footshock stress, and changes 
herein during the chronic stress experiment, blood samples were collected by tail 
bleeding and analyzed for adrenocorticotropic hormone (ACTH) and corticosterone 
(Meerlo et al., 2002). Blood samples were taken in both the acute stress experiment 
and in the chronic stress experiment. In the chronic stress experiment, blood was 
collected on the first and the last day of the chronic stress period. Each time, three 
samples were taken from all stress group rats: baseline (before the footshock 




after the session in the footshock box). Home-cage control rats were sampled once at 
the beginning of the light phase, simultaneously with the stress group rats. Blood 
samples were collected in microcentrifuge tubes containing EDTA as the 
anticoagulant, and kept on ice. Then, blood was centrifuged at 2600 g for 15 min and 
the supernatant stored at −80 °C until radioimmunoassay measurements of ACTH 
and corticosterone were performed.  
 
Ultrasonic vocalization 
Under conditions of stress and pain, rats are known to emit ultrasonic distress calls 
at a frequency of about 22 kHz (Sanchez, 2003). We therefore measured ultrasonic 
vocalization during the entire 20 min footshock session on day 1, 8, 15 and 21 of the 
chronic stress experiment, in order to assess the degree of stress and, possibly, 
habituation to the daily footshock exposure. Each animal was recorded separately 
with a Mini-3 Bat Detector (Ultra Sound Advice, London, UK). 22 kHz ultrasonic 
vocalizations consisting of calls with a minimal duration of 500 ms were recorded 
and analyzed by UltraVox 2.0 program (Noldus, Wageningen, The Netherlands). 
Total time of ultrasonic vocalization was calculated and expressed as a percentage of 
the 20 min footshock session. 
 
BrdU labeling 
In order to study survival of newly-born cells in the hippocampus during chronic 
stress period, rats received an injection of bromodeoxyuridine (BrdU), a synthetic 
analogue of thymidine which is incorporated into newly synthesized DNA of 
replicating cells during the S phase of the cell cycle (Christie and Cameron, 2006). 
New cells were labeled 4 days before the start of the experiment with a single 
intraperitoneal injection with 300 mg/kg BrdU (Sigma, St. Louis, MO, USA). This 
specific time-point of BrdU labeling for studying cell survival was chosen since it was 
shown that labeled progenitor cells stop proliferating after 4 days (Dayer et al., 
2003). Such injection schedule was similarly applied in our laboratory previously 
(Van der Borght et al., 2005b). 
 
Brain collection and immunocytochemistry 
At the end of the experiment, rats were anesthetized with sodium pentobarbital and 
transcardially perfused with heparinized saline followed by 4% paraformaldehyde 
solution in 0.1 M phosphate buffer. Brains were extracted and post-fixed in the same 
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solution overnight at 4°C and subsequently cryoprotected by immersion in a 30% 
sucrose solution for up to 48 h. Coronal serial sections of 30 μm were cut using a 
cryostat and stored in 0.01 M phosphate-buffered saline with 0.1% sodium azide at 
4°C until immunocytochemistry was performed. 
In order to assess effects of acute and chronic footshock stress on different 
aspects of hippocampal neurogenesis, we applied immunocytochemistry for Ki-67, 
doublecortin (DCX), and BrdU. Ki-67 is a nuclear protein which is expressed during 
all phases of the cell cycle, except G0 (Scholzen and Gerdes, 2000), which would 
therefore give an indication of cell proliferation on the last day of the experiment. 
DCX is a protein which is transiently expressed in newly-born but not yet mature 
neurons (Rao and Shetty, 2004), and might therefore reveal changes in neuronal 
differentiation. Finally, since we labeled a pool of new cells with an injection of BrdU 
4 days before the start of the experiment, BrdU immunostaining would indicate 
changes in survival of new cells in the course of the experiment. 
The immunostainings were performed on free-floating sections under continuous 
agitation. BrdU immunocytochemistry required extra steps for DNA denaturation. 
For this purpose, sections were exposed to 2x saline sodium citrate (2xSSC) 
containing 50% formamide for 30 min at 65° C, followed by a rinse with 2xSSC, 
incubation with 2 M HCl for 30 min at 37° C and a washing step with 0.1 M borate 
buffer. Brain sections for all three immunostainings were preincubated in 3% normal 
serum and 0.1% TritonX-100, and then incubated with one of the following 
antibodies for 60 h at 4°C: primary mouse-anti-Ki-67 (1:200; Monosan, Uden, The 
Netherlands), goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) or rat-anti-BrdU (1:800; Serotec, Oxford, UK). Subsequently, sections were 
rinsed in 0.01 M Tris-buffered saline and incubated for 2 h at room temperature with 
secondary biotinylated goat anti-mouse, rabbit anti-goat or donkey anti-rat antibody 
depending on the primary antibody host (1:500 for all secondary antibodies, Jackson 
ImmunoResearch Suffolk, UK). Then, avidin-biotin complex (1:500, Vector ABC kit, 
Vector Laboratories, Burlingame, CA, USA) was added for 2 h, after which the 
staining was visualized with 1 mg/ml diaminobenzidine and 0.003% H2O2. 




All analyses were performed by an observer blind to the group assignment. Ki-67 
and BrdU positive cells were counted in the subgranular zone (SGZ) and granular 




under 500× magnification. Immunopositive cells that were located one cell diameter 
away from SGZ were also included in the analysis. The number of immunopositive 
cells in each section was expressed relative to the length of the dentate gyrus in 
order to correct for variation in size of the hippocampus along the rostro-caudal axis 
of the brain. The length of the dentate gyrus was measured by delineating the entire 
SGZ in each hippocampus. The results were presented as the number of 
immunopositive cells per mm of the dentate gyrus. DCX immunoreactivity in cell 
bodies and dendrites of the newly generated neurons was measured by a method 
adapted from previous studies (Van der Borght et al., 2007; Van der Borght et al., 
2009). Optical density (OD) of DCX expression was measured in the DG and 
corrected for non-specific background labeling, which was measured in the corpus 
callosum. In total, 7-8 sections per animal (Bregma –2.80 to –6.30, according to the 
rat brain atlas, Paxinos & Watson, 2nd edition) were analyzed by delineating a 
similarly sized area covering the entire width of SGZ and GCL in each hippocampus. 
Images were taken using a Leica charged-coupled device digital camera mounted on 
a microscope (DMIRB, Leica, Cambridge, UK) at 100× magnification. The OD was 
expressed in arbitrary units corresponding to grey levels using a Quantimet 550 
image analysis system (Leica, Cambridge, UK). In all three stainings, dorsal and 
ventral hippocampi were analyzed separately. Since no differences were detected, 
the data were pooled in order to present effects in the entire hippocampus. 
Additionally, to verify if changes in OD of DCX expression correspond to changes in 
the number of DCX-positive neurons, we counted the number of DCX-positive cells in 
the dentate gyrus. DCX-positive cells were quantified under 500× magnification in 3 
sections of dorsal hippocampus per animal (Bregma –2.80 to –4.30, according to the 
rat brain atlas, Paxinos & Watson, 2nd edition). The reason for counting DCX-
positive neurons in dorsal hippocampus only was a big variation in size and shape of 
dentate gyrus in ventral hippocampus. The number of DCX-positive cells was 
expressed relative to the length of the dentate gyrus as described above for Ki-67 
and BrdU immunostainings. 
 
Statistics 
One-way ANOVA was used to analyze the effects of stress on hippocampal 
neurogenesis. Repeated measures ANOVA was used to analyze the ACTH and 
corticosterone responses in stress group animals, as well as baseline values in both 
control and stress group animals across two days in the chronic stress experiment. 
Food intake and body weight gain data were analyzed by repeated measures ANOVA 
as well. When appropriate, Tukey HSD test was used for post-hoc analysis. Time of 
ultrasonic vocalization on the first and the last day of the chronic stress period was 
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compared by nonparametric Wilcoxon Signed Ranks test because of unequal 
variances in the sample groups. 
 
RESULTS 
ACTH and corticosterone levels 
Changes in plasma ACTH and corticosterone concentrations in response to footshock 
exposure in both the acute and chronic stress experiments are shown in figure 2.1. 
Baseline ACTH and corticosterone levels did not differ among control and stress 
groups in both experiments. As expected, footshock stress induced a robust HPA axis 
activation.  
In the first experiment, when animals were exposed to a single session of 
footshocks, ACTH and corticosterone reached peak levels of about 1100 pg/ml and 
450 ng/ml, respectively (repeated measures ANOVA, treatment effect: ACTH:  




Figure 2.1 Plasma concentrations of ACTH and CORT in response to acute and chronic footshock stress. 
Exposure to footshock significantly elevated both ACTH (A, B, C) and CORT (D, E, F) levels as compared to 
baseline values (p<0.001). In the chronic stress experiment, peak ACTH and CORT responses on day 1 (B, E) 




Upon cessation of the stress session and return to the home cage, ACTH levels 
decreased but did not reach baseline values after 30 min (recovery vs. baseline: 
p<0.01; recovery vs. stress: p<0.001). Corticosterone values, on the other hand, 
remained high and were not yet lower than immediately after the stress (recovery 
vs. baseline: p<0.001; recovery vs. stress p>0.05). There were no differences in ACTH 
or corticosterone levels between the two acute stress groups at any time point. 
In the case of chronic footshock stress, similar patterns of ACTH and 
corticosterone increase were observed on day 1 and 21 of the experiment (repeated 
measures ANOVA, treatment effect: ACTH: F(5,35)=51.77, p<0.001; CORT: 
F(5,35)=46.27, p<0.001; stress vs. baseline: p<0.001). Importantly, the peak ACTH and 
corticosterone levels at the end of the 20-min stress session did not differ between 
the first and the last day of the experiment. However, upon removal from the 
footshock box and return to the home cage, HPA axis activity seemed to return to 
baseline faster on the last day of the experiment. Particularly, on day 21 of the 
experiment, corticosterone levels after 30 min recovery were significantly lower than 
the 30-min recovery levels after the first shock session on day 1 (p=0.022). 
 
Ultrasonic vocalization 
Exposure to the footshock stress induced massive ultrasonic vocalization (figure 2.2). 
While control rats never vocalized at 22 kHz in their home cage, most stressed rats 
vocalized throughout the entire 20 min session in the footshock box. Importantly, in 
line with the peak HPA axis response, the immediate response to the footshock 
stress in terms of vocalization did not habituate in the course of the 3-week stress 
protocol. In fact, time of ultrasonic vocalization in stressed rats by the end of the 
chronic stress period was somewhat increased. However, due to large variation, this 
effect was not statistically significant (Wilcoxon Signed Ranks test: p=0.093, day 1 
vs. day 21).  
 
Food intake and body weight 
Food intake and body weight were measured from day –4 to day 22 of the chronic 
stress experiment. Food intake and growth rates of control and stress group animals 
were similar during the acclimatization period. However, during the 3-week stress 
period chronically stressed rats ate significantly less and consumed 19.3±0.3 g of 
food per day vs. 23.1±0.3 g in control animals (time x treatment interaction: 
F(20,280)=1.78,  p=0.02).  At  the  beginning of  the  experiment, average body weight of 
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Figure 2.2 Ultrasonic vocalization during a 
20-min footshock session on different days of 
the chronic stress period. Control rats did not 
get a footshock and did not vocalize in their 






control and stress group rats was 331.3±3.2 g and 333.9±5.0 g respectively. Chronic 
footshock stress significantly reduced body weight gain (time x treatment 
interaction: F(20,280)=7.32, p<0.001). In the course of the 3-week experiment, control 
rats gained a total of 68.3±4.9 g in body weight whereas stressed rats gained only 
35.3±5.4 g. 
 
Hippocampal cell proliferation 
In the first experiment, there was no difference in the number of Ki-67 positive cells 
among the groups after a single footshock session (F(2,21)=0.92, p=0.41). Acute 
footshock stress did not influence the rate of cell proliferation, neither 2 hours (figure 
2.3A) nor 24 hours (figure 2.3B) after stress. In contrast, the rate of cell proliferation 
in chronically stressed rats was significantly reduced 2 hours after the last exposure 
to footshock (figure 2.3C, F(1,14)=7.36, p=0.017). The number of proliferating cells 
recovered and had returned to control levels 24 hours after the last stress session 
(figure 2.3D, F(1,14)=2.43, p=0.14). 
 
Survival and differentiation of new hippocampal cells 
The brains of chronically stressed rats that were sacrificed 24 hours after the last 
footshock session were subsequently used to investigate chronic stress-induced 
changes on other aspects of hippocampal neurogenesis, such as cell survival and 
differentiation. We found that chronic footshock stress did not influence survival of 
cells that were born before the stress procedure (figure 2.4A) as there was no 





Figure 2.3 Effect of acute and chronic footshock stress on hippocampal cell proliferation as assessed by Ki-
67 immunocytochemistry. The number of Ki-67-positive cells in the dentate gyrus was not significantly 
affected after a single footshock session, neither immediately after the stressor (A) nor 24 h later (B). In 
contrast, cell proliferation rate was significantly reduced 2 h (C) but not 24 h (D) after exposure to the last 
session of chronic footshock stress. *p<0.05. 
 
p=0.83). However, chronic footshock stress significantly reduced the optical density 
of DCX expression in the dentate gyrus (figure 2.4B, F(1,12)=28.02, p<0.001). Further 
analysis revealed that chronic stress significantly decreased the number of DCX-




This study shows that footshock stress leads to strong activation of the HPA axis, 




Figure 2.4 Effect of chronic footshock stress 
on hippocampal cell survival and newly-born 
immature neurons. Chronic footshock stress did 
not affect survival of cells labeled with BrdU 
before the stress procedure (A). However, it 
significantly reduced optical density of DCX 
expression in the dentate gyrus (B) and 
decreased the number of DCX-positive neurons 
born during the chronic stress period (C). 

















in corticosterone, a single session of footshock stress did not affect hippocampal cell 
proliferation. However, repeated exposure to footshock stress caused a temporary 
suppression in the number of Ki-67-positive proliferating cells in the dentate gyrus. 
In line with this, we also observed a chronic stress-induced reduction in DCX 
expression corresponding to a decreased number of DCX-positive neurons. This 




hippocampal neurogenesis may be subtle and only visible after chronic exposure to 
the stressor.  
Although many studies suggest that stress results in reduced rates of adult 
hippocampal neurogenesis, these effects are by no means consistent (Banasr and 
Duman, 2007; Lucassen et al., 2010). In the case of acute and brief stress exposure, 
some studies show a rapid decrease in hippocampal cell proliferation (Gould et al., 
1997; Gould et al., 1998; Tanapat et al., 2001; Vollmayr et al., 2003; Heine et al., 
2004c; Shors et al., 2007; Koo and Duman, 2008), whereas others fail to observe such 
changes (Pham et al., 2003; Thomas et al., 2006; Yap et al., 2006; Thomas et al., 
2007) or suggest that they are short lasting (Heine et al., 2004c), dependent on 
animal species (Bain et al., 2004), strain (Veenema et al., 2007) or gender (Falconer 
and Galea, 2003). The negative impact of stress on neurogenesis appears to be more 
pronounced and consistent after prolonged and chronic exposure to a stressor, 
although the effects on different stages of neurogenesis may still vary. Some chronic 
stress studies fail to detect changes in hippocampal cell proliferation (Lee et al., 
2006; Oomen et al., 2007; Snyder et al., 2009), differentiation (Heine et al., 2004c; 
Lee et al., 2006) or cell survival (Pham et al., 2003; Heine et al., 2004c). Such 
variability may depend on sensitivity of the individual animal (e.g., genes or gender) 
or on the nature of the stressor (intensity, duration, quality), or even on details of 
the study design. Our data show that suppression of cell proliferation after chronic 
footshock stress is significant but short-lasting and may easily go undetected in 
experiments where brains are not collected immediately after stress. As such it 
supports the suggestion that a lack of chronic stress effect on cell proliferation may 
be due to delay between the final stress exposure and sacrifice of the animal (Snyder 
et al., 2009). In our study, chronic footshock stress had no effect on survival of 
hippocampal cells that were born several days before the start of the chronic stress 
protocol. Importantly, we cannot definitely conclude that our footshock stress does 
not affect survival of cells that are born during the chronic stress period. 
Furthermore, a recent study, in which hippocampal cells were also labeled before the 
start of stress procedure, reported that chronic stress increased survival of 14-day 
old cells, but did not affect survival of 21-day old cells (Snyder et al., 2009). Again, 
this shows that subtle changes in the study design may explain some of the variation 
in the literature.  
Our data reveal that chronic footshock stress temporarily suppresses cell 
proliferation. A recent study reported that chronic stress increases the expression of 
p27Kip1, an endogenous cell cycle inhibitor, in SGZ of the dentate gyrus, thus 
suggesting that stress might cause cell cycle arrest (Heine et al., 2004a). We propose 
that such inhibition of cell proliferation (or cell cycle arrest) may occur after each 
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stress exposure, however, it is yet negligible after a single footshock session and 
becomes evident only after repeated stress. Such gradually developing and transient 
reductions in the production of new cells in the course of chronic stress, while they 
may easily go unnoticed, may have consequences in the long run. Our data show that 
chronic stress is associated with a reduction in expression of DCX, a marker of 
newly-born immature neurons, which may reflect abnormal neuronal differentiation. 
We confirmed that the reduction in OD of DCX expression in the dentate gyrus 
corresponded to a decreased number of DCX-positive neurons, thus verifying OD 
measurement as a reliable method to determine changes in the number of DCX-
positive cells. Our data are not fully conclusive as to whether the changes in DCX-
positive neuron population are due to decreased cell proliferation, survival, or 
changes in maturation of young neurons, or even due to combination of these causes. 
In our experiment, the transient reduction in generation of new cells by the end of 
the chronic stress period is a likely cause since fewer cells born after stress may yield 
fewer young neurons. Although a stress-induced decrease in the number of DCX-
positive cells has been reported by other studies in the field (Lemaire et al., 2006; 
Oomen et al., 2007; Jayatissa et al., 2008; Lucassen et al., 2009), its mechanism and 
functional meaning is far from being well understood. Yet, these data support the 
notion that chronic stress impairs hippocampal neurogenesis.  
A striking observation was that a single and acute exposure to footshock stress 
did not affect cell proliferation, despite a robust increase in corticosterone. The lack 
of change in numbers of proliferating cells after acute footshock stress, measured by 
Ki-67 labeling, was confirmed by BrdU immunostaining (Dagyte, unpublished data). 
This finding seems in contrast with other reports showing effects of acute stress on 
neurogenesis and the suggestion that such effects are mediated by glucocorticoids 
(Cameron and Gould, 1994; Tanapat et al., 2001; Mirescu and Gould, 2006). 
Apparently, the role of glucocorticoids in regulation of neurogenesis is not simple 
and direct. Although an increase in corticosteroid levels seems to be necessary for 
effects of stress on neurogenesis, it is, however, not sufficient and does not strictly 
correlate with the effect on newly-generated cells. Importantly, in some situations, 
raised glucocorticoid levels are not associated with a suppression of hippocampal cell 
proliferation or may even be accompanied with an increase in the number of new 
cells, e.g., in the case of voluntary exercise (van Praag et al., 1999), environmental 
enrichment (Kempermann et al., 2002) or after training in certain learning 
paradigms (Van der Borght et al., 2005b). Also, while several studies have reported a 
suppression of cell proliferation after acute and brief stress exposure, it seems 
unlikely that this is a direct glucocorticoid effect since other studies, including our 
own, show no effect on cell proliferation, despite a robust increase in corticosterone 




corticoid receptors are barely expressed on hippocampal precursor cells (Cameron et 
al., 1993; Garcia et al., 2004) further suggests that corticosteroids act via indirect 
pathways, possibly through glutamate and N-methyl-D-aspartate (NMDA) receptor 
dependent mechanisms (Mirescu and Gould, 2006).  
Although the diverse effects of stress on different aspects of neurogenesis cannot 
solely be explained by elevated glucocorticoids, they may still play a role in the 
effects of chronic stress that we found. Our data show that chronic stress has a 
negative impact on hippocampal cell proliferation and neuronal maturation which 
may be a cumulative effect of glucocorticoids, achieved via changes in gene 
expression and transcription (de Kloet et al., 2005). 
The rather mild effects on hippocampal neurogenesis observed in our footshock 
stress model compared to some other stress models might also be explained by the 
distinct stress response due to footshock. While activation of the sympathetic 
nervous system and HPA axis is common to most stressors, other physiological 
changes may greatly vary between stressors. For instance, footshock stress increases 
plasma ß-endorphin levels much more robustly than restraint stress (Tsukada et al., 
2001). Given that ß-endorphin positively regulates cell proliferation (Persson et al., 
2003; Koehl et al., 2008), the higher amounts of ß-endorphin released in response to 
footshock stress may thus counteract the negative stress effect on hippocampal 
progenitor cells. Stressor-specific effects have been observed in a variety of other 
processes, such as release of steroid hormones (Andersen et al., 2004) and pro-
inflammatory cytokines (Deak et al., 2005). How such differences contribute to the 
effects of stress on neurogenesis remains to be established but they may explain 
some of the variation between stress studies. This also suggests that various 
molecules released in response to stress act in concert to shape the final overall 
stress effect on hippocampal neurogenesis. 
In conclusion, we have shown that acute footshock stress, although associated 
with a robust increase in corticosterone, did not affect the rate of hippocampal cell 
proliferation. In contrast, daily exposure to footshock stress for 3 weeks resulted in a 
transient suppression of cell proliferation and a significant decrease in the number of 
DCX-positive neurons. Although the impact of footshock stress on hippocampal 
neurogenesis appeared to be modest, in the long run such small and temporary 
effects on cell proliferation after each stressor may add up to a major reduction in 
the pool of new neurons which might compromise hippocampal circuitry. Together, 
this study supports the notion that chronic stress may lead to cumulative changes in 
the brain that are not seen after a single stress event. Such changes may indicate 
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Agomelatine is a novel antidepressant which acts as a melatonergic (MT1/MT2) 
receptor agonist and serotonergic (5-HT2C) receptor antagonist. The antidepressant 
properties of agomelatine have been demonstrated in animal models as well as in 
clinical studies. Several preclinical studies reported agomelatine-induced effects on 
brain plasticity, mainly under basal conditions in healthy animals. Yet, it is 
important to unravel agomelatine-mediated changes in the brain affected by 
psychopathology or exposed to conditions that might predispose to mood disorders. 
Since stress is implicated in the etiology of depression, it is valid to investigate 
antidepressant-induced effects in animals subjected to chronic stress. In this context, 
we sought to determine changes in the brain after agomelatine treatment in 
chronically stressed rats. Adult male rats were subjected to footshock stress and 
agomelatine treatment for 21 consecutive days. Rats exposed to footshock showed a 
robust increase in adrenocorticotropic hormone (ACTH) and corticosterone. Chronic 
agomelatine treatment did not markedly influence this HPA-axis response. Whereas 
chronic exposure to daily footshock stress reduced c-Fos expression in the 
hippocampal dentate gyrus, agomelatine treatment reversed this effect and 
normalized neuronal activity to basal levels. Moreover, chronic agomelatine 
administration was associated with enhanced hippocampal cell proliferation and 
survival in stressed but not in control rats. Furthermore, agomelatine reversed the 
stress-induced decrease in doublecortin expression in the dentate gyrus. Taken 
together, these data show a beneficial action of agomelatine in the stress-compromised 
brain, where it restores stress-affected hippocampal neuronal activity and promotes 





Affective disorders, such as major depression, represent a serious health problem 
with long-lasting consequences for both patients and society (Greden, 2001). 
Antidepressants, firstly discovered by serendipity, revolutionized the treatment of 
mood disorders (Nestler et al., 2002b). Yet, more than half a century later, the 
treatment of these disorders remains a challenge. Only about 50% of depressed 
patients treated with currently available medications achieve complete remission 
(Nestler et al., 2002a; Fagiolini and Kupfer, 2003). Moreover, rather poor tolerability 
of antidepressant drugs and late onset of their therapeutic effects further increase 
the risk of unsuccessful treatment (Berton and Nestler, 2006). Altogether, this urges 
the introduction of newer medications with fundamentally different mechanisms of 
action than the older agents.  
Agomelatine is a novel antidepressant which acts as a potent melatonergic (MT1 
and MT2) receptor agonist (Audinot et al., 2003) and serotonergic (5-HT2C) receptor 
antagonist (Millan et al., 2003). Current literature indicates that the therapeutic 
actions of agomelatine are mediated at least partly through different mechanisms 
than selective serotonin reuptake inhibitors (SSRI) or tricyclics (Hanoun et al., 
2004). For example, some of its effects may involve modulation of circadian rhythms 
and changes in sleep-wake cycle (Tuma et al., 2005; Kasper and Hamon, 2009). The 
antidepressant properties of agomelatine have been demonstrated both in animal 
models (Papp et al., 2003; Bourin et al., 2004; Barden et al., 2005; Bertaina-Anglade 
et al., 2006) and in clinical studies (Loo et al., 2002; Kennedy and Emsley, 2006; 
Pandi-Perumal et al., 2006a; Olie and Kasper, 2007; Goodwin et al., 2009). Yet, the 
effects of agomelatine merit further investigation. 
Beneficial effects of antidepressant drugs are observed in depressed patients but 
not in healthy volunteers, suggesting that the neurochemical effects of anti-
depressants might differ in disturbed versus intact systems (Berton and Nestler, 
2006). Therefore, it is important to unravel agomelatine-mediated changes in the 
brain affected by psychopathology (clinical studies) or exposed to conditions that 
might predispose to mood disorders (animal models). It therefore seems a suitable 
approach to apply agomelatine treatment in chronically stressed animals, in order to 
reliably explore its beneficial actions and mechanisms behind them.  
Stress, especially when severe and prolonged, is one of the major predisposing 
risk factors for developing depression (Kendler et al., 1999; Paykel, 2001). Animal 
models of chronic stress provide a valuable tool to investigate behavioral, endocrine 
and neurobiological changes underlying stress-related psychopathologies and 
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mechanism of antidepressant therapies (Fuchs et al., 2001; Nestler et al., 2002b). 
Such models have revealed a variety of stress-induced effects in the brain, such as 
impaired neurotrophin signaling (Rasmusson et al., 2002; Gronli et al., 2006), 
atrophy of hippocampal CA3 pyramidal neurons (Magarinos et al., 1996), reduced 
synaptic plasticity (Joels et al., 2009) and suppressed neurogenesis in the dentate 
gyrus (Fuchs and Flugge, 1998; Gould and Tanapat, 1999). Together, these changes 
have been suggested to play a role in the development of neuronal dysfunctions and 
ultimately increase one’s vulnerability to psychopathology (Krishnan and Nestler, 
2008). One of the brain areas particularly sensitive to stress is the hippocampus, a 
region involved in cognition, mood and neuroendocrine stress reactivity. There is a 
large body of data supporting the notion that the hippocampus plays a role in 
depression and the action of antidepressant drugs (Alfonso et al., 2005). The 
hippocampus is also one of the few regions of the brain where new neurons are 
generated in adulthood (Abrous et al., 2005; Ming and Song, 2005). Hippocampal 
neurogenesis has been established in several different species (Gould, 2007), 
including primates (Gould et al., 1999c) and humans (Eriksson et al., 1998). During 
the last decade, numerous studies focused on the hypothesis that changes in 
hippocampal neurogenesis and plasticity in general contribute to the etiology of 
depression as well as to the action of antidepressant drugs (Jacobs et al., 2000; 
Duman, 2004b; Fuchs et al., 2004; Drew and Hen, 2007; Lucassen et al., 2010). 
Preclinical studies suggest that antidepressants may exert their therapeutic effects 
by enhancing neurotrophin signaling and promoting the formation of new 
hippocampal neurons as well as new synaptic connections in the brain (Castren, 
2004a; Duman, 2004a). Such effects have been described for many antidepressant 
treatments, including serotonin- and norepinephrine-enhancing drugs (Malberg et 
al., 2000; Manev et al., 2001), electroconvulsive seizures (Madsen et al., 2000), and 
lithium (Chen et al., 2000). In agreement with this, also the novel antidepressant 
agomelatine promotes hippocampal neurogenesis under basal conditions (Banasr et 
al., 2006; Soumier et al., 2009).  
In the present study we used a chronic footshock stress model in order to test the 
effects of agomelatine under conditions of severe and prolonged stress. This 
footshock model was previously shown to promote HPA-axis hyperactivity, induce 
robust changes in gene expression in stress-related brain areas, target intracellular 
signaling cascades involved in neuronal plasticity and affect hippocampal 
neurogenesis (Trentani et al., 2002; Kuipers et al., 2003; Trentani et al., 2003; 
Westenbroek et al., 2004; Kuipers et al., 2006; Dagyte et al., 2009). Here we 
investigated whether treatment with agomelatine is effective in the brain, exposed to 
chronic stress. First, we examined whether daily treatment with agomelatine for 21 




order to gain further insight in the processes targeted by stress and antidepressant 
therapy, we investigated whether agomelatine induced changes in neuronal activity 
as well as hippocampal neurogenesis. 
 
EXPERIMENTAL PROCEDURES 
Animals and housing 
The experiments were performed using adult (10-12 weeks of age) male Wistar rats 
(Harlan, Horst, The Netherlands) weighing 300-350 g at the beginning of the 
experiment. The animals were housed individually in a climate-controlled room with 
constant temperature (21±1ºC) and a 12 h light / 12 h dark cycle (lights on at 06:00 
h). Food and water was available ad libitum. The experiments were approved by the 
ethical committee for the use of experimental animals of the University of Groningen 
and carried out in accordance with the European Communities Council Directive of 
24 November 1986 (86/609/EEC). 
 
Experimental protocol 
Four groups of rats were used for the present experiments: two groups of home cage 
control rats (CTR), which were treated either with vehicle (CTR Veh) or agomelatine 
(CTR Ago), and two groups of chronically stressed rats (STR), which were also 
treated either with vehicle (STR Veh) or agomelatine (STR Ago). Each group 
consisted of 8 animals. The home cage control rats were sacrificed concomitantly 
with the stressed rats which were euthanized 24 h after the last footshock exposure. 
 
Stress procedure 
During a 2-week acclimatization period before the start of the experiments, all rats 
were weighed and handled daily. Footshock stress was applied in a footshock box 
with a grid floor connected to a shock generator and scrambler (Trentani et al., 2003; 
Dagyte et al., 2009). Stress group rats were subjected to a daily session of footshock 
stress for 21 consecutive days. During the session in the footshock box rats received 
5 uncontrollable and inescapable footshocks (0.8 mA in intensity and 8 s in 
duration). All footshock sessions took place during the light phase. In order to 
increase unpredictability and minimize habituation, both timing and duration of 
footshock sessions as well as intervals between shocks within a session varied 
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randomly (session starting time: between 08:00 and 13:00 h; session duration: 15-80 
min; shock interval: 1-15 min), with the exception of the sessions on day 1, 11 and 
21. On these days, all animals received footshock sessions of 20 min with shock 
intervals of 5 min to allow standardized neuroendocrine measurements. Control rats 
stayed undisturbed in their home cages throughout the experiment. 
  
Drug treatment 
1% hydroxyethylcellulose (HEC) was used as a vehicle for agomelatine delivery. 
Agomelatine solution was prepared every day by dissolving agomelatine powder in 
1% HEC at a concentration of 40 mg/ml. The choice of the agomelatine dose was 
made on the basis of its activity at this concentration in animal models of depression 
and anxiety (Papp et al., 2003; Millan et al., 2005), and on neurogenesis (Banasr et 
al., 2006; Soumier et al., 2009). Rats were injected intraperitoneally either with 




In order to determine activation of the HPA-axis by footshock stress and changes 
herein during the experiment, blood samples were collected by tail bleeding and 
analyzed for adrenocorticotropic hormone (ACTH) and corticosterone (Meerlo et al., 
2002). Blood was collected on day 1, 11 and 21 of the chronic stress period. Each 
time, three samples were taken from all stress group rats: baseline (before the 
footshock procedure), stress (at the end of the 20-min footshock session), and 
recovery (30 min after the session in the footshock box). Home-cage control rats were 
sampled once at the beginning of the light phase, simultaneously with the stress 
group rats. Blood samples were collected in microcentrifuge tubes containing EDTA 
as the anticoagulant, and kept on ice. Then, blood was centrifuged at 2600 g for 
15 min and the supernatant stored at −80 °C until radioimmunoassay measure-
ments of ACTH and corticosterone were performed. 
  
BrdU labeling 
In order to study survival of newly-born cells in the hippocampus during the 
experiment, rats received an injection of bromodeoxyuridine (BrdU: Sigma, St. Louis, 
MO, USA), a synthetic analogue of thymidine which is incorporated into newly 




and Cameron, 2006). New cells were labeled 4 days before the start of the experi-
ment with a single intraperitoneal injection (300 mg/kg). This specific time-point of 
BrdU labeling for studying cell survival was chosen since it was shown that labeled 
progenitor cells stop proliferating after 4 days (Dayer et al., 2003). Such an injection 
schedule was similarly applied in our laboratory previously (Van der Borght et al., 
2005b; Dagyte et al., 2009). 
 
Brain collection & immunohistochemistry 
At the end of the experiment, 24 h after the last stress session and 18 h after the last 
agomelatine injection, rats were anesthetized with sodium pentobarbital and 
transcardially perfused with heparinized saline followed by 4% paraformaldehyde 
solution in 0.1 M phosphate buffer. Brains were extracted and post-fixed in the same 
solution overnight at 4°C and subsequently cryoprotected by immersion in a 30% 
buffered sucrose solution for up to 48 h. Coronal serial sections of 30 μm were cut 
using a cryostat and stored in 0.01 M phosphate-buffered saline with 0.1% sodium 
azide at 4°C until immunohistochemistry was performed. 
In order to assess effects of agomelatine and chronic footshock stress on different 
aspects of hippocampal neurogenesis, immunohistochemistry for Ki-67, doublecortin 
(DCX), and BrdU was performed. Ki-67 is a nuclear protein which is expressed 
during all phases of the cell cycle, except G0 (Scholzen and Gerdes, 2000), which 
would therefore give an indication of cell proliferation on the last day of the 
experiment. DCX protein is expressed in newly-born cells from 1 day to about 4 
weeks of age, and might therefore reveal sustained changes in the neurogenesis 
process and its modulation (Brown et al., 2003; Rao and Shetty, 2004). Finally, since 
a pool of newborn cells was labeled with an injection of BrdU 4 days prior to the 
start of the experiment, BrdU immunostaining would indicate changes in survival of 
new cells in the course of the experiment. 
Effects of agomelatine and chronic footshock stress on neuronal activity were 
assessed by immunohistochemistry for the immediate early gene c-Fos (Kovacs, 
1998; Hoffman and Lyo, 2002).  
The immunostainings were performed on free-floating sections under continuous 
mild agitation. BrdU immunohistochemistry required extra steps for DNA 
denaturation. For this purpose, sections were exposed to 2x saline sodium citrate 
(2xSSC) containing 50% formamide for 30 min at 65°C, followed by a rinse with 
2xSSC, incubation with 2 M HCl for 30 min at 37°C and a washing step with 0.1 M 
borate buffer. Brain sections for all four immunostainings were preincubated in 3% 
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normal serum and 0.1% TritonX-100, and then incubated with one of the following 
antibodies for 60 h at 4°C: primary mouse-anti-Ki-67 (1:200; Monosan, Uden, The 
Netherlands), goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), rat-anti-BrdU (1:800; Serotec, Oxford, UK) or rabbit-anti-c-Fos (1:10000; 
Calbiochem, Darmstadt, Germany). Subsequently, sections were rinsed in 0.01 M 
Tris-buffered saline and incubated for 2 h at room temperature with secondary 
biotinylated goat-anti-mouse, rabbit-anti-goat, donkey-anti-rat or goat-anti-rabbit 
antibody depending on the primary antibody host (1:500 for all secondary antibodies, 
Jackson ImmunoResearch Suffolk, UK). Then, avidin-biotin complex (1:500, Vector 
ABC kit, Vector Laboratories, Burlingame, CA, USA) was added for 2 h, after which 
the staining was visualized with 1 mg/ml diaminobenzidine and 0.003% H2O2. 
Thereafter, sections were rinsed, mounted on slides, dehydrated and coverslipped for 
microscopic analysis. Due to technical problems, brain sections of two animals were 
excluded from DCX and c-Fos immunostainings. 
 
Quantification 
All analyses were performed by an observer blind to the group assignment. Ki-67 
and BrdU positive cells were counted in the subgranular zone (SGZ) and granular 
cell layer (GCL) of the dentate gyrus in every twelfth section of the hippocampus 
under 500× magnification. Immunopositive cells that were located one cell diameter 
away from SGZ were also included in the analysis. The number of immunopositive 
cells in each section was expressed relative to the length of the dentate gyrus in 
order to correct for variation in size of the hippocampus along the rostro-caudal axis 
of the brain. The length of the dentate gyrus was measured by delineating the entire 
SGZ in each hippocampus. DCX immunoreactivity (ir) in cell bodies and dendrites of 
the newly generated cells was measured by a previously described method (Dagyte et 
al., 2009). Briefly, optical density (OD) of DCX expression was measured in the DG 
and corrected for non-specific background labeling, which was measured in the 
corpus callosum. In total, 7-8 sections per animal (Bregma –2.56 to –6.30, according 
to the rat brain atlas, Paxinos & Watson, 2nd edition) were analyzed by delineating a 
similarly sized area covering the entire width of SGZ and GCL in each hippocampus. 
Images were taken using a Leica charged-coupled device digital camera mounted on 
a microscope (DMIRB, Leica, Cambridge, UK) at 100× magnification. The OD was 
expressed in arbitrary units corresponding to grey levels using a Quantimet 550 
image analysis system (Leica, Cambridge, UK). In all three stainings, dorsal and 
ventral hippocampi were analyzed separately. When similar changes in the dorsal 
and ventral parts of hippocampus were detected, these data were pooled and effects 




c-Fos positive cells were quantified in 3 hippocampal regions of interest (ROI): 
CA1, CA3 and dentate gyrus (DG). In total, 4-5 sections per animal (Bregma –2.56 to 
–4.52, according to the rat brain atlas, Paxinos & Watson, 2nd edition) were analyzed 
by counting immunoreactive cell nuclei in each ROI. Images were taken using a 
Leica charged-coupled device digital camera mounted on a microscope (DMIRB, 
Leica, Cambridge, UK) at 50× magnification. Positive cell nuclei above the 
background threshold in each ROI were counted using a Quantimet 550 image 
analysis system (Leica, Cambridge, UK) and the data were reported as the number 
of positive cells / 0.1 mm2. 
 
Statistics 
Two-way ANOVA was used to analyze the effects of stress and agomelatine 
treatment on hippocampal neurogenesis and neuronal activation. Repeated 
measures ANOVA was used to analyze the ACTH and corticosterone responses in 
stress group animals, as well as baseline values in both control and stress group 
animals across three days. Food intake and body weight gain data were analyzed by 
repeated measures ANOVA. When appropriate, the Fisher LSD test was used for 
post-hoc analysis.  
 
RESULTS 
Food intake and body weight 
Food intake and body weight were measured from day –4 to day 22 of the 
experiment. All rats ate and grew at similar rates during the acclimatization period. 
Chronic footshock stress reduced food intake (repeated measures ANOVA, time x 
stress interaction: F(20,560)=22.02, p<0.001), whereas agomelatine had no significant 
effect (figure 3.1A). In contrast, body weight gain was strongly reduced by both 
chronic stress and agomelatine treatment (repeated measures ANOVA, time x stress 








Figure 3.1 Changes in 
cumulative food intake and 
body weight gain in rats 
subjected to chronic stress 
and/or agomelatine treatment 
for 21 days. Exposure to the 
footshock stress significantly 
reduced food intake in both 
rats treated with agomelatine 
and vehicle (A). Both footshock 
stress and agomelatine treat-
ment significantly reduced 













ACTH and corticosterone levels 
Changes in plasma ACTH and corticosterone concentrations in response to footshock 
exposure and agomelatine treatment are shown in figure 3.2. Baseline ACTH and 
corticosterone levels did not differ among the groups. As expected, footshock stress 
induced a robust HPA-axis activation (repeated measures ANOVA, stress effect: 
ACTH: F(8,112)=91.06, p<0.001; CORT: F(8,112)=111.31, p<0.001; stress vs. baseline: 
p<0.001). The peak ACTH levels in vehicle treated animals on day 21 did not differ 
from the peak ACTH levels on day 1 and day 11 of the experiment. In agomelatine 





Figure 3.2 Plasma concentrations of ACTH and CORT in response to footshock stress on day 1, 11 and 21 
of the experiment. Since on day 1 blood was sampled before the drug treatment started, the data of rats 
assigned to either vehicle or agomelatine groups were pooled. Exposure to the footshock significantly elevated 
both ACTH and corticosterone levels as compared to baseline values (p<0.001). Chronic agomelatine treatment 
did not significantly influence either basal or stress-induced HPA-axis activity. 
 
compared to the peak ACTH levels on day 1, but not day 11 of the experiment 
(repeated measures ANOVA, stress x drug interaction: F(8,112)=2.39, p=0.02; day1-
stress vs. day21-stress: p=0.008; day1-stress vs. day11-stress and day11-stress vs. 
day21-stress: p>0.05). However, there were no significant differences between the 
peak ACTH levels of vehicle and agomelatine treated rats on any of the days tested 
(p>0.05). There were no differences in corticosterone response between vehicle and 
agomelatine treated rats at any time point.  
 
Hippocampal neuronal activity 
Figure 3.3 shows a representative example of c-Fos immunostaining in the 
hippocampus (A) with a higher magnification of c-Fos-positive cells in the dentate 
gyrus (B), CA3 (C) and CA1 (D) areas. Changes in basal c-Fos expression in 
hippocampal  subregions due to chronic stress and agomelatine treatment are shown  
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Figure 3.3 A represen-
tative photomicrograph of 
c-Fos immunostaining in 
the hippocampus (A). 
Arrows point at c-Fos-
positive cells in the dentate 













Figure 3.4 Effects of 
chronic stress and agome-
latine treatment on basal 
levels of c-Fos expression in 
hippocampal subregions. In 
the dentate gyrus, a chronic 
stress-induced decrease in 
c-Fos-ir was reversed by 
agomelatine treatment. Si-
milar effects were noted in 
CA3 and CA1 regions of the 
hippocampus, but they did 










in figure 3.4. Two-way ANOVA revealed a significant drug effect and a significant 
stress  x  drug  interaction  in  c-Fos-ir  in the dentate gyrus  (F(1,26)=5.54, p=0.03 and 
F(1,26)=13.76, p<0.001, respectively; CTR Veh: 12.53±1.06; STR Veh: 8.18±0.74; CTR 
Ago: 11.46±0.91; STR Ago: 12.97±0.29 c-Fos cells / 0.1 mm2). Post-hoc Fisher LSD 
test showed a significant chronic stress-induced decrease in c-Fos-ir in vehicle 
treated animals (CTR Veh vs. STR Veh: p<0.001), which was reversed by 
agomelatine treatment (STR Veh vs. STR Ago: p<0.001). Although similar changes 
in c-Fos-ir were noted in CA3 (CTR Veh: 4.58±0.73; STR Veh: 2.32±0.46; CTR Ago: 
4.69±0.46; STR Ago: 4.25±0.96 c-Fos cells / 0.1 mm2) and CA1 (CTR Veh: 2.04±0.66; 
STR Veh: 1.14±0.41; CTR Ago: 3.18±0.55; STR Ago: 2.47±0.72 c-Fos cells / 0.1 mm2) 
areas of hippocampus, they were not statistically significant (drug effect and stress x 
drug interaction: p>0.05). 
 
Hippocampal neurogenesis 
Figure 3.5 shows representative examples of Ki-67 (A), BrdU (B) and DCX (C) 
immunostainings in the hippocampal dentate gyrus. Changes in various stages of 
hippocampal neurogenesis after chronic stress and agomelatine treatment are 
depicted in figure 3.6. Hippocampal cell proliferation was assessed by Ki-67 
immunohistochemistry (figure 3.5A). Similar changes in proliferating cell numbers 
were found in both dorsal (CTR Veh: 4.01±0.35; STR Veh: 3.36±0.23; CTR Ago: 
4.31±0.24; STR Ago: 4.90±0.29 Ki-67 cells / mm) and ventral dentate gyrus (CTR 
Veh: 2.58±0.23; STR Veh: 2.16±0.11; CTR Ago: 2.72±0.31; STR Ago: 3.07±0.18 Ki-67 
cells / mm). Therefore, these data were pooled in order to present effects in the entire 
hippocampus (figure 3.6A). Two-way ANOVA revealed a significant drug effect and a 
significant stress x drug interaction in proliferating cell numbers (F(1,28)=10.33, 
p=0.003 and F(1,28)=5.08, p=0.03, respectively). Post-hoc Fisher LSD test showed that 
agomelatine significantly increased the number of Ki-67-positive cells in stressed 
animals (STR Veh vs. STR Ago, p<0.001), whereas it had no effect in control animals 
(CTR Veh vs. CTR Ago, p>0.05). 
Hippocampal cell survival was assessed by BrdU immunohistochemistry (figure 
3.5B). Whereas no significant effects were observed in the dorsal dentate gyrus (CTR 
Veh: 4.26±0.55; STR Veh: 4.08±0.51; CTR Ago: 4.10±0.33; STR Ago: 5.50±0.60 BrdU 
cells / mm), a significant stress x drug interaction was found in the ventral dentate 
gyrus (figure 3.6B; F(1,28)=4.49, p=0.04; CTR Veh: 2.92±0.40; STR Veh: 2.33±0.20; 
CTR Ago: 2.46±0.34; STR Ago: 3.45±0.50 BrdU cells / mm). Post-hoc Fisher LSD test 











Figure 3.5 Representative photomicrographs of 
Ki-67 (A), BrdU (B) and DCX (C) immunostainings 
in the hippocampal dentate gyrus. Arrows point at 
Ki-67 (A), BrdU (B) and DCX (C) labeled cells 
Figure 3.6 Effects of chronic stress and 
agomelatine treatment on hippocampal neuro-
genesis. Agomelatine promoted hippocampal cell 
proliferation in stressed rats (A). A specific 
agomelatine-induced effect on cell survival was 
observed in the ventral hippocampus (B). Both 
chronic stress and agomelatine therapy reduced 
DCX expression in the dentate gyrus, whereas a 
combination of stress and drug treatment reversed 
this effect (C).  




stressed animals (STR Veh vs. STR Ago, p=0.04), whereas it had no effect in control 
animals (CTR Veh vs. CTR Ago, p>0.05). 
Effects of stress and agomelatine on newly-born hippocampal cell maturation 
were assessed by DCX labeling (figure 3.5C). Similar changes in DCX expression 
were found in both dorsal (CTR Veh: 0.31±0.01; STR Veh: 0.27±0.01; CTR Ago: 
0.27±0.01; STR Ago: 0.30±0.01 DCX OD) and ventral dentate gyrus (CTR Veh: 
0.32±0.01; STR Veh: 0.28±0.01; CTR Ago: 0.28±0.01; STR Ago: 0.32±0.01 DCX OD). 
Therefore, these data were pooled in order to present effects in the entire 
hippocampus (figure 3.6C). Two-way ANOVA revealed a significant stress x drug 
interaction (F(1,26)=29.39, p<0.001). Post-hoc Fisher LSD test showed that both 
chronic stress and agomelatine reduced DCX expression in the dentate gyrus (CTR 
Veh vs. STR Veh: p<0.001; CTR Veh vs. CTR Ago, p<0.001). In stressed animals, 
agomelatine reversed the decrease in DCX expression in the dentate gyrus (STR Veh 
vs. STR Ago: p=0.001). 
 
DISCUSSION  
Agomelatine administered to chronically stressed rats induced changes in the brain, 
extending from hippocampal neuronal activity to adult neurogenesis. Whereas 
chronic exposure to daily footshock stress reduced c-Fos expression in the dentate 
gyrus, agomelatine treatment reversed this effect and normalized neuronal activity 
to basal levels. Chronic agomelatine also enhanced hippocampal cell proliferation in 
rats concurrently exposed to chronic stress and promoted survival of the newly-born 
cells selectively in the ventral hippocampus. Finally, agomelatine treatment 
reversed the stress-induced decrease in DCX expression. Taken together, these data 
show that agomelatine is beneficial in the stress-compromised brain. Our findings 
suggest that antidepressant action of agomelatine may depend on its ability to 
reverse stress-affected neuronal activity and promote hippocampal neurogenesis. 
Chronic footshock stress was associated with a significant hypophagic effect, 
confirming the previous reports on reduced body weight gain in stressed male rats 
(Trentani et al., 2003; Dagyte et al., 2009). The 3-week treatment with agomelatine 
also led to a reduction in growth, although a similar change in body weight in rats of 
the same strain was not observed in an earlier study after 7-week agomelatine 
treatment (Papp et al., 2003).  Reductions in growth were also reported after SSRI 
administration in rats, in which case it appeared to be a result of decreased food 
intake (Wurtman and Wurtman, 1977; Luo and Li, 1991). However, agomelatine 
administration in our study did not affect food intake. Although agomelatine is not 
78 
 
only a potent melatonin receptor agonist but also acts as a 5-HT2C antagonist, the 
decrease in body weight is most likely a melatonin receptor-mediated effect. In 
rodents, melatonin was reported to decrease body weight without changes in food 
intake, whereas different 5-HT2C antagonists were either shown to increase it or to 
have no effect (Wolden-Hanson et al., 2000; Vickers and Dourish, 2004). In contrast 
to the body weight decrease in rats, agomelatine does not appear to affect body 
weight in monkeys and humans (Rouillon, 2006; Kasper and Hamon, 2009). 
Footshock stress has been shown to cause a severe activation of the HPA-axis 
(Dagyte et al., 2009). Pronounced increases in both ACTH and corticosterone were 
observed here in response to this form of stress. No habituation in the peak 
responses was noted, even after three weeks of daily exposure to footshock. 
Agomelatine treatment did not dramatically influence either basal or stress-induced 
HPA-axis activity. Our data are in line with previous reports where chronic 
agomelatine had no effect on the HPA-axis parameters after immobilization stress in 
mice or after predator stress in rats (Barden et al., 2005; Conboy et al., 2009). On the 
other hand, this antidepressant has been shown to normalize stress-induced increase 
in cortisol in the tree shrew model of chronic stress (Fuchs et al., 2006). Differences 
in the type of stressors and animal species used might be responsible for this 
inconsistency. 
Our c-Fos data suggest that agomelatine acts by normalizing reduced neuronal 
activity in hippocampus, a brain area sensitive to stress and often implicated in 
mood disorders. It is interesting to note that whereas several stress-related brain 
areas display increased c-Fos expression in response to repeated footshock stress, the 
dentate gyrus of the hippocampus is associated with reduced activation of this 
immediate early gene (Trentani et al., 2003; Huang et al., 2004). Here, we observed 
that such chronic stress-induced suppression of c-Fos expression in the dentate 
gyrus is prevented by agomelatine treatment. Similar changes were noted in CA3 
and CA1 regions of the hippocampus, although these did not reach statistical 
significance. The CA regions showed fewer c-Fos-positive cells than the dentate 
gyrus, which might have hampered the detection of significant differences between 
the groups. The c-Fos induction reflects the functional activity of the neurons 
(Kovacs, 1998). Therefore, alterations in neuronal activity may indirectly indicate 
changes in hippocampal information processing. Although the functional 
interpretation of c-Fos changes deserves caution, it is tempting to speculate that by 
normalizing stress-affected neuronal activity in the dentate gyrus, agomelatine may 
rescue the functional integrity of hippocampal circuitry. 
Prolonged footshock stress did not significantly affect hippocampal cell 




effects on these processes may depend on the timing of sacrifice of the animals as 
compared to the last stress session or BrdU labeling. Animals were in fact 
euthanized 24 hours after the final footshock session. This delay may be sufficient to 
weaken the inhibitory influences of stress on cell proliferation. A recent study 
revealed that chronic footshock stress leads to short-lasting suppression of cell 
proliferation which can easily go unnoticed if animals are sacrificed 24 hours after 
stress (Dagyte et al., 2009). Interestingly, agomelatine promoted hippocampal cell 
proliferation and, to a lesser extent, cell survival, in rats subjected to chronic 
footshock stress. Whereas agomelatine-induced increase in cell proliferation was 
observed in the entire hippocampus, cell survival was selectively enhanced in the 
ventral hippocampus, a region particularly involved in response to stress and 
anxiety (Bannerman et al., 2004). Current literature regarding agomelatine-induced 
effects on hippocampal neurogenesis is scarce. Yet, it has been shown that 3-week 
agomelatine treatment increased cell proliferation in the ventral dentate gyrus of 
non-stressed Wistar rats, whereas extending the treatment for additional 3 weeks 
also promoted cell survival in the entire dentate gyrus (Banasr et al., 2006). 
Agomelatine-mediated effect on hippocampal cell proliferation was recently 
corroborated by another study, which, in addition, reported that agomelatine 
administration for 15 or 21 days increased cell survival (Soumier et al., 2009). 
However, unpublished data suggest that 6-week agomelatine treatment had no effect 
on cell survival in non-stressed Sprague-Dawley rats (Maccari et al., 2005). Notably, 
our data indicate that chronic agomelatine did not influence hippocampal cell 
proliferation or survival in non-stressed rats. Discrepant effects among studies may 
be due to subtle changes in the experimental protocols, such as timing of BrdU 
injection in relation to agomelatine administration and animal sacrifice. Group-
housing conditions (three rats per cage) in the experiments performed by the team of 
Daszuta might also account for different outcomes in the rates of cell proliferation 
and survival (Banasr et al., 2006; Soumier et al., 2009). Recently, it has been shown 
that social isolation affects hippocampal function by decreasing expression of brain 
derived neurotrophic factor (BDNF) (Scaccianoce et al., 2006) and preventing or 
delaying exercise-induced increase in neurogenesis (Stranahan et al., 2006; Leasure 
and Decker, 2009). In view of this, the positive effect of agomelatine on cell 
proliferation and survival might have been attenuated in our experiment by the 
individual housing conditions. Nevertheless, agomelatine promoted hippocampal 
neurogenesis in chronically stressed rats, confirming the previous observations on 
agomelatine’s action in animal models of depression (Maccari et al., 2005; Paizanis 
et al., 2010). Although the agomelatine-induced stimulation of hippocampal cell 
proliferation and survival was rather mild, yet, it may indicate a compensatory 
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process, targeted at improving neuronal connectivity in the brain affected by chronic 
stress.  
In order to get more insight into agomelatine-induced changes in hippocampal 
neurogenesis after chronic stress, we examined the patterns of DCX expression in 
the dentate gyrus. Chronic footshock stress was associated with a significant decline 
of DCX expression. Our previous study revealed that such a stress-induced reduction 
in DCX labeling corresponds to a decreased number of DCX-positive immature 
neurons (Dagyte et al., 2009). Agomelatine also reduced DCX expression, which may 
depend on its ability to speed up the maturation of newly-born cells (Soumier et al., 
2009) and shortening in the time window of the expression of this marker (Banasr et 
al., 2006). Interestingly, our data demonstrate that such effects on DCX expression 
are negated when animals are exposed to both chronic stress and agomelatine 
treatment. Agomelatine reversed the stress-induced reduction in DCX expression, 
suggesting a beneficial effect of this novel antidepressant on neurogenesis despite 
the concomitant stressful conditions.  
It seems that regulation of DCX-positive cells by stress and agomelatine is 
executed via different mechanisms. DCX protein is transiently expressed during a 
period of several weeks that extends from proliferative progenitors to post-mitotic 
neurons (Brandt et al., 2003; Kempermann et al., 2004b). About 70% of DCX-positive 
cells are post-mitotic and represent young immature neurons, whereas about 20% 
are still in cell cycle and the remaining 10% are progressing from late neuroblasts to 
immature neurons (Plumpe et al., 2006). It was proposed that regulation of adult 
hippocampal neurogenesis primarily occurs during the stages associated with DCX 
expression (Kempermann et al., 2004b). Importantly, we measured DCX reactivity in 
the entire cell population expressing this protein, extending from proliferating 
progenitors to immature yet post-mitotic neurons. It is possible that stress and 
antidepressants induce changes only in specific populations of DCX-positive cells. 
Indeed, a recent study raised the possibility of differential regulation of the distinct 
populations of DCX cells by pharmacological (chronic escitalopram treatment) and 
environmental (chronic mild stress) stimuli (Jayatissa et al., 2008). In particular, 
chronic stress was associated with less DCX-expressing post-mitotic neurons, 
whereas escitalopram treatment resulted in an increased number of DCX-positive 
proliferating progenitors (Jayatissa et al., 2008). Earlier, fluoxetine had been 
reported to cause an increase in the number of DCX-positive neuroblasts (Encinas et 
al., 2006). Moreover, chronic fluoxetine also accelerates the maturation of DCX-
positive immature neurons, as shown by an increased number of DCX cells with 
more complex dendritic arborization and an increased proportion of newborn 




observations, we propose that the chronic stress-induced decrease in the number of 
DCX-expressing immature neurons is counteracted by agomelatine which promotes 
the proliferating DCX-positive cells and accelerates their progression towards post-
mitotic neurons.  
In summary, this study elucidated several neurobiological processes targeted by 
agomelatine treatment in chronically stressed rats. First, agomelatine normalized 
stress-affected neuronal activity in the dentate gyrus of the hippocampus. Second, 
agomelatine stimulated hippocampal cell proliferation and survival under conditions 
of chronic stress. Third, treatment with agomelatine reversed the stress-induced 
decrease in DCX expression in the dentate gyrus. Taken together, these data 
indicate that agomelatine is beneficial in the stressed brain, where it preserves the 
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The antidepressant agomelatine is a MT1/MT2 receptor agonist and 5-HT2C an-
tagonist. Its antidepressant activity is proposed to result from the synergy between 
these sets of receptors. Agomelatine-induced changes in the brain have been reported 
under basal conditions. Yet, little is known about its effects in the brain exposed to 
chronic stress as a risk factor for major depressive disorder. Recently, we described 
agomelatine-induced changes on neuronal activity and adult neurogenesis in the 
hippocampus of rats subjected to chronic footshock stress. In order to better 
characterize the actions of agomelatine in the stress-compromised brain, here we 
investigated its effects on hippocampal neurogenesis in the chronic mild stress (CMS) 
model. Adult male rats were subjected to various mild stressors for 5 weeks, and 
treated with agomelatine during the last 3 weeks of the stress period. The sucrose 
preference test was performed weekly to measure anhedonia, and the marble burying 
test was carried out at the end of the experiment to assess anxiety-like behavior. In 
our model, the CMS paradigm did not change sucrose preference; however, it 
increased marble burying behavior, indicating enhanced anxiety. Interestingly, this 
stress model differentially affected distinct stages of the neurogenesis process. 
Whereas CMS did not influence the rate of hippocampal cell proliferation, it 
significantly decreased the newborn cell survival and doublecortin expression in the 
dentate gyrus. Importantly, treatment with agomelatine completely normalized stress-
affected cell survival and partly reversed reduced doublecortin expression. Taken 
together, these data show that agomelatine has beneficial effects on hippocampal 





Depression is a devastating illness and a major contributor to the global disease 
burden (Greden, 2001; Greenberg and Birnbaum, 2005). Treatment of depressive 
disorder remains a challenge, despite of several classes of antidepressant drugs 
available. Currently, most of depressed patients are treated with monoaminergic 
compounds, such as selective serotonin reuptake inhibitors (SSRI), serotonin and 
noradrenaline reuptake inhibitors (SNRI), and noradrenaline reuptake inhibitors 
(NRI), which potentiate the brain’s monoaminergic system and elevate the 
monoamine levels (Wong and Licinio, 2001). However, only about 50% of the 
depressed patients treated with these medications achieve complete remission 
(Nestler et al., 2002a; Fagiolini and Kupfer, 2003). Moreover, rather poor tolerability 
of currently used antidepressants and late onset of their therapeutic effects further 
increase the risk of unsuccessful treatment (Berton and Nestler, 2006). Thus, there 
is a need for novel and more efficient medications with fundamentally different 
mechanism of action.  
Search for new targets in treatment of depression has led to the development of 
the first melatonergic antidepressant, agomelatine (de Bodinat et al., 2010). This 
novel drug acts as a potent agonist of melatonergic (MT1/MT2) receptors as well as 
an antagonist of the serotonergic (5-HT2C) receptors (Audinot et al., 2003; Millan et 
al., 2003). The antidepressant properties of agomelatine have been demonstrated in 
both animal models (Papp et al., 2003; Bourin et al., 2004; Bertaina-Anglade et al., 
2006) and in clinical studies (Kennedy and Emsley, 2006; Montgomery, 2006; Olie 
and Kasper, 2007; Goodwin et al., 2009). The antidepressant efficacy of agomelatine 
includes beneficial effect on sleep quality, achieved via synergy between the 
melatonergic and 5-HT2C receptors (Popoli, 2009). Current literature indicates that 
the therapeutic actions of agomelatine are mediated through different mechanisms 
as compared to SSRI and tricyclics (Hanoun et al., 2004; Paizanis et al., 2010). 
Nevertheless, molecular correlates underlying the antidepressant action of 
agomelatine merit further investigation. 
In an attempt to unravel the working mechanism of agomelatine, preclinical 
studies reported a variety of its mediated changes in the brain. In experiments with 
unchallenged laboratory animals, agomelatine was shown to enhance adult 
hippocampal neurogenesis, to increase expression of brain-derived neurotrophic 
factor (BDNF), and to activate several cellular signals, i.e. extracellular signal-
regulated kinase 1/2 (ERK1/2), protein kinase B (Akt), and glycogen synthase kinase 
3ß (GSK3ß) (Banasr et al., 2006; Soumier et al., 2009). This information considerably 
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advanced understanding of agomelatine’s action in the brain. However, since effects 
of antidepressant drugs might differ in disturbed versus intact systems (Berton and 
Nestler, 2006), the latter findings under basal conditions are not possible to directly 
extrapolate to the therapeutic action of agomelatine in depression. This gap may be 
partially bridged by applying an animal model approach, in order to elucidate effects 
of agomelatine under conditions that might predispose to mood disorders. 
Animal models of chronic stress represent a valuable tool to investigate 
behavioral, endocrine and neurobiological changes underlying stress-related 
psychopathologies, such as major depression, and efficacy of antidepressant 
therapies (Fuchs et al., 2001; Nestler et al., 2002b). The chronic mild stress (CMS) 
paradigm has been proposed as an animal model of depression (Willner et al., 1992). 
In laboratory animals, this chronic stress procedure attempts to mimic some of the 
dysfunctions associated with human depressive disorder. As such, CMS was reported 
to induce anhedonia, which could be reversed by antidepressant treatment (Willner, 
1997; Papp et al., 2003; Bessa et al., 2009). Also, CMS was demonstrated to reduce 
expression of BDNF and activation of cyclic adenosine monophosphate responsive 
element binding protein (CREB), both implicated in pathophysiology of depression 
and working mechanism of antidepressants (Gronli et al., 2006; Castren et al., 2007; 
Hu et al., 2010). Moreover, CMS was shown to suppress adult hippocampal 
neurogenesis, suggested to play a role in depressive disorder and action of 
antidepressant drugs (Jayatissa et al., 2008; Krishnan and Nestler, 2008; Elizalde et 
al., 2010). Although impairments in hippocampal neurogenesis have not yet provided 
functional mechanism for the pathophysiology of depression, this phenomenon 
gained an enormous interest among researchers (Dagyte et al., 2010a). In particular, 
the notion that hippocampal neurogenesis may be oppositely regulated by stress and 
antidepressants gave rise to the possibility of using it as a readout in testing the 
efficacy of novel treatments for major depressive disorder.  
Altogether, this encouraged us to apply agomelatine treatment in chronically 
stressed animals, in order to explore its therapeutic actions and mechanisms behind 
them. Recently, we characterized agomelatine-induced changes in the brain of rats 
exposed to chronic footshock stress. In this model, treatment with agomelatine 
normalized stress-affected neuronal activity and promoted neurogenesis in the 
hippocampus (Dagyte et al., 2010b). In order to better characterize the action of 
agomelatine in the stress-compromised brain, here we investigated its effects on 
hippocampal neurogenesis in the CMS model. We asked whether this stress 
paradigm induced differential changes in distinct stages of the neurogenesis process 
(cell proliferation, survival and neuronal differentiation), and whether agomelatine 




on anhedonia and anxiety-like behavior by using sucrose preference and marble 
burying tests as respective behavioral paradigms.  
 
EXPERIMENTAL PROCEDURES 
Animals and housing 
The experiments were performed using adult male Wistar rats (Harlan, Horst, The 
Netherlands) weighing 250-300 g at the beginning of the experiment. The animals 
were housed individually in a climate-controlled room with constant temperature 
(21±1ºC) and a 12 h light / 12 h dark cycle (lights on at 05:00 h). Food and water was 
available ad libitum, except when food deprivation was applied as a stressor. The 
experiments were approved by the ethical committee for the use of experimental 
animals of the University of Groningen and carried out in accordance with the 
European Communities Council Directive of 24 November 1986 (86/609/EEC). 
 
Experimental protocol 
During a 2-week acclimatization period before the start of the experiment, all rats 
were handled, weighed and trained to consume 1% sucrose solution. Three 
habituation tests for sucrose were performed, followed by a baseline sucrose 
preference test (SPT). On the basis of their sucrose preference in the baseline SPT, 
animals were divided into two matched groups, home-cage control and chronic 
stress. Both groups were further subdivided into three subgroups, based on the drug 
treatment (untreated, treated with vehicle or agomelatine). Thus, six groups of rats 
were used for the present experiment: three groups of control rats, which were either 
untreated (CTR) or treated with vehicle (CTR Veh) or agomelatine (CTR Ago), and 
three groups of chronically stressed rats, which were also either untreated (STR) or 
treated with vehicle (STR Veh) or agomelatine (STR Ago). Each group consisted of 7-
8 animals. Stress group rats were exposed to a 5-week chronic mild stress (CMS) 
procedure, whereas control rats stayed undisturbed in a separate room. Drug 
treatment started on the third week of the experiment, and continued daily 
throughout the final three weeks of the 5-week experimental period. At the end of 
every week, the SPT was applied to all rats. In the last week of the experiment, the 
marble burying test was performed. At the end of the 5-week experiment, the home-
cage control rats were sacrificed concomitantly with the stressed rats which were 
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euthanized 4-6 h after the last stressor exposure and 18-20 h after the last treatment 
administration. 
 
Chronic mild stress procedure 
The CMS protocol was adapted from previous studies (Willner et al., 1987; Papp et 
al., 2003). In the current experiment, the CMS procedure consisted of five different 
mild stressors, applied randomly every week for 5 weeks. These five stressors were: 
16 h of food deprivation, 16 h of soiled cage (500 ml water in 250 g sawdust bedding), 
16 h of tilted cage (45°), 12 h of predator sounds (high-pitch medium volume, 
resembling snake sounds) and 12 h of medium intensity of stroboscopic light flashes. 
These stressors were applied during the entire dark phase and first 4 h of the light 
phase, in case of the stressors with 16 h duration. Every experimental week 
consisted of five days with random stressors, and two days of no-stress. 
 
Sucrose preference test 
The sucrose preference test (SPT) was conducted as a measure for the anhedonic 
effect of CMS (Willner et al., 1987). A two bottle preference test was used, where all 
animals got access to both water and a 1% sucrose solution for 24 hours during a 
period of no-stress. In order to habituate animals to the sucrose solution, they were 
trained during the acclimatization period. Three habituation tests were performed, 
where animals had access to both water and sucrose solution for 24 hours. This 
training period was followed by the baseline SPT, one day before the start of the 
CMS protocol. During the 5-week CMS procedure, SPT was performed at the end of 
each experimental week for 24 hours during a period of no-stress. Bottles with water 
and sucrose solution were switched regularly to control for the place preference. The 
final SPT was performed 24 hours before the last treatment administration. Sucrose 
preference (SP) was calculated as the percentage of sucrose solution ingested relative 
to the total amount of liquid consumed (SP= [sucrose solution, g / sucrose solution, g 
+ water, g] x 100).  
 
Marble burying test 
The marble burying test was used to measure an anxiety-induced behavioral 
response to environmental challenge. It was performed in the last week of the 
experiment, during the light phase of a stress-free period. The method was adapted 




marbles (2.5 cm in diameter) were placed along a side-wall of each home-cage, and 
behavior of rats was observed during a 30-min test period. The following parameters 
were recorded: the number of rats showing burying behavior, and the number of 
buried marbles (at least two thirds of the surface covered with sawdust). Marble 
burying behavior reflected an active effort of a rat to hide the unfamiliar object in 




1% hydroxyethylcellulose (HEC) was used as a vehicle for agomelatine delivery. 
Agomelatine solution was prepared every day by dissolving agomelatine powder in 
1% HEC at a concentration of 40 mg/ml. The choice of agomelatine dose was made on 
the basis of its activity at this concentration in animal models of depression and 
anxiety (Papp et al., 2003; Millan et al., 2005), and on neuroplasticity (Banasr et al., 
2006; Soumier et al., 2009; Dagyte et al., 2010b). Rats were injected intra-
peritoneally either with agomelatine (40 mg/kg) or vehicle daily at 15:00 (2 h prior to 
the dark phase) for 21 days. Injections started on the third week of the 5-week 
experimental period. Agomelatine and HEC were provided by Servier (France). 
 
BrdU labeling 
In order to study survival of newly-born cells in the hippocampus during the 
experiment, rats received an injection of bromodeoxyuridine (BrdU: Sigma, St. Louis, 
MO, USA), a synthetic analogue of thymidine which is incorporated into newly 
synthesized DNA of replicating cells during the S phase of the cell cycle (Christie 
and Cameron, 2006). New cells were labeled 4 days before the start of the experi-
ment with a single intraperitoneal injection (300 mg/kg). This specific time-point of 
BrdU labeling for studying cell survival was chosen since it was shown that labeled 
progenitor cells stop proliferating after 4 days (Dayer et al., 2003). Such an injection 
schedule was similarly applied in our laboratory previously (Van der Borght et al., 
2005b; Dagyte et al., 2009; Dagyte et al., 2010b). 
 
Brain collection and immunohistochemistry 
At the end of the experiment rats were anesthetized with sodium pentobarbital and 
transcardially perfused with heparinized saline followed by 4% paraformaldehyde 
solution in 0.1 M phosphate buffer. Brains were extracted and post-fixed in the same 
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solution overnight at 4°C and subsequently cryoprotected by immersion in a 30% 
buffered sucrose solution for up to 48 h. Coronal serial sections of 30 μm were cut 
using a cryostat and stored in 0.01 M phosphate-buffered saline with 0.1% sodium 
azide at 4°C until immunohistochemistry was performed. 
In order to assess effects of CMS and agomelatine on different aspects of 
hippocampal neurogenesis, immunohistochemistry for Ki-67, doublecortin (DCX), 
and BrdU was performed. Ki-67 is a nuclear protein which is expressed during all 
phases of the cell cycle, except G0 (Scholzen and Gerdes, 2000), which would 
therefore give an indication of cell proliferation on the last day of the experiment. 
DCX protein is expressed in newly-born cells from 1 day to about 4 weeks of age, and 
might therefore reveal sustained changes in the neurogenesis process and its 
modulation (Brown et al., 2003; Rao and Shetty, 2004). Finally, since a pool of 
newborn cells was labeled with an injection of BrdU 4 days prior to the start of the 
experiment, BrdU immunostaining would indicate changes in survival of new cells in 
the course of the experiment. 
The immunostainings were performed on free-floating sections under continuous 
mild agitation. BrdU immunohistochemistry required extra steps for DNA 
denaturation. For this purpose, sections were exposed to 2x saline sodium citrate 
(2xSSC) containing 50% formamide for 30 min at 65°C, followed by a rinse with 
2xSSC, incubation with 2 M HCl for 30 min at 37°C and a washing step with 0.1 M 
borate buffer. Brain sections for all three immunostainings were preincubated in 3% 
normal serum and 0.1% TritonX-100, and then incubated with one of the following 
antibodies for 60 h at 4°C: primary mouse-anti-Ki-67 (1:200; Monosan, Uden, The 
Netherlands), goat-anti-DCX (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), or rat-anti-BrdU (1:800; Serotec, Oxford, UK). Subsequently, sections were 
rinsed in 0.01 M Tris-buffered saline and incubated for 2 h at room temperature with 
secondary biotinylated goat-anti-mouse, rabbit-anti-goat or donkey-anti-rat antibody 
depending on the primary antibody host (1:500 for all secondary antibodies, Jackson 
ImmunoResearch Suffolk, UK). Then, avidin-biotin complex (1:500, Vector ABC kit, 
Vector Laboratories, Burlingame, CA, USA) was added for 2 h, after which the 
staining was visualized with 1 mg/ml diaminobenzidine and 0.003% H2O2. 




All analyses were performed by an observer blind to the group assignment. Ki-67 




cell layer (GCL) of the dentate gyrus in every twelfth section of the hippocampus 
under 500 × magnification. Immunopositive cells that were located one cell diameter 
away from SGZ were also included in the analysis. The number of immunopositive 
cells in each section was expressed relative to the length of the dentate gyrus in 
order to correct for variation in size of the hippocampus along the rostro-caudal axis 
of the brain. The length of the dentate gyrus was measured by delineating the entire 
SGZ in each hippocampus. DCX immunoreactivity (ir) in cell bodies and dendrites of 
the newly generated cells was measured by a previously described method (Van der 
Borght et al., 2007; Dagyte et al., 2009). Measurements were performed with a 
computerized system (Leica, Cambridge, UK). Images were taken using a Leica 
charged-coupled device digital camera mounted on a microscope (DMIRB, Leica, 
Cambridge, UK) at 100 × magnification. In total, 7-8 sections per animal (Bregma –
2.56 to –6.30, according to the rat brain atlas (Paxinos and Watson, 2007) were 
analyzed by delineating a similarly sized area covering the entire width of the SGZ 
and GCL in each hippocampus. Optical density (OD) of DCX expression was 
measured in the dentate gyrus and corrected for non-specific background labeling, 
which was measured in the corpus callosum. The OD was expressed in arbitrary 
units corresponding to grey levels using a Quantimet 550 image analysis system 
(Leica, Cambridge, UK). Simultaneously, a second measure of the DCX immuno-
staining was taken, complementary to the DCX OD analysis. Within each delineated 
area covering the SGZ and GCL, the percentage of the total surface that was covered 
with DCX-positive cell bodies and dendrites was calculated, and presented as area 
coverage (%). In all three stainings, dorsal and ventral hippocampi were analyzed 
separately. Since similar changes in the dorsal and ventral parts of hippocampus 




Two-way ANOVA was used to analyze the effects of stress and drug treatment on 
hippocampal neurogenesis and marble burying. The body weight gain and sucrose 
preference data were analyzed by repeated measures ANOVA. When significant 
effects were found, post-hoc analysis was performed using the Fisher LSD test. The 






Figure 4.1 Changes in 
body weight gain throughout 
the experiment. Both CMS and 
agomelatine treatment signi-
ficantly reduced body weight 
gain. Arrows point at short-
term body weight decreases 








Body weight gain 
Body weight was measured from day -7 to day 35 of the experiment. All rats grew at 
similar rates during the acclimatization period. However, CMS and agomelatine 
treatment significantly reduced body weight gain (repeated measures ANOVA, time 
x stress interaction: F(30,1230)= 32.85, p<0.001; time x drug interaction: F(60,1230)= 
15.79, p<0.001; figure 4.1).  
 
Sucrose preference test 
Preference for 1% sucrose solution over water was measured before the start of the 
CMS procedure (baseline) and weekly during the 5-week experimental period. 
Repeated measures ANOVA did not reveal any significant differences in sucrose 
preference among the groups throughout the experiment (p>0.05; figure 4.2). 
 
Marble burying test 
The number of buried marbles by each animal was recorded during a 30-min test 





Figure 4.2 Effects of CMS 
and agomelatine treatment on 
sucrose preference. A prefe-
rence for 1% sucrose solution 
over water was measured 
before the start of the CMS 
procedure (baseline) and 
weekly during the 5-week 
experimental period. CMS did 
not induce significant changes 
in sucrose preference among 




mental group. Individual variation associated with this behavioral measure is 
illustrated in figure 4.3B. The data points correspond to individual animals, and 
show the number of their buried marbles. Two-way ANOVA revealed a significant 
stress-induced increase in burying behavior (F(1,41)=5.18, p=0.03, when the number of 
animals showing burying behavior was analyzed;  F(1,41)=5.06, p=0.03, when the 
number of buried marbles across the groups was compared). Agomelatine treatment 
reduced burying behavior (only 29% of stressed agomelatine-treated rats buried 
marbles as compared to 63% of stressed non-injected and 50% of stressed vehicle-
treated animals), but this effect did not reach statistical significance. 
 
Hippocampal neurogenesis 
Figure 4.4 shows representative examples of Ki-67 (A), BrdU (B) and DCX (C) 
immunostainings in the hippocampal dentate gyrus. Changes in different stages of 
hippocampal neurogenesis after CMS and agomelatine treatment are depicted in 
Figure 4.5. 
Hippocampal cell proliferation was assessed by Ki-67 immunohistochemistry 
(figure 4.4A). There were no significant differences in the number of proliferating 
cells among the groups (p>0.05; figure 4.5A).  
Hippocampal cell survival was assessed by BrdU immunohistochemistry (figure 
4.4B). Two-way ANOVA revealed significant stress and drug effects (F(1,41)=9.77, 
p=0.003 and F(2,41)=4.20, p=0.02, respectively; figure 4.5B). Post-hoc Fisher LSD test 




Figure 4.3 Effects of CMS 
and agomelatine treatment on 
marble burying. The graph 
depicts the average number of 
buried marbles in each experi-
mental group (A). This measure 
was associated with a high 
individual variation, and not 
all animals showed burying 
behavior (B). The data points 
correspond to individual rats, 
and reveal the number of their 
buried marbles. Some data 
points represent more than one 
animal; their n is indicated 
below each point. CMS induced 
a significant increase in burying 
behavior (both in the number of 
rats showing burying behavior 
and in the number of their 
buried marbles). Although ago-
melatine treatment seemed to 
reduce burying behavior, its 
effects did not reach statistical 
significance.  








untreated and vehicle treated animals (CTR vs. STR: p=0.03; CTR Veh vs. STR Veh: 
p=0.01). Agomelatine reversed this stress-induced effect (STR Veh vs. STR Ago: 
p=0.02), whereas it did not influence the rate of cell survival in control animals (CTR 
Veh vs. CTR Ago: p>0.05).  
Effects of CMS and agomelatine on newly-born hippocampal neuron maturation 
were assessed by DCX labeling (figure 4.4C). First, we quantified the OD of DCX 
expression (figure 4.5C). Two-way ANOVA revealed a significant stress effect and a 
stress x drug interaction (F(1,41)=12.38, p=0.001 and F(2,41)=11.41, p<0.001, 





Figure 4.4 Representative photomicrographs of Ki-67 (A), BrdU (B) and DCX (C) immunostainings in the 
hippocampal dentate gyrus. Arrows point at Ki-67 (A), BrdU (B) and DCX (C) labeled cells. 
 
decreased the OD of DCX expression in the dentate gyrus (CTR vs. STR: p=0.03; 
CTR Veh vs. STR Veh: p<0.001; CTR Veh vs. CTR Ago: p<0.001). In stressed 
animals, agomelatine significantly reversed the decrease in DCX expression (STR 
Veh vs. STR Ago: p=0.04), but did not restore it to the control level (CTR Veh vs. 
STR Ago: p=0.004). Additionally, we analyzed the percentage of area covered with 
DCX-positive cells (figure 4.5D). Two-way ANOVA revealed a significant stress x 
drug interaction (F(2,41)=6.89, p=0.003). Post-hoc Fisher LSD test showed that both 
CMS and agomelatine decreased the percentage of dentate gyrus area covered with 
DCX-positive cells (CTR vs. STR: p=0.008; CTR Veh vs. STR Veh: p=0.015; CTR Veh 
vs. CTR Ago: p=0.002). Agomelatine increased DCX area coverage in stressed 
animals, but this effect did not reach statistical significance (p>0.05). 
 
DISCUSSION  
The present study investigated action of agomelatine in the rat CMS model. Our 
data show that this stress paradigm differentially affected distinct stages of the 
adult neurogenesis process. Whereas CMS did not influence the rate of hippocampal 
cell proliferation, it significantly decreased the newborn cell survival and double-
cortin expression in the dentate gyrus. Notably, treatment with agomelatine 
completely normalized stress-affected cell survival and partly reversed the reduced 
doublecortin expression. Altogether, these data show that agomelatine has beneficial 
effects on hippocampal neurogenesis in the stress-compromised brain.  
Exposure to CMS led to a significant decrease in body weight gain. Similar 
effects on growth were previously reported in male rats subjected to various chronic 
stress models (Karst and Joels, 2003; Rygula et al., 2005; Dagyte et al., 2009).  In the 
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Figure 4.5 Effects of CMS and agomelatine 
treatment on adult hippocampal neurogenesis. 
Neither CMS nor agomelatine influenced hippo-
campal cell proliferation (A). Whereas CMS 
decreased hippocampal cell survival, agomelatine 
completely reversed this stress effect (B). Both 
CMS and agomelatine treatment reduced optical 
density of the DCX expression in the dentate 
gyrus, whereas a combination of stress and drug 
treatment partly rescued this effect (C). Accor-
dingly, both CMS and agomelatine decreased the 
percentage of dentate gyrus area covered with the 
DCX-positive neurons (D). 























CMS model, reduction in growth may depend on a combination  of specific  stressors, 
since both decrease (Bielajew et al., 2002; Ushijima et al., 2006; Jayatissa et al., 
2009) and no change in body weight (Grippo et al., 2005; Gronli et al., 2006) were 
found in this stress paradigm. In our experiment, the food deprivation stressor had 
obvious effects on growth; however, its induced weight loss was short-lasting and 
fully recovered on the following day. Thus, the overall reduction in growth in the 
current CMS model cannot be attributed to a single food deprivation stressor, but 
rather depends on a synergistic effect of multiple stressors. The 3-week treatment 
with agomelatine also led to a significant decrease in body weight gain, as observed 
in our previous study (Dagyte et al., 2010b). This reduction in growth is most likely 
mediated through agomelatine’s action on melatonergic receptors, as melatonin was 
reported to decrease body weight in rodents (Wolden-Hanson et al., 2000). In 
contrast to the growth reduction in rats, agomelatine treatment does not change 
body weight in humans (Rouillon, 2006; Kasper and Hamon, 2009). 
Our results reveal that exposure to the CMS paradigm did not change the rate of 
hippocampal cell proliferation. Nevertheless, it significantly decreased the survival 
of hippocampal cells, born before the stress period. Furthermore, CMS was 
associated with a reduction in the expression of DCX, a protein present mainly in the 
newborn immature neurons. It is interesting to note that distinct aspects of the 
neurogenesis process might be differentially influenced by stressful stimuli. Our 
data confirm a previously observed discrepancy between stress effects on hippo-
campal cell proliferation and survival in the CMS model (Lee et al., 2006). A similar 
dissociation between different stages of neurogenesis was also found in a related 
paradigm of chronic unpredictable stress (Oomen et al., 2007). These results suggest 
that the CMS paradigm influences a part, but not the entire process of hippocampal 
neurogenesis. Such differential effects associated with CMS may hint to the role of 
this form of stress in regulation of adult neurogenesis in the hippocampus. Sustained 
glucocorticoid exposure is considered as one of the mediators of stress-induced 
changes in neurogenesis (Fuchs et al., 2001; de Kloet et al., 2005). A degree of the 
hypothalamic-pituitary-adrenal (HPA) axis activation in the CMS model varies 
across different studies. Whereas some researchers report mild to moderate 
increases in plasma corticosterone concentrations after exposure to CMS (Bielajew et 
al., 2002; Grippo et al., 2005; Ushijima et al., 2006; Toth et al., 2008), others do not 
find lasting changes in basal corticosterone levels (Stout et al., 2000; Lee et al., 
2006), as also observed in our laboratory (unpublished results). The action of 
corticosterone is mediated through two types of receptors, the glucocorticoid receptor 
(GR) and the mineralocorticoid receptor (MR). Both of these receptors are barely 
found on hippocampal progenitors, but their expression increases dynamically while 
newborn cells progress through different stages of the neurogenesis process to 
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develop into mature neurons (Cameron et al., 1993; Garcia et al., 2004). Altogether, 
this points to a limited role of corticosteroids in regulating adult neurogenesis in the 
CMS model. Furthermore, these observations suggest that a variable sensitivity of 
the newborn cells to changes in the local glucocorticoid environment might influence 
stress effects on different aspects of the neurogenesis process (Wong and Herbert, 
2004, 2005). As mentioned above, proliferating cells have low GR and MR levels that 
may contribute to the lack of CMS effects on the rate of cell proliferation. In contrast, 
the survival of older hippocampal cells, expressing higher GR and MR levels, may be 
more severely influenced by stress. In addition, many other factors, including 
various proteins, neurotransmitters and hormones, are suggested to regulate the 
proliferation and survival of newborn cells, and have differential effects on these two 
processes (Hagg, 2005; Balu and Lucki, 2009). Growth factors, especially, vascular 
endothelial growth factor (VEGF) and BDNF, seem to play a crucial role in 
regulating survival and differentiation of newly generated cells (Cao et al., 2004; 
Mattson et al., 2004). In line with this notion, reduced neurotrophin expression has 
been repeatedly reported in the CMS model (Gronli et al., 2006; Bergstrom et al., 
2008; Toth et al., 2008; Hu et al., 2010). In sum, adult hippocampal neurogenesis, 
and cell proliferation in particular, is a highly dynamic process (Dagyte et al., 2009; 
Ma et al., 2009). Hence, the future research should consider the temporal dynamics 
of the stress response and time-dependent effects of various stress mediators when 
designing new studies of this kind (Koolhaas et al., 1997; Buwalda et al., 2001).  
Importantly, agomelatine treatment completely reversed the CMS-induced 
decrease in hippocampal cell survival. This finding confirms the previous obser-
vations on actions of agomelatine in the stress-compromised brain (Maccari et al., 
2005; Dagyte et al., 2010b) as well as in a transgenic animal model of depression 
(Paizanis et al., 2010). Moreover, our data show that this antidepressant partly 
reversed stress-induced reduction in the DCX labeling in the dentate gyrus. 
Agomelatine treatment in stressed animals significantly increased the OD of DCX 
expression; however, its effects on the second measure of this analysis, the area 
covered with DCX-positive cells, did not reach statistical significance. Such 
discrepancy might indicate that distinct dimensions measured by two methods differ 
in their magnitude. The OD reveals the intensity of the staining, and thus, reflects 
the amount of expressed protein. Previously, we showed that changes in the OD of 
DCX labeling correlate with alterations in the number of immature DCX-positive 
neurons (Dagyte et al., 2009). We also acknowledged the differential influence of 
neurogenic regulators, such as stress and antidepressants, on DCX-positive cells 
(Dagyte et al., 2010b). Earlier studies demonstrated that DCX protein is expressed 
dynamically by heterogeneous cell populations, ranging from proliferating 




et al., 2004b; Plumpe et al., 2006). A possibility that stress and antidepressant 
treatment differentially regulate the distinct populations of DCX cells was also 
confirmed in the CMS model (Jayatissa et al., 2008). According to the proposed 
hypothesis, chronic stress might preferentially affect DCX-expressing post-mitotic 
neurons, whereas antidepressant drugs might promote the proliferating DCX-
positive progenitors and accelerate their progression towards mature neurons 
(Encinas et al., 2006; Jayatissa et al., 2008; Wang et al., 2008; David et al., 2009). 
Our DCX data show that CMS reduced both the amount of this protein as well as the 
relative number of cell bodies and dendrites that express it. It is feasible that stress 
downregulates the expression of DCX by decreasing the number of immature 
neurons. On the other hand, agomelatine also reduced both of these measures. 
Previous studies revealed that this antidepressant speeds up maturation of newborn 
neurons (Soumier et al., 2009), resulting in lower number of DCX-positive cells 
(Banasr et al., 2006), and thereby, reduced expression of DCX protein (Dagyte et al., 
2010b). Interestingly, the present data show that agomelatine significantly, albeit 
partly, counteracted the stress-induced decrease in DCX reactivity but did not 
significantly change the relative number of cells that express this protein. The effect 
of agomelatine on stress-altered DCX immunoreactivity was rather mild. Therefore, 
it might have not manifested as a significant change in the measurement of area of 
coverage, associated with higher individual variation. 
The neurobiological effects achieved in the CMS model granted valuable 
information on the action of agomelatine in the stress-compromised brain. 
Strikingly, however, CMS did not induce anhedonia as measured by preference for 
1% sucrose solution over water. In fact, rats showed a very high preference for 
sucrose which did not diminish during a 5-week stress period. Both control and 
stressed animals drank an excessive amount of sweetened solution as compared to 
their daily water intake. Such elevated sucrose consumption indicates that rats 
liked/wanted it highly. Notably, different neural systems underlie the conditions of 
liking and wanting of pleasurable stimuli, suggesting a possible dissociation between 
these processes (Berridge, 2009). Although usually a brain likes the rewards that it 
wants, yet, sometimes it may just want them (Berridge et al., 2009). In view of this, 
the excess intake of sucrose solution may indicate a strong wanting component of 
reward, not necessarily accompanied by a liking element. The measurement of 
sucrose consumption over water, thus, might not adequately reflect the hedonic 
behavior. Consequently, data on sucrose intake and preference in the CMS studies 
should be interpreted with caution. In some cases, for instance, the so called 
anhedonic state is a result of increased sucrose consumption by control animals, 
without a change in sucrose intake by their stressed counterparts (Gronli et al., 
2006). Altogether, there is a great deal of controversy in the methods used for 
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determination of anhedonia, and in their measured effects in CMS studies. Despite 
numerous reports on stress-induced changes in either sucrose preference or intake 
(Papp et al., 2003; Bekris et al., 2005; Grippo et al., 2005; Koo and Duman, 2008; 
Toth et al., 2008; Bessa et al., 2009; Jayatissa et al., 2009; Elizalde et al., 2010; Hu et 
al., 2010), literature also reveals many contrasting results (Matthews et al., 1995; 
Forbes et al., 1996; Nielsen et al., 2000; Haidkind et al., 2003; Bergstrom et al., 2008; 
Wu and Wang, 2010). Such controversy is suggested to stem from differences in 
experimental designs and animal strains used; however, a solid explanation for 
discrepant findings is still lacking (Nielsen et al., 2000; Willner, 2005; Wu and 
Wang, 2010).  
Interestingly, our CMS paradigm induced changes in marble burying behavior. 
Both the number of rats showing this behavior as well as the number of their buried 
marbles was increased in the groups subjected to CMS. The marble burying test is 
suggested to measure anxiety-like and impulsive behavior, and is proposed to detect 
potential antidepressant drugs; yet, the functional interpretation of marble burying 
remains uncertain (Gyertyan, 1995; Borsini et al., 2002; Millan et al., 2002). 
Nevertheless, our findings reveal that exposure to CMS influenced the animals’ 
response to a novel object in the cage. Increased burying behavior might indicate 
stress-heightened anxiety (Farley et al., 2010). Although agomelatine had no 
statistically significant effects in the marble burying test, it did show a tendency to 
reduce the burying behavior. This observation may reflect the anxiolytic action of 
agomelatine, previously demonstrated in various animal models (Millan et al., 2005; 
Papp et al., 2006), including the marble burying test (unpublished results).  
In summary, the present study used the CMS model in order to elucidate effects 
of stress and agomelatine treatment on adult hippocampal neurogenesis. 
Interestingly, this stress paradigm differentially affected distinct aspects of the 
neurogenesis process: whereas CMS did not alter the rate of cell proliferation, it 
decreased the newborn cell survival and DCX expression in the dentate gyrus. 
Importantly, treatment with agomelatine interfered with these stress-associated 
changes in the brain. This antidepressant completely normalized stress-affected cell 
survival and partly reversed reduced DCX expression. Taken together, these 
findings reveal the ability of agomelatine to counteract stress-induced changes in 
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Agomelatine is a novel antidepressant which acts as a melatonergic receptor 
(MT1/MT2) agonist and 5-HT2C antagonist. Agomelatine has been shown to be an 
effective treatment for major depressive disorder but its neurobiological effects merit 
further investigation. Several preclinical studies reported agomelatine-mediated 
changes in the brain, including enhanced adult hippocampal neurogenesis and 
increased expression of neuroplasticity-associated molecules. Recently, we showed 
that agomelatine is beneficial in the stress-compromised brain, where it normalizes 
stress-affected neuronal activity and promotes hippocampal neurogenesis. In order to 
further characterize effects of this antidepressant in the stressed brain, here we 
investigated whether it induces changes in the expression of synapsin I (SynI), a key 
regulator of synaptic transmission and plasticity. Adult male rats were subjected to 
daily footshock stress and agomelatine treatment for 3 weeks. Their brains were 
subsequently stained for total and phosphorylated SynI. Chronic footshock and 
agomelatine induced region-specific changes in SynI expression. Whereas chronic 
stress increased total SynI expression in all layers of the medial prefrontal cortex, 
agomelatine treatment reversed some of these effects. Furthermore, chronic 
agomelatine administration decreased total SynI expression in the hippocampal 
subregions of both stressed and non-stressed rats. Importantly, chronic stress 
decreased the fraction of phosphorylated SynI in all layers of the medial prefrontal 
cortex as well as selectively in the outer and middle molecular layers of the 
hippocampal dentate gyrus. These stress effects were at least partly reversed by 
agomelatine treatment. Taken together, the present data show that chronic stress and 
agomelatine treatment induce region-specific changes in SynI expression and its 
phosphorylation. Moreover, agomelatine partly counteracts the stress effects on SynI, 





Agomelatine is a novel antidepressant which acts as a potent melatonergic receptor 
(MT1/MT2) agonist (Audinot et al., 2003) and serotonergic receptor (5-HT2C) 
antagonist (Millan et al., 2003). Interestingly, the antidepressant activity of 
agomelatine results from a potential synergy between these sets of receptors (Popoli, 
2009). Neither melatonin nor 5-HT2C receptor antagonists alone show antidepressant 
properties in all tested animal models of depression; moreover, the effect of 
agomelatine is abolished by co-administration of a MT1/MT2 antagonist (Papp et al., 
2003; Bourin et al., 2004; Bertaina-Anglade et al., 2006). Importantly, agomelatine 
has been shown to be effective in treatment of major depressive disorder (Kennedy 
and Emsley, 2006; Montgomery, 2006; Olie and Kasper, 2007; Goodwin et al., 2009).  
Preclinical studies have demonstrated a variety of agomelatine-mediated 
changes in the brain, including increased hippocampal neurogenesis, enhanced 
expression of brain-derived neurotrophic factor (BDNF) and neural cell adhesion 
molecule (NCAM), as well as activation of several cellular signals, i.e. extracellular 
signal-regulated kinase 1/2 (ERK1/2), protein kinase B (Akt), and glycogen synthase 
kinase 3ß (GSK3ß) (Banasr et al., 2006; Conboy et al., 2009; Soumier et al., 2009). 
Moreover, agomelatine was shown to be effective in the stress-compromised brain 
where it normalized hippocampal neuronal activity and promoted neurogenesis in 
chronically stressed rats (Dagyte et al., 2010b). Also, agomelatine was reported to 
reverse altered hippocampal neurogenesis and BDNF expression in the gluco-
corticoid receptor-impaired (GR-i) mice, a transgenic animal model of depression 
(Paizanis et al., 2010). 
Stress is a significant risk factor for development of many psychiatric disorders, 
including major depression (Heim and Nemeroff, 1999; Kendler et al., 1999). Thus, 
animal models of chronic stress provide a valuable tool to investigate neurobiological 
changes underlying stress-related psychopathologies and therapeutic actions of 
antidepressant drugs (Fuchs et al., 2001; Nestler et al., 2002a). Such models have 
revealed that stress is associated with impaired neurotrophin signaling (Rasmusson 
et al., 2002; Gronli et al., 2006), neuronal and dendritic atrophy (Magarinos and 
McEwen, 1995a; Radley et al., 2004; Bessa et al., 2009), and reduced synaptic 
plasticity (Cerqueira et al., 2007; Goldwater et al., 2009; Joels et al., 2009) in the 
hippocampus and prefrontal cortex. On the other hand, antidepressants were shown 
to increase neurotrophin signaling and promote neuronal and synaptic remodeling in 
these limbic brain regions (Duman, 2004a; Castren et al., 2007; Sairanen et al., 
2007; Bessa et al., 2009). Enhanced neuronal connectivity and strengthening of 
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specific synapses is hypothesized to underlie the mechanism of antidepressant 
action, however, the precise changes at the synaptic level are largely unknown.  
Synapsins are the most abundant synaptic vesicle-associated proteins that play 
multiple roles in synaptic transmission and plasticity (De Camilli et al., 1983; 
Greengard et al., 1993; Hilfiker et al., 1999; Cesca et al., 2010). Synapsins tether 
synaptic vesicles to the cytoskeleton in a phosphorylation-dependent manner, and 
thereby regulate neurotransmitter release. Also, synapsins are suggested to play a 
role in the formation of new nerve terminals, maturation of synaptic contacts, 
neurite elongation, and synthesis of other synaptic vesicle proteins (Ferreira and 
Rapoport, 2002; Fdez and Hilfiker, 2006). Three distinct synapsin genes (SYN1, 
SYN2, and SYN3) give rise to several differentially spliced isoforms whose 
expression is developmentally regulated (Sudhof et al., 1989; Ferreira et al., 2000). 
Synapsins Ia and Ib (collectively referred to as synapsin I (SynI)) are the most 
abundant isoforms in mature neurons accounting for 6% of total vesicle proteins 
(Huttner et al., 1983; Baldelli et al., 2007).  
The present study aimed to examine SynI expression and its phosphorylation 
pattern in forebrain regions of rats exposed to chronic stress and treated with the 
antidepressant agomelatine. We used a chronic footshock stress model, which was 
previously shown to induce a variety of changes in stress-related brain areas 
(Trentani et al., 2002; Kuipers et al., 2003; Trentani et al., 2003; Westenbroek et al., 
2004; Kuipers et al., 2006; Dagyte et al., 2009). Our recent study using this model 
revealed that chronic treatment with agomelatine normalizes stress-compromised 
neuronal activity in the dentate gyrus and promotes adult hippocampal neurogenesis 
(Dagyte et al., 2010b). Here, we investigated whether chronic stress and agomelatine 
treatment induce distinct changes in SynI expression in several brain regions, in 




Animals and housing 
The experiments were performed using adult (10-12 weeks of age) male Wistar rats 
(Harlan, Horst, The Netherlands) weighing 300-350 g at the beginning of the 
experiment. The animals were housed individually in a climate-controlled room with 
constant temperature (21±1ºC) and a 12 h light / 12 h dark cycle (lights on at 06:00 




ethical committee for the use of experimental animals of the University of Groningen 
and carried out in accordance with the European Communities Council Directive of 
24 November 1986 (86/609/EEC). All efforts were made to minimize animal suffering 
and to reduce the number of animals used. 
 
Experimental protocol 
Four groups of rats were used for the present experiment: two groups of home cage 
control rats (CTR), which were treated either with vehicle (CTR Veh) or agomelatine 
(CTR Ago), and two groups of chronically stressed rats (STR), which were also 
treated either with vehicle (STR Veh) or agomelatine (STR Ago). Each group 
consisted of 8 animals. The home cage control rats were sacrificed concomitantly 
with the stressed rats which were euthanized 24 h after the last footshock exposure. 
 
Stress procedure 
During a 2-week acclimatization period before the start of the experiment, all rats 
were weighed and handled daily. Footshock stress was applied in a footshock box 
with a grid floor connected to a shock generator and scrambler (Trentani et al., 2003; 
Dagyte et al., 2009). Stress group rats were subjected to a daily session of footshock 
stress for 21 consecutive days. During the session in the footshock box rats received 
5 uncontrollable and inescapable footshocks (0.8 mA in intensity and 8 s in 
duration). All footshock sessions took place during the light phase. In order to 
increase unpredictability and minimize habituation, both timing and duration of 
footshock sessions as well as intervals between shocks within a session varied 
randomly (session starting time: between 08:00 and 13:00 h; session duration: 15-80 
min; shock interval: 1-15 min). Control rats stayed undisturbed in their home cages 
throughout the experiment.  
 
Drug treatment 
1% hydroxyethylcellulose (HEC) was used as a vehicle for agomelatine delivery. 
Agomelatine solution was prepared every day by dissolving agomelatine powder in 
1% HEC at a concentration of 40 mg/ml. The choice of agomelatine dose was made on 
the basis of its activity at this concentration in animal models of depression and 
anxiety (Papp et al., 2003; Millan et al., 2005), and on neuroplasticity (Banasr et al., 
2006; Soumier et al., 2009; Dagyte et al., 2010b). Rats were injected intraperi-
108 
 
toneally either with agomelatine (40 mg/kg) or vehicle daily at 16:00 (2 h prior to the 
dark phase) for 21 days. 
 
Brain collection and immunohistochemistry 
At the end of the experiment, 24 h after the last stress session and 18 h after the last 
agomelatine injection, rats were anesthetized with sodium pentobarbital and 
transcardially perfused with heparinized saline followed by 4% paraformaldehyde 
solution in 0.1 M phosphate buffer. Brains were dissected and post-fixed in the same 
solution overnight at 4°C and subsequently cryoprotected by immersion in a 30% 
buffered sucrose solution for up to 48 h. Coronal serial sections of 30 μm were cut 
using a cryostat and stored in 0.01 M phosphate-buffered saline (PBS) with 0.1% 
sodium azide at 4°C until immunohistochemistry was performed. 
Effects of agomelatine and chronic footshock stress on synaptic function were 
assessed by immunohistochemistry for total and phosphorylated synapsin I (SynI), a 
marker of synaptic vesicles.  
The immunostainings were performed on free-floating sections under continuous 
mild agitation. Brain sections were preincubated in 5% normal serum and 0.3% 
TritonX-100, and then incubated with one of the following antibodies for 40 h at 4°C: 
primary rabbit-anti-SynI (1:600; HPA000397, Sigma-Aldrich, Stockholm, Sweden) or 
rabbit-anti-phospho-Ser549-SynI (1:100; p1560-549, Phosphosolutions, Aurora, CO, 
USA; Ser549 is one of the sites of SynI that is phosphorylated by mitogen-activated 
protein kinase (MAPK) (Jovanovic et al., 1996)). Subsequently, sections were rinsed 
in 0.01 M PBS and incubated for 2 h at room temperature with secondary 
biotinylated goat-anti-rabbit antibody (1:500, Jackson ImmunoResearch, Suffolk, 
UK). Then, avidin-biotin complex (1:500, Vector ABC kit, Vector Laboratories, 
Burlingame, CA, USA) was added for 2 h, after which the staining was visualized 
with 1 mg/ml diaminobenzidine and 0.003% H2O2. Thereafter, sections were rinsed, 
mounted on slides, dehydrated and coverslipped for microscopic analysis.  
 
Quantification 
All analyses were carried out by an observer blind to the group assignment. The 
immunoreactivity (ir) of total and phosphorylated SynI was quantified by measuring 
optical density (OD) of each staining. Images were taken using a Leica charged-
coupled device digital camera mounted on a microscope (DMIRB, Leica, Cambridge, 




quantified in multiple brain regions of interest (ROIs) and corrected for non-specific 
background labeling, measured in the corpus callosum. ROIs included the medial 
prefrontal cortex (mPFC; layer I-VI of the prelimbic area: Bregma +3.70 to +2.20), 
the hippocampal dentate gyrus (DG; outer, middle and inner molecular layer (OML, 
MML, and IML, respectively) and hilus: Bregma –2.80 to –4.30), the CA3 area 
(stratum radiatum (SR), stratum lucidum (SL) and stratum oriens (SO): Bregma –
2.80 to –4.30), the CA1 area (stratum lacunosum-moleculare (SLM), stratum 
radiatum (SR) and stratum oriens (SO): Bregma –2.80 to –4.30), and the lateral 
posterior thalamic nucleus (its mediorostral and laterorostral parts, LPMR and 
LPLR, respectively: Bregma –3.80 to –4.30). The latter ROI was chosen as a control 
region, since LPMR and LPLR are not directly involved in processes associated with 
chronic stress and antidepressant treatment. Bregma coordinates were determined 
according to the rat brain atlas (Paxinos and Watson, 2007). The corrected OD 
(COD), quantified in each ROI, was expressed in arbitrary units corresponding to 
grey levels using a Quantimet 550 image analysis system (Leica, Cambridge, UK). 
The ratio between phosphorylated and total SynI was determined by dividing 
the COD of phospho-SynI by the COD of total-SynI in each ROI. Since the COD was 
measured in arbitrary units corresponding to the intensity of the staining, certain 
ROIs with a relatively high phospho-SynI expression had ratio values higher than 1. 
 
Statistics 
Two-way ANOVA was used to determine the effects of stress and agomelatine 
treatment on SynI expression and its phosphorylation. When significant effects were 
found, post-hoc analysis was performed using the Fisher LSD test. The level of 
significance was set at p<0.05. 
 
RESULTS 
Total and phosphorylated SynI expression after chronic stress and 
agomelatine treatment 
mPFC 
Figure 5.1 shows examples of SynI and phospho-SynI immunostainings in the 
mPFC. Changes in total SynI expression and its phosphorylation in different layers 
of  the mPFC  due to  chronic  stress  and  agomelatine  treatment are  shown in figu- 
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Figure 5.1 A representative 
photomicrograph of SynI immu-
nostaining in the mPFC (A). 
Insets show higher magnifi-
cation of SynI expression in 
layers I, III and VI (B). Arrows 
point at total-SynI (C) and 
phospho-SynI (D) labeling in 
different layers (I-VI) of the 
mPFC.  
One square with detailed over-
















re 5.2. Two-way ANOVA revealed a significant stress effect on total-SynI-ir in all 
layers of the mPFC (figure 5.2A; layer I: F(1,28)=4.99, p=0.03; layer II: F(1,28)=5.22, 
p=0.03; layer III: F(1,28)=6.41, p=0.02; layer V: F(1,28)=7.02, p=0.01; layer VI: 
F(1,28)=9.82, p=0.004). Post-hoc analysis showed a significant chronic stress-induced 
increase in total-SynI-ir in all layers of the mPFC in vehicle treated animals (CTR 
Veh vs. STR Veh: layer I: p=0.01; layer II: p=0.03; layer III: p=0.03; layer V: p=0.04;  





Figure 5.2 Effects of chronic 
stress and agomelatine treatment 
on total and phosphorylated 
SynI expression in different 
layers (I-VI) of the mPFC. 
Chronic stress increased total-
SynI-ir in all layers of the 
mPFC, and agomelatine treat-
ment partly reversed these 
changes (A). Whereas no signi-
ficant effects were found on the 
levels of phospho-SynI-ir (B), the 
ratio between phosphorylated 
and total SynI revealed that 
chronic stress significantly de-
creased the fraction of phospho-





















Figure 5.3 A representative photomicrograph of SynI immunostaining in the hippocampus (A). Insets 
show higher magnification of SynI expression in the DG, CA3 and CA1 areas (B). Arrows point at total-SynI 
(C) and phospho-SynI (D) labeling in different layers of the hippocampal subregions. One square with detailed 
overview (C, D) equals to 15x15 μm. 
DG, dentate gyrus; OML, outer molecular layer; MML, middle molecular layer; IML, inner molecular layer; 




ment in layer I of the mPFC (STR Veh vs. STR Ago: p=0.03). In other layers of the 
mPFC agomelatine treatment showed a similar trend, however, it did not reach 
statistical significance (STR Veh vs. STR Ago: layer II: p=0.066; layer III: p=0.11; 
layer V: p=0.15; layer VI: p=0.076). Figure 5.2B shows the expression of phospho-
SynI in different layers of the mPFC. Two-way ANOVA revealed no significant 
effects. Nevertheless, there was a consistent pattern of stress-associated decrease in 
phospho-SynI-ir throughout all layers. A significant stress effect emerged when ratio 
between phosphorylated and total SynI was calculated (figure 5.2C). This stress 
effect was found in all layers of the mPFC (layer I: F(1,28)=6.60, p=0.02; layer II: 
F(1,28)=10.04, p=0.004; layer III: F(1,28)=17.08, p=0.0003; layer V: F(1,28)=13.15, 
p=0.001; layer VI: F(1,28)=8.70, p=0.006). Post-hoc analysis showed that chronic stress 
significantly decreased the ratio of SynI phosphorylation in all layers of the mPFC in 
vehicle treated animals (CTR Veh vs. STR Veh: layer I: p=0.046; layer II: p=0.01; 
layer III: p=0.002; layer V: p=0.006; layer VI: p=0.03). Although treatment with 
agomelatine seemed to partly reverse this stress-induced decrease in the ratio of 
SynI phosphorylation, none of its effects reached statistical significance.  
 
Hippocampus 
Figure 5.3 shows examples of SynI and phospho-SynI immunostainings in the 
hippocampus. Changes in total SynI expression and its phosphorylation in the 
hippocampal subregions due to chronic stress and agomelatine treatment are 
depicted in figures 5.4–5.6.  
 
Dentate gyrus 
Two-way ANOVA revealed a significant drug effect on total-SynI-ir in the DG of the 
hippocampus (figure 5.4A). Whereas stress had no significant effect on total-SynI 
expression, agomelatine decreased total-SynI-ir in all the molecular layers of the DG 
and in the hilus (OML: F(1,28)=9.99, p=0.004; MML: F(1,28)=17.59, p=0.0003; IML: 
F(1,28)=12.01, p=0.002; hilus: F(1,28)=10.65, p=0.003). Analysis of phospho-SynI 
expression in the DG also showed a drug effect (figure 5.4B). Agomelatine treatment 
significantly increased phospho-SynI-ir in the IML and hilus (F(1,28)=5.27, p=0.03 and 
F(1,28)=7.50, p=0.01, respectively) and showed a trend towards increase in the OML 
and MML (F(1,28)=2.98, p=0.095 and F(1,28)=3.58, p=0.069, respectively). Although 
stress seemed to decrease phospho-SynI-ir in the molecular layers of the DG, these 
effects did not reach statistical significance. Effects on SynI phosphorylation in the 
DG  became  clearer  when  the ratio  between  phosphorylated  and  total  SynI  was 
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Figure 5.4 Effects of chronic 
stress and agomelatine treatment 
on total and phosphorylated SynI 
expression in different layers of  
the hippocampal dentate gyrus. 
Whereas stress had no significant 
effect on total-SynI-ir, agomelatine 
decreased it in all molecular layers 
of the DG and in the hilus (A). 
Moreover, agomelatine treatment 
significantly increased phospho-
SynI-ir in the IML and hilus and 
showed a trend towards increase 
in the OML and MML (B). The 
ratio between phosphorylated and 
total SynI revealed a significant 
stress-induced decrease in the 
fraction of phospho-SynI in the 
OML and MML, which was 
reversed by agomelatine (C).  
DG, dentate gyrus; OML, outer 
molecular layer; MML, middle 
molecular layer; IML, inner 
molecular layer. 

















Figure 5.5 Effects of chronic 
stress and agomelatine treatment 
on total and phosphorylated SynI 
expression in different layers of the 
hippocampal CA3 area. Whereas 
stress had no significant effect on 
total-SynI-ir, agomelatine decre-
ased it in all layers of the CA3 
area (A). Moreover, agomelatine 
treatment significantly increased 
phospho-SynI-ir in the SO (B). The 
ratio between phosphorylated and 
total SynI revealed a significant 
agomelatine-associated increase in 
the fraction of phospho-SynI in all 
layers of the CA3 area (C).  
SO, stratum oriens; SL, stratum 
lucidum; SR, stratum radiatum.  



















calculated (figure 5.4C). Significant stress and drug effects were found in the OML 
(F(1,28)=7.92, p=0.009 and F(1,28)=25.87, p=0.00002, respectively) and in the MML 
(F(1,28)=7.57, p=0.01 and F(1,28)=28.06, p=0.00001, respectively), whereas only a 
significant drug effect was observed in the IML (F(1,28)=33.55, p=0.000003) and in the 
hilus (F(1,28)=23.72, p=0.00004). Post-hoc analysis revealed a significant stress-
induced decrease in the ratio of SynI phosphorylation in the OML and MML (CTR 
Veh vs. STR Veh: p=0.02 and p=0.02, respectively), which was reversed by 
agomelatine treatment (STR Veh vs. STR Ago: p=0.0004 and p=0.0002, respectively).  
 
CA3 area 
Two-way ANOVA revealed a significant drug effect on total-SynI-ir in the CA3 area 
of the hippocampus (figure 5.5A). Stress had no significant effect on total-SynI 
expression, but agomelatine treatment decreased total-SynI-ir in all layers of the 
CA3 area (SO: F(1,28)=10.98, p=0.003; SL: F(1,28)=10.20, p=0.004; SR: F(1,28)=13.56, 
p=0.001). Phospho-SynI expression in the CA3 area was low (figure 5.5B). 
Agomelatine treatment significantly increased phospho-SynI-ir in the SO 
(F(1,28)=9.02, p=0.006). A significant drug effect was found on the ratio between 
phosphorylated and total SynI in all layers of the CA3 area (figure 5.5C; SO: 
F(1,28)=19.46, p=0.0001; SL: F(1,28)=6.88, p=0.01; SR: F(1,28)=6.35, p=0.02). 
 
CA1 area 
Two-way ANOVA revealed a significant drug effect on total-SynI-ir in the CA1 area 
of the hippocampus (figure 5.6A). Stress in itself did not affect total-SynI expression. 
Agomelatine decreased total-SynI-ir in all layers of the CA1 area (SO: F(1,28)=18.85, 
p=0.0002; SR: F(1,28)=21.23, p=0.00008; SLM: F(1,28)=14.05, p=0.0008). Phospho-SynI 
expression in the CA1 area was low, except in the SLM (figure 5.6B). Agomelatine 
treatment significantly increased phospho-SynI-ir in the SO and SR (F(1,28)=10.82, 
p=0.003 and F(1,28)=7.47, p=0.01, respectively). When ratio between phosphorylated 
and total SynI was calculated (figure 5.6C), a significant drug effect was found in all 
layers of the CA1 area (SO: F(1,28)=29.67, p=0.000008; SR: F(1,28)=21.61, p=0.00007; 







Figure 5.6 Effects of chronic 
stress and agomelatine treatment 
on total and phosphorylated SynI 
expression in different layers of the 
hippocampal CA1 area. Whereas 
stress had no significant effect on 
total-SynI-ir, agomelatine decre-
ased it in all layers of the CA1 
area (A). Moreover, agomelatine 
treatment significantly increased 
phospho-SynI-ir in the SO and SR 
(B). The ratio between phospho-
rylated and total SynI revealed a 
significant agomelatine-associated 
increase in the fraction of phospho-
SynI in all layers of the CA1 area 
(C).  
SO, stratum oriens; SR, stratum 
radiatum; SLM, stratum lacuno-
sum-moleculare.  


















Lateral posterior thalamic nucleus 
SynI expression in the lateral posterior thalamus was measured for control purpose, 
since this nucleus is not directly involved in processes associated with chronic stress 
and antidepressant treatment. Table 5.1 depicts optical density values of total-SynI-
ir and SynI phosphorylation in mediorostral and laterorostral parts of the lateral 
posterior thalamic nucleus (LPMR and LPLR). No significant changes were found. 
 
Table 5.1 The optical densities of total and phosphorylated SynI-ir and their ratios in mediorostral and 
laterorostral parts of the lateral posterior thalamic nucleus (LPMR and LPLR). There were no significant 
changes between the groups. 
   
 Brain region Experimental group 
 
 CTR Veh STR Veh CTR Ago STR Ago 
   Total-SynI 
 
 LPMR 0.30 ± 0.03 0.29 ± 0.04 0.24 ± 0.03 0.24 ± 0.03 
 LPLR 0.26 ± 0.04 0.23 ± 0.03 0.19 ± 0.02 0.21 ± 0.03 
   Phospho-SynI 
 
 LPMR 0.18 ± 0.02 0.16 ± 0.02 0.19 ± 0.01 0.17 ± 0.03 
 LPLR 0.18 ± 0.02 0.15 ± 0.02 0.19 ± 0.01 0.16 ± 0.03 
   Phospho-SynI / Total-SynI ratio 
 
 LPMR 0.61 ± 0.10 0.56 ± 0.09 0.80 ± 0.11 0.73 ± 0.18 
 LPLR 0.71 ± 0.12 0.65 ± 0.10 0.97 ± 0.12 0.74 ± 0.18 




Chronic stress and agomelatine treatment induced region-specific changes in the 
immunoreactivity of total and phosphorylated SynI protein. In the mPFC, chronic 
stress increased total SynI expression in all cortical layers. Whereas agomelatine did 
not affect total SynI-ir in control animals, it partly reversed the stress-induced 
effects, significantly only in layer I of the mPFC. In order to examine changes in the 




forms (also referred to as the fraction of phosphorylated SynI) was calculated. 
Chronic stress robustly decreased the fraction of phosphorylated SynI in all layers of 
the mPFC, and agomelatine showed a non-significant tendency to partly reverse 
these changes, without altering SynI phosphorylation in control animals. In the 
hippocampus, chronic stress did not influence total SynI expression, whereas 
agomelatine significantly reduced it in both control and stressed animals. However, 
chronic stress selectively decreased the fraction of phosphorylated SynI in the outer 
and middle molecular layers (OML and MML) of the dentate gyrus. Agomelatine 
completely reversed this stress-induced effect, and increased the fraction of 
phosphorylated SynI in all layers of the dentate gyrus, CA3 and CA1 areas. As 
expected, neither chronic stress nor agomelatine treatment changed SynI expression 
in the lateral posterior thalamic nucleus.  
SynI appears to be a stress and antidepressant responsive gene product, 
regulated in a region-dependent manner. In order to functionally interpret the 
changes observed in our study, it is necessary to consider function of this presynaptic 
protein. SynI acts as a phosphorylation-state-dependent regulator of synaptic vesicle 
mobilization, and hence neurotransmitter release (Greengard et al., 1993; Chi et al., 
2001; Cesca et al., 2010). SynI tethers synaptic vesicles to each other and links them 
to the actin filaments, thereby forming a reserve pool of vesicles away from the 
docking site. Phosphorylation of SynI reduces its binding to synaptic vesicles and 
cytoskeleton which allows vesicles to enter the readily releasable pool and to be 
released during a presynaptic depolarization. Thus, it is thought that the dephos-
phorylated form of SynI provides an inhibitory constraint for synaptic vesicle 
exocytosis, which is relieved upon SynI phosphorylation (Greengard et al., 1993; 
Hilfiker et al., 1999). Regulation of the relative number of vesicles in the releasable 
and reserve pools represents an important mechanism by which nerve cells regulate 
the amount of neurotransmitter released, and therefore, the efficiency and strength 
of synaptic signaling (Bahler et al., 1990).  
Our data reveal that chronic footshock stress selectively decreases the fraction of 
phosphorylated SynI in the mPFC and in the OML and MML of the dentate gyrus. 
Interestingly, total SynI is significantly increased after chronic stress in the mPFC, 
but not in any of the hippocampal subregions. Since phosphorylated SynI enables 
vesicle release, it is tempting to speculate that the decrease in the ratio of SynI 
phosphorylation due to prolonged stress may lead to a lower vesicle release. Chronic 
stress in our study selectively affected the degree of SynI phosphorylation in the 
OML and MML of the dentate gyrus, the layers which receive input from the 
entorhinal cortex via the lateral and medial perforant pathways (Witter et al., 2000). 
This finding, thus, indicates that chronic stress may compromise synaptic 
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transmission from the entorhinal-hippocampal projections. This notion is sub-
stantiated by an observation that chronic stress reduces the ability to induce long-
term potentiation at this pathway (Pavlides et al., 2002; Alfarez et al., 2003). In our 
experiment, chronic footshock did not change SynI expression in other synapses of 
the hippocampal circuitry. These findings are in agreement with a report showing 
that chronic restraint stress did not influence SynI-ir in the inner molecular layer 
(IML) and hilus of the dentate gyrus as well as in the CA3 and CA1 areas, although 
it changed the expression of other synaptic markers, synaptobrevin and synapto-
physin (Gao et al., 2006). However, altered expression patterns of SynI protein and 
mRNA were observed throughout the hippocampal subregions after chronic mild 
stress (Wu et al., 2007; Silva et al., 2008), suggesting that distinct stress paradigms 
may have different effects on synaptic marker regulation.  
The effects of chronic footshock stress on SynI-ir are region-specific. Our data 
indicate that this form of stress leads to changes in basal synaptic transmission in 
the entire mPFC, however, its effects in the hippocampus are less severe and 
restricted to the OML and MML of the dentate gyrus. Such region-dependent 
changes suggest that chronic footshock stress has distinct effects on different cell 
populations. In line with this notion, region-specific regulatory effects of stress and 
glucocorticoids have been observed previously (Joels, 2006; McEwen, 2007). 
Furthermore, certain chronic stress effects on synaptic transmission may only 
emerge when there is demand for enhanced neurotransmission and synaptic vesicle 
turnover. Thus, these stress-induced baseline changes in SynI expression may 
manifest differently if an individual is concurrently exposed to a cognitive task or a 
challenging situation. This view is supported by chronic stress effects on learning 
and memory (McEwen, 2000b; Kim and Diamond, 2002; Sandi and Pinelo-Nava, 
2007; Pittenger and Duman, 2008). 
Importantly, agomelatine treatment completely abolishes chronic stress-induced 
decrease in the fraction of phosphorylated SynI in the OML and MML, and thereby 
may rescue stress-compromised synaptic transmission from the perforant path to the 
hippocampal dentate gyrus. Moreover, agomelatine increases the ratio of SynI 
phosphorylation in all hippocampal subregions of both control and stressed animals, 
which may boost synaptic transmission and strengthen neuronal communication in 
the entire hippocampus.  
Our study shows that agomelatine treatment decreases the expression of total 
SynI in the hippocampus. These data are in line with the previously observed effects 
of different antidepressants on SynI. Similarly to our findings, decreases in total 
SynI expression in the hippocampal subregions were reported after treatment with a 




depressant, imipramine (Iwata et al., 2006). Also, a reduced reactivity of SynI in 
hippocampal synaptosomes and synaptic membranes was found after chronic 
administration of a SSRI, fluoxetine, and a noradrenaline reuptake inhibitor (NRI), 
reboxetine (Barbiero et al., 2007). Furthermore, a glucocorticoid receptor (GR) 
antagonist, mifepristone, and a mood stabilizer, lithium, were shown to reverse the 
chronic stress-induced alterations in hippocampal SynI expression (Wu et al., 2007; 
Silva et al., 2008).  
A striking finding was that agomelatine exerts its effects on SynI in a region-
specific manner. Whereas it changes SynI expression in the hippocampus of both 
control and stressed animals, this novel antidepressant does not alter SynI-ir in the 
mPFC of control rats, yet, it partly reverses the stress-induced effects. These distinct 
changes in two stress-related brain regions may hint to the mechanism of 
agomelatine action. This antidepressant acts via melatonergic (MT1/MT2) and 5-
HT2C receptors, which are highly expressed in the hippocampus (Di Giovanni et al., 
2006; Pandi-Perumal et al., 2008; Popoli, 2009). By inducing global presynaptic 
changes in this brain region, agomelatine may exert its effects on hippocampal 
plasticity. Since agomelatine treatment in control animals does not alter SynI-ir in 
the mPFC, it may not modulate basal synaptic transmission in the afferents to the 
mPFC. Alternatively, this drug may induce presynaptic changes only in distinct 
pathways, and its sum effect on multiple systems that project to the mPFC may be 
difficult to detect by SynI immunohistochemistry. MT1, MT2 and 5-HT2C receptors, 
implicated in the mechanism of agomelatine action, are differentially expressed in 
distinct brain areas that send their input to the mPFC (Clemett et al., 2000; Di 
Giovanni et al., 2006; Pandi-Perumal et al., 2008). Thus, the effects of this 
antidepressant may differ per brain region; however, SynI expression in the mPFC 
may not adequately reflect these presynaptic changes. Analysis of additional 
synaptic markers may, therefore, provide a more thorough understanding of the 
molecular correlates that underlie the therapeutic action of agomelatine.  
As mentioned previously, agomelatine interacts with 5-HT2C receptors which are 
abundant in the brain structures involved in regulation of mood and cognitive 
deficits associated with depression (Di Giovanni et al., 2006; Popoli, 2009). Through 
its antagonism at 5-HT2C receptors agomelatine enhances basal (pre)frontocortical 
noradrenergic and dopaminergic transmission as well as increases basal 
noradrenaline release in the dorsal hippocampus (Millan et al., 2003; Millan et al., 
2005). Unlike the classical antidepressants, agomelatine does not influence serotonin 
release (Millan et al., 2003; Millan et al., 2005). Recent findings show that in 
(pre)frontocortical synaptosomes, agomelatine abolishes the acute stress-induced 
increase in glutamate release, but has no effect on depolarization-evoked glutamate 
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release in non-stressed animals (Musazzi et al., 2010). Interestingly, this ago-
melatine effect is mediated by a potential synergy between melatonergic and 5-HT2C 
receptor-dependent pathways (Tardito et al., 2010). The setup of our experiment 
does not allow determination of specific neurotransmitters released due to chronic 
stress and agomelatine treatment. Although the selective stress effect in the OML 
and MML of the dentate gyrus hints to the involvement of glutamate, the 
agomelatine-induced uniform changes in SynI-ir across all layers of the hippocampal 
subregions, however, argue against a sole contribution of glutamate. Multiple 
neurotransmitter systems have been suggested to play a role in stress, depression 
and the action of antidepressant drugs (Joca et al., 2007; Millan, 2009; Dagyte et al., 
2010a; McEwen et al., 2010). Thus, altered SynI-ir patterns in our experiment may 
reflect the net result of chronic stress and agomelatine effects on different 
neurotransmitters and neuromodulators. Taken together, it is plausible that 
agomelatine adjusts the balance of various neurotransmitters in stress-related brain 
regions, and thereby exerts its beneficial effects on neuroplasticity. 
The present study revealed the effects of chronic stress and the antidepressant 
agomelatine on the expression of total and phosphorylated SynI in several stress-
related brain regions: the mPFC, and the hippocampal dentate gyrus, CA3, and CA1 
areas. Both chronic stress and agomelatine treatment were associated with region-
specific changes in SynI. Importantly, agomelatine prevented some of the stress 
effects in the mPFC and completely reversed stress-induced alterations in the 
hippocampal dentate gyrus. As the primary role of SynI is the regulation of vesicle 
turnover, it is predicted that changes in its expression affect synaptic plasticity. Our 
data, thus, indicate that modulation of synaptic function underlies the action 
mechanism of agomelatine, which may include more efficient synaptic signaling in 
specific stress-related brain areas. 
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Major depressive disorder is a severe psychiatric condition which forms a substantial 
burden to patients and society. Despite continuous efforts to unravel its etiology and 
pathophysiology, many questions remain. The majority of neurobiological research 
and classical pharmacotherapy regimens have approached this illness as the 
consequence of a failing monoaminergic neurotransmitter system. In the last decades, 
involvement of adult hippocampal neurogenesis in the pathogenesis and treatment of 
depressive disorder has gained an enormous interest. Numerous neurobiological 
systems and circuits thus appear to underlie this complex multifactorial disease. One 
of them is the cholinergic system, which plays a major role in the regulation of 
various CNS functions, such as arousal, attention, cognition and memory. Cognitive 
impairments are often observed in depression, next to low mood, anhedonia and other 
clinical symptoms. Cholinergic dysfunctions may account for the development of 
cognitive symptoms during the course of depression. Changes in hippocampal 
neurogenesis, often associated with chronic stress in animal models, may be in part 
mediated by cholinergic dysfunction, which in turn could underlie the cognitive 
disturbances observed in depression. Here, we discuss the involvement of the 
cholinergic system in depressive disorder, with particular focus on its role in 
associated cognitive impairment. Since such deficits are often modified by cholinergic 
drugs, application of these neuropharmacological findings may provide a new 






Major depressive disorder is a multidimensional syndrome which involves disruption 
of mood, cognition and other processes, including sleep, appetite and libido (Nestler 
et al., 2002a). Depression has been described since antiquity but it is still 
conceptualized as a common and complex disease of unknown etiology. Research 
attempts to elucidate the mechanisms responsible for development and treatment of 
depression have yielded valuable insight, but its puzzling nature persists. For half a 
century, the majority of neurobiological research and classical pharmacotherapy 
regimens have explained this illness with the monoamine hypothesis of depression, 
which proposes that low levels of brain monoamines, such as serotonin, 
noradrenaline and dopamine, are responsible for the development of depressive 
symptoms. In contrast, many currently used antidepressant drugs, such as selective 
serotonin reuptake inhibitors (SSRI), noradrenaline reuptake inhibitors (NRI), 
serotonin and noradrenaline reuptake inhibitors (SNRI), tricyclics and monoamine 
oxidase inhibitors (MAOI) potentiate the brain’s monoaminergic system and elevate 
the monoamine levels (Wong and Licinio, 2001). Despite their acute effects on the 
monoaminergic system, however, the mood-alleviating properties of all these 
medications take at least several weeks to become manifest (Berton and Nestler, 
2006). Therefore, although considerably advancing the way depression was viewed 
and treated, the monoamine hypothesis has failed to fully explain the nature of this 
disorder (Maes, 2009). The discovery of adult hippocampal neurogenesis seemed 
again to revolutionize the understanding of the neurobiological mechanisms 
governing depression and antidepressant therapies as it proved to be affected by 
stress, yet restored by antidepressants (Krishnan and Nestler, 2008). Despite 
contradictions in literature, the possibility that hippocampal neurogenesis may be 
oppositely regulated by depression and antidepressants, gained enormous interest 
among researchers and great enthusiasm among clinicians. Nevertheless, although 
initially promising, this phenomenon has lost some of its appeal due to difficulties 
providing functional mechanism for the etiology of depression. Not surprisingly, 
failure of one neurobiological system is not sufficient to explain the nature of such a 
complex disorder as depression. Numerous brain systems and neuronal networks act 
in concert to maintain normal functioning; likewise, in depression many of them may 
get dysregulated. One of those is the cholinergic system, responsible for a number of 
CNS functions, including arousal, attention, learning and memory.  
Cognitive impairments are often observed in depression, in addition to mood 
disturbances and other motoric, autonomic, endocrine and sleep-wake abnormalities. 
This spectrum of symptoms is thought to arise from the complex interaction between 
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multiple genetic and environmental factors (Manji et al., 2001). It has been 
hypothesized that different neurotransmitter-mediated dysfunctions may subserve 
specific symptom domains. Depression-associated anxiety is thought to arise from 
abnormal serotonergic function, whereas loss of pleasure, interest and energy may 
be due to dopaminergic and noradrenergic deficits (Nutt et al., 2007). Cholinergic 
dysfunctions may account for the development of cognitive symptoms associated with 
depression, especially when the disease is long-lasting and treatment resistant. 
Moreover, changes in hippocampal neurogenesis may be in part mediated by the 
cholinergic system and may also relate to the cognitive disturbances diagnosed in 
depression.  
Here, we review the literature regarding involvement of the cholinergic system 
in the pathophysiology of depressive disorder. First, the history of the cholinergic 
hypothesis of depression is summarized. Then, the contribution of cholinergic 
changes to the development of mood and cognitive impairments associated with 
depression is discussed. In view of this, we outline a potential link between the 
cholinergic system, hippocampal neurogenesis and cognitive dysfunction in 
depression. In addition to the hippocampal changes mediated by cholinergic 
transmission, we briefly discuss the alterations in other brain areas, implicated in 
depression and innervated by cholinergic neurons, i.e. the prefrontal cortex, 
amygdala, and the suprachiasmatic nucleus (SCN). On a final note, we emphasize 
that depression-associated symptoms depend on complex changes in a variety of 
neurobiological systems and multiple brain areas. Thus, future research would 
benefit from an integrated view on depression, attempting to unravel these multi-
factorial interactions in search of novel therapeutic targets. 
  
THE CHOLINERGIC HYPOTHESIS OF DEPRESSION 
Implication of the cholinergic system in the etiology of major depression, although 
not as widely accepted as the monoamine hypothesis, was postulated several decades 
ago. It was suggested that central cholinergic activation caused depressant 
inhibitory effects, while anticholinergic drugs or adrenergic stimulation induced 
behavioral activation and arousal (Carlton, 1963; Vaillant, 1967; Domino and Olds, 
1968). Based on these observations, Janowsky and co-workers postulated the 
cholinergic-adrenergic imbalance hypothesis of depression and mania (Janowsky et 
al., 1972). Central cholinergic factors were suggested to play a role in the etiology of 
affective disorders, and depression was proposed to be a disease of cholinergic 




inhibitors induced depressive symptoms, presumably through increased central 
acetylcholine levels. The first study of this kind involved administration of the 
irreversible cholinesterase inhibitor diisopropylfluorophosphonate (DFP), which was 
found to induce depression-like symptoms in normal subjects and decrease mania-
like symptoms in manic patients (Rowntree et al., 1950). This was supported by the 
case reports of individuals poisoned with cholinesterase inhibitor insecticides, who 
developed depression symptoms and peripheral parasympathetic toxicity (Gershon 
and Shaw, 1961). Another irreversible cholinesterase inhibitor, EA-1701, was also 
noted to cause depressed mood and lethargy in healthy volunteers (Bowers et al., 
1964). Later, the reversible inhibitor of cholinesterase, physostigmine, was shown to 
induce depressive symptoms and exacerbate mood disorders (Janowsky et al., 1973; 
Janowsky et al., 1974; Davis et al., 1976). Choline treatment was also associated 
with depressive symptoms, but only sporadically (Tamminga et al., 1976). Additional 
evidence for a cholinergic mechanism in depression came from the observation that 
the monoamine depletor reserpine, a drug which induced mood depressing effects, 
had central cholinomimetic properties (Janowsky et al., 1972; Davis et al., 1978). 
Cholinergic hypersensitivity was thus considered essential in depression with 
evidence of anticholinesterases and cholinomimetics producing acute syndromes 
characterized by dysphoria, psychomotor retardation and energy loss (Dilsaver, 
1986). Despite their seemingly acute depressiogenic and antimanic properties, 
however, it is unclear whether these were illustrative of specific depression 
symptomology or a non-specific response of behavioral inhibition, secondary to 
cholinergic manipulation (Leong and Brown, 1987). Nevertheless, given these 
clinical observations, anticholinergic drugs have been investigated as potential 
treatments for depression, but studies have not reported consistent antidepressant 
effects (Goldman and Erickson, 1983; Shytle et al., 2002; Howland, 2009). In fact, the 
agonists of cholinergic nicotinic receptors have been associated with antidepressant 
properties, arguing against the cholinergic dominance hypothesis of depression 
(Ferguson et al., 2000; Gatto et al., 2004).  
Neuroimaging studies have reported an increased concentration of the 
acetylcholine precursor, choline, in the brains of patients suffering from mood 
disorders and its reversal after recovery from depression (Charles et al., 1994; 
Steingard et al., 2000). However, postmortem brain analysis yielded no consistent 
results on the involvement of acetylcholine receptors in depression. Although a 
higher number of muscarinic acetylcholine receptor binding sites was reported in the 
frontal cortex of suicide victims (Meyerson et al., 1982), subsequent studies did not 
replicate this finding (Kaufmann et al., 1984; Stanley, 1984; Zavitsanou et al., 2004) 
or even opposed it (Gibbons et al., 2009). Cholinergic hypersensitivity was linked to a 
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personality trait predisposing to depression, such as stress sensitivity, rather than to 
depression itself (Fritze et al., 1995). 
Importance of the cholinergic hypothesis of depression diminished over time, due 
to insufficient evidence linking it to the etiology of major depression. Even in the 
1980s when this hypothesis was prominent, it was recognized that cholinergic 
pathology is unlikely to explain all the nuances of depression (Dilsaver, 1986). 
Nevertheless, recognizing the role of the cholinergic system in depression may shed 
light upon mechanisms involved in certain aspects of this disease. Therefore, the 
following text of this review will focus on cholinergic changes that may develop 
during the course of depression, and may thus account for specific clinical symptoms 
associated with this disorder. 
 
ALTERED CHOLINERGIC FUNCTION IN DEPRESSION: 
INVOLVEMENT IN COGNITIVE RATHER THAN AFFECTIVE 
SYMPTOMS? 
Low mood is the most prominent clinical symptom of major depressive disorder. 
Also, depression is often accompanied by significant impairments in neurocognitive 
functioning that may be independent of mood (Austin et al., 2001; Porter et al., 2003; 
Clark et al., 2009). Cognitive symptoms of depression, such as poor attention and 
concentration as well as impaired memory and information processing, point to 
deficits in cholinergic function. Acetylcholine is largely responsible for regulating 
these cognitive processes (Deutsch, 1971). Cholinergic projections from the basal 
forebrain system modulate the function of numerous brain areas implicated in 
depression, and the optimal range of cholinergic tone is vital for optimal behavioral 
and brain function (Roland et al., 2008). It is thus feasible that an imbalance of 
multiple neurobiological systems underlying depression results in cholinergic 
dysfunction which, in turn, causes further disruption (see figure 6.1). 
 
Neuropharmacological evidence 
Evidence regarding altered cholinergic function in depression mainly comes from 
drug studies targeting nicotinic or muscarinic cholinergic receptors. These two types 
of cholinergic receptors are widely expressed in the brain and often co-expressed 
within neurons (Schroder et al., 1991; van der Zee et al., 1991). Their action is 






Figure 6.1 Depressive disorder is thought to arise from the complex interaction of multiple genetic and 
environmental factors. These factors may also lead to higher susceptibility to stress. Whereas the acute stress 
response is adaptive, prolonged stress may predispose to depression. Both chronic stress and depression are 
associated with cholinergic dysfunctions as well as with structural and functional alterations in multiple 
brain areas. Changes in the hippocampus, PFC and amygdala, observed in chronically stressed animals 
and/or depressed subjects, may party arise from the cholinergic dysfunction. Altogether, these neurobiological 
alterations account for development of the cognitive symptoms of depression, such as attention deficit, memory 
impairment and negativity bias. Thus, cholinergic dysfunction may in part underlie depression-associated 
cognitive impairments, that in turn can precipitate the course of this illness. On the other hand, cholinergic 
dysfunction may also predispose to depression, via dysregulation of numerous neurobiological systems and 
circuits involved in the pathophysiology of this complex disorder.  
Dashed arrows represent predisposing factors to depression. Solid arrows indicate the consequences that arise 
from pathological states of chronic stress and depression, causing further disruptions, that in turn may 
predispose and/or precipitate depressive disorder.  





the latter seem to be more plausible given the functional role of acetylcholine in the 
brain’s cognitive processes. Nevertheless, nicotine has been shown to alleviate 
symptoms of depression in non-smoking depressed patients (Salin-Pascual et al., 
1995). On the other hand, nicotine withdrawal can exacerbate depressive symptoms 
(Laje et al., 2001). Nicotine dependence is strongly correlated to mood disorders, e. g. 
smoking behavior relates to the genetic susceptibility to depression (Kendler et al., 
1993; Lerman et al., 1998). Interestingly, schizophrenic subjects, also known to have 
a very high rate of smoking, may be using nicotine to self-medicate their cognitive 
impairments associated with schizophrenia (George et al., 2002; Sacco et al., 2005). 
The precise changes in cholinergic signaling through nicotinic receptors in 
depression are not known. Furthermore, the literature is confounded by studies 
reporting that both nicotine receptor agonists and antagonists may display 
antidepressant properties (Ferguson et al., 2000; Shytle et al., 2002; Gatto et al., 
2004; Lippiello et al., 2008). However, their effects on cognitive functions seem to be 
diverse; whereas nicotinic agonists can improve attention, learning and memory, 
nicotinic antagonists can impair these processes (Levin and Simon, 1998; Hasselmo, 
2006; McKay et al., 2007). Although both activation and desensitization of nicotinic 
acetylcholine receptors have been suggested to contribute to behaviors related to 
nicotine addiction and mood (Picciotto et al., 2008), their distinct role in depression 
remains unclear.  
Similarly, there is little research providing direct evidence for a role of 
muscarinic receptors in the pathophysiology of major depressive disorder. Yet, 
pharmacological studies continue to recognize a potential for reducing depression-
associated symptoms via modulation of the muscarinic system (Scarr, 2009). 
Cholinergic muscarinic agonists are shown to facilitate learning and memory, 
whereas antagonists are associated with deficits in these processes (Jerusalinsky et 
al., 1997; Power et al., 2003; Hasselmo, 2006). M1 metabotropic muscarinic receptors 
represent a viable target for amelioration of affective disorder-associated cognitive 
deficits, given their role in cognition (Scarr, 2009). M2 receptors were suggested to be 
involved in major depressive disorder by single-nucleotide polymorphism (SNP) 
association studies (Comings et al., 2002; Wang et al., 2004). This notion was further 
supported by a recent postmortem study, reporting decreased binding of M2 and/or 
M4 muscarinic receptors in the dorsolateral prefrontal cortex of depressed subjects 
(Gibbons et al., 2009).  
Loss of cholinergic terminals results in memory deficits, confirming the above 
described neuropharmacological findings on cholinergic transmission and cognition 
(Jerusalinsky et al., 1997). Given the highly interactive nature of central nicotinic 




depression-induced changes in one subset of the cholinergic system modulate the 
other one too (Schroder et al., 1991; van der Zee et al., 1991; Lucas-Meunier et al., 
2003). At present it is difficult to attribute distinct involvement of these two 
cholinergic receptor systems in the pathophysiology of depressive disorder, and the 
extent of this complexity goes beyond the scope of this review. As such, we will not 
elaborate upon specific effects achieved through the cholinergic receptor subtypes, 
but focus instead on the greater framework of cholinergic changes associated with 
mood disorders and their treatment.  
It appears that some classical antidepressants also partially target cholinergic 
neurotransmission. The SSRI, citalopram, has been shown to reverse memory 
impairment by enhancing acetylcholine release in the hippocampus of laboratory 
animals (Egashira et al., 2006). It has also been reported to improve psychotic 
symptoms and behavioral disturbances in patients with dementia (Pollock et al., 
2002) and facilitate memory consolidation in healthy volunteers (Harmer et al., 
2002). Citalopram may thus possibly improve memory impairment in depressed 
patients by enhancing acetylcholine release (Egashira et al., 2006). The mood 
stabilizer, lithium, has also been shown to upregulate hippocampal cholinergic 
muscarinic receptors (Marinho et al., 1998), further emphasizing a role for the 
cholinergic system in the pathology of depression. 
 
Cholinergic changes in depression and stress:  
contribution to cognitive dysfunction 
Altered acetylcholine release in depression has been hypothesized but not clearly 
proven. Changes in central acetylcholine turnover have been reported in response to 
prolonged stress, a major predisposing risk factor for developing depression 
(Finkelstein et al., 1985; Gilad, 1987). Whereas an acute stress response is adaptive, 
chronic stress, especially when it is unpredictable and uncontrollable, may increase 
brain vulnerability to neuropathology (McEwen, 2004; de Kloet et al., 2005; Dagyte 
et al., 2009). Stress is known to alter the functioning of the cholinergic system (Gold, 
2003; Srikumar et al., 2006). The stress response induces acetylcholine release in the 
forebrain and activates the septohippocampal pathway (Gilad, 1987). This mediates 
physiological and emotional responses, in part through acetylcholine action on the 
HPA-axis (Newman et al., 2001). While acute stressors increase acetylcholine release 
in the hippocampus (Mark et al., 1996; Dong et al., 2004), the effects of chronic stress 
are less clear (Mizoguchi et al., 2001; Srikumar et al., 2006), but may involve a 
gradual decline of cholinergic function. Chronic stress has been reported to decrease 
acetylcholinesterase (AChE) activity in the hippocampus of laboratory animals (Das 
132 
 
et al., 2000; Sunanda et al., 2000). Subsequently, such decrease in AChE activity 
was associated with learning and memory deficits after exposure to chronic stress 
(Srikumar et al., 2006). Cholinergic dysfunctions have also been reported in rats 
subjected to chronic unpredictable stress or corticosterone treatment, where a 
decrease in AChE-stained neurons in the medial septum was observed (Tizabi et al., 
1989; Douma et al., 1999). Such stress-induced malfunctioning of the cholinergic 
system may in turn impair learning and memory processes (Gold, 2003; Srikumar et 
al., 2006). Preclinical studies using in vivo microdialysis techniques have shown that 
increased and decreased acetylcholine levels correlate with increased and decreased 
memory performance, respectively (Ragozzino et al., 1994; Ragozzino et al., 1996). In 
line with this, pharmacological augmentation of septohippocampal cholinergic 
activity enhances learning and memory performance in cognitively impaired animals 
(Roland et al., 2008). 
There is a wealth of evidence indicating that stress, especially when severe and 
prolonged, can precipitate affective disorders and impair learning and memory 
(McEwen, 2000a, McEwen, 2000b). Chronic stress in laboratory animals has been 
associated with deficits in several learning and memory tasks, e.g. radial arm maze 
and Y-maze (Luine et al., 1994; Conrad et al., 1996; Srikumar et al., 2006). The 
hippocampal formation, governing these learning paradigms and densely innervated 
by cholinergic neurons (Gaykema et al., 1990; Woolf, 1991), is highly impacted by 
stress. Exposure to chronic stress or glucocorticoids has been demonstrated to affect 
the hippocampal neurons, causing a dendritic atrophy of CA3 pyramidal neurons, 
alteration in the density of dendritic spines and excrescences, and neuronal cell loss 
(Woolley et al., 1990; Sapolsky, 1993). Among the multiple neurochemical changes 
that occur in response to stress, excessive glutamatergic neurotransmission is 
thought to play a major role in stress-induced hippocampal neurotoxicity. Several 
studies have reported that exposure to stress increased the release of glutamate in 
the hippocampus and other brain regions, such as the prefrontal cortex and the basal 
ganglia (Watanabe et al., 1992; Moghaddam, 1993; Moghaddam et al., 1994). As 
such, excessive glutamate release is also implicated in neurodegeneration (Lee et al., 
2002a). As the glutamatergic and cholinergic systems act in concert, changes in the 
former may synergically affect the latter, causing perturbations in learning, memory 





Relationship between the cholinergic system and hippocampal 
neurogenesis: implication in depression 
Several lines of evidence support the enhanced neurodegeneration and decreased 
neurogenesis hypothesis of depression (Maes, 2009). Structural brain changes have 
been reported in depressed patients, involving volumetric changes in hippocampus, 
amygdala, prefrontal cortex, anterior cingulate cortex and basal ganglia (Sheline, 
2003; Campbell and MacQueen, 2006). Moreover, postmortem studies have revealed 
neuronal and glial cell modifications in the hippocampus in major depression 
(Stockmeier et al., 2004). The hippocampus serves as an integrator of input from 
various brain regions related to mood, learning and memory. Structural and 
functional changes in this vital brain area may thus contribute to impairments 
associated with depression.  
The hippocampus receives abundant cholinergic innervation from the diagonal 
band and septum (Houser et al., 1983; Gaykema et al., 1990; Semba and Fibiger, 
1992; van der Zee and Luiten, 1999). The decreased cholinergic input may account 
for diminished hippocampal functioning and increase its vulnerability to stress 
(Craig et al., 2008). Lesion of cholinergic neurons projecting to the hippocampus are 
known to suppress adult neurogenesis (Cooper-Kuhn et al., 2004; Van der Borght et 
al., 2005c) and concurrently impair spatial memory in rats (Mohapel et al., 2005). 
Acetylcholine thus appears crucial for regulating hippocampal neurogenesis (Bruel-
Jungerman et al., 2010). Transgenic mice expressing an inactive form of AChE, and 
hence expected to have elevated acetylcholine levels, show increased cell pro-
liferation in the dentate gyrus (Cohen et al., 2008). Likewise, pharmacological 
inhibition of AChE also enhances hippocampal neurogenesis (Mohapel et al., 2005; 
Kotani et al., 2006). The AChE inhibitor, donepezil, widely used to enhance cognitive 
function in Alzheimer’s disease, has even been shown to reverse chronic stress-
induced decrease in survival of the newly-born hippocampal neurons (Kaneko et al., 
2006).  
Adult hippocampal neurogenesis is hypothesized to be relevant in the 
pathophysiology and treatment of major depression (Jacobs et al., 2000; Duman, 
2004b). In animal models, rodents often display decreased hippocampal neurogenesis 
(Gould and Tanapat, 1999; Mirescu and Gould, 2006; Krishnan and Nestler, 2008). 
Such reductions in the generation of new neurons are reversible by antidepressants, 
comprising in part their mood-improving actions (Santarelli et al., 2003). However, 
artificially disrupted hippocampal neurogenesis in laboratory animals has not led to 
the depressive phenotype (Sapolsky, 2004; Eisch et al., 2008). Also, subsequent 
research has failed to uniformly confirm that the mood-alleviating effects of anti-
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depressants depend on hippocampal neurogenesis (Bessa et al., 2009). Although 
disruption of the neurogenesis process does not fully explain the etiology of 
depression, yet it may account partly for the associated cognitive impairments as 
altered cholinergic transmission can reduce neurogenesis and subsequently induce 
learning and memory deficits. Changes in hippocampal neurogenesis are thus 
thought to contribute to the hippocampal aspects of major depression. The 
hippocampus plays a major role in declarative (explicit) memory function (Scoville 
and Milner, 2000; Burgess et al., 2002; Squire et al., 2004). People who suffer from 
major depression exhibit memory deficits that are characteristic of hippocampal 
damage (Sheline et al., 1999; Becker and Wojtowicz, 2007). In a subset of depressed 
subjects, reduced hippocampal volumes have also been related to functional 
consequences, such as depression-specific neurocognitive deficits (Sheline et al., 
1996; Sheline et al., 1999; Brown et al., 2004). Reduced hippocampal neurogenesis 
has been suggested as a final common pathway in many brain disorders associated 
with mood (Duman, 2004b) and cognitive dysfunction, such as geriatric depression 
and the depression-mild cognitive impairment (MCI)-dementia complex (Maes, 
2009). Since acetylcholine regulates neurogenesis, changes in new neuron production 
may follow the more global changes in the cholinergic system. Depression-associated 
cognitive and memory deficits may thus represent potential clinical correlates of 
impaired cholinergic transmission and altered hippocampal neurogenesis (Manji et 
al., 2001; Becker and Wojtowicz, 2007). 
A major predisposing factor to depression, chronic stress, induces damage to 
hippocampal structure and function in animal models (Duman et al., 1999; McEwen, 
2000a; Sapolsky, 2000). Besides affecting the cholinergic system, it decreases 
hippocampal neurogenesis, and impairs hippocampal-dependant learning and 
memory (Gould et al., 1999a; Sapolsky, 2003; Mirescu and Gould, 2006). 
Accumulating evidence supports a relationship between hippocampal neurogenesis 
and various types of learning and memory (Leuner et al., 2006). It remains 
unknown, however, whether hippocampal neurogenesis is causally implicated in 
memory function (Gould et al., 1999a; Feng et al., 2001; Shors et al., 2002; Van der 
Borght et al., 2005b; Van der Borght et al., 2005a). It seems unlikely that changes in 
hippocampal neuron production would have an immediate effect on processes 
underlying learning since the newly-born cells require time to differentiate into 
functional neurons and become integrated into the pre-existing circuitry (Carlen et 
al., 2002; Leuner et al., 2006). Therefore, although stress may diminish hippocampal 
cell proliferation, it may not necessarily induce acute learning deficits on 
hippocampus-dependent tasks (Akirav et al., 2004). It has been suggested that 
hippocampal neurogenesis underlies remote, rather than recent, memory formation, 




Alternatively, adult dentate neurogenesis has been proposed to play a role in 
periodic clearance of outdated hippocampal memory traces (Feng et al., 2001; Van 
der Borght et al., 2007). This notion has been supported by a recent study 
demonstrating that suppressed neurogenesis in rodents is accompanied by a 
prolonged hippocampus-dependent period of associative fear memory (Kitamura et 
al., 2009). Reduced neurogenesis might thus hinder erasure of the hippocampal 
memory trace and its transfer to the neocortex. Such impaired clearance of old 
disused memories from the hippocampus could in turn compromise its learning 
capacity and affect the formation of long-term memory. In view of the above, 
presumed chronic impairment of hippocampal neurogenesis in depression may at 
least partly account for development of hippocampal dysfunction leading to cognitive 
and mnemonic deficits.  
Taken together, alterations in the central cholinergic system could affect adult 
neurogenesis and hippocampal function, giving way to depression-associated 
memory deficits. However, besides the explicit memory dysfunction, depressed 
patients often show a more widespread impairment in cognitive function, deficits in 
attention and working memory (Austin et al., 2001; Porter et al., 2003; Clark et al., 
2009), suggesting that dysfunctions are not focally localized to the hippocampus, but 
may be present more globally. 
 
Involvement of the cholinergic system in depression:  
beyond the hippocampus 
Although major depressive disorder is associated with functional impairment of 
multiple brain regions, the hippocampus has been the preferred region of 
investigation. Such bias may have occurred due to the discovery of hippocampal 
neurogenesis and its linkage to depression, as well as due to the fact that 
hippocampus is highly enriched with glucocorticoid receptors and is severely affected 
by stress. Nevertheless, the structural and functional changes associated with 
depression point to the involvement of several other brain regions in addition 
(Sheline, 2003). Here, we limit our discussion to a selected few. First, we will address 
the potential role of the cholinergic system in depression-associated changes in the 
prefrontal cortex and amygdala. Then, we will briefly discuss the cholinergic input to 
the SCN, the regulator of circadian rhythms shown to be often disturbed in 
depression.  
Importantly, both the prefrontal cortex and amygdala receive vast cholinergic 
input, suggesting a vital role for acetylcholine in the modulation of their function 
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(Houser et al., 1983; Woolf, 1991; Semba and Fibiger, 1992). Moreover, cognitive 
symptoms accompanying depression often reflect dysfunctions in these limbic 
structures (Clark et al., 2009). For instance, depressed individuals show deficits in 
executive function, such as impaired performance in tests of attention and working 
memory, which relate to structural abnormalities often observed in the prefrontal 
cortex during depression (Rogers et al., 2004). Different subregions of the prefrontal 
cortex are suggested to contribute to diverse symptoms of depression, and their role 
has been previously reviewed (Koenigs and Grafman, 2009). Postmortem analysis 
suggests a causal role for altered muscarinic receptor expression, particularly in the 
dorsolateral prefrontal cortex of depressed subjects (Gibbons et al., 2009). Potential 
cholinergic involvement of the prefrontal cortex in the cognitive dysfunctions of 
affective disorders is further substantiated by a preclinical study reporting cognitive 
deficits in mice lacking M2 muscarinic receptors (Seeger et al., 2004).  
Cognitive dysfunction in depression is also characterized by  a negativity bias – 
an enhanced responsiveness to, and memory for, emotionally negative stimuli, 
attributed to the impaired functioning of both the prefrontal cortex and the 
amygdala complex (Fales et al., 2008). Mental rumination is a frequent symptom of 
depression, and may depend on hyperactivity of the amygdala leading to enhan-
cement of negative thoughts and memories. Increased activity of the amygdala has 
been demonstrated in depressed patients, and is thought to parallel the suppressed 
activity of the dorsolateral prefrontal cortex and dampened hippocampal function 
(Sheline et al., 2001; McDonald et al., 2004; Fales et al., 2008). Among the 
heterogeneous nuclei of amygdala, the basolateral amygdala (BLA) is especially 
important since it serves as an interface between the sensory and cognitive realms 
(Davis et al., 1994; LeDoux, 2003). Notably, the BLA is critically involved in the 
modulation of memory consolidation, which is achieved through influences from 
cholinergic, noradrenergic and other brain systems (McGaugh, 2004). The BLA is 
abundantly innervated by cholinergic neurons, originating mainly from the nucleus 
basalis of the forebrain (Woolf and Butcher, 1982; Houser et al., 1983; Semba and 
Fibiger, 1992; Roozendaal et al., 1997; van der Zee et al., 1997). In laboratory 
animals, experimental suppression of this cholinergic transmission by lesion of the 
nucleus basalis or intra-amygdalar infusion of muscarinic antagonists impairs 
memory for various learning tasks. Conversely, intra-BLA infusion of muscarinic 
agonists or AChE inhibitors enhances memory or attenuates its impairment 
(Vazdarjanova and McGaugh, 1999; Power and McGaugh, 2002; Schroeder and 
Packard, 2002). These findings suggest that cholinergic activity is essential for 
amygdalar modulation of memory consolidation (McGaugh et al., 2002; Power et al., 
2003). Glucocorticoids also play a role in the consolidation of learning experiences, 




2000; Roozendaal, 2000; McGaugh and Roozendaal, 2002). Glucocorticoids as well as 
stress have been shown to change structure and function of the BLA, resulting in 
hypertrophy and increased excitability (Rainnie et al., 2004; de Quervain et al., 
2009). Associated impairments in working memory are attributed to the interaction 
of the hyperactive BLA with the medial prefrontal cortex (Roozendaal et al., 2004; de 
Quervain et al., 2009). The functional consequences of increased amygdala influence 
on thoughts and emotions are however not possible to adequately assess in 
preclinical research models. Yet, the stress and depression-associated prefrontal 
cortical and amygdalar dysfunctions may be due, at least in part, to altered activity 
of the cholinergic system, given its strong projections to these areas.  
The SCN, situated in the anterior hypothalamus, receives direct cholinergic 
input from the nucleus basalis of the forebrain and is responsible for controlling 
circadian rhythms (Bina et al., 1993; Tuma et al., 2005; Castillo-Ruiz and Nunez, 
2007). Clinical findings suggest that many diverse rhythms can be disrupted in 
depression, including the 24-hour profiles of various hormones, neurotransmitters, 
body temperature as well as sleep architecture and timing (Turek, 2007; Lam, 2008). 
Given the cholinergic input to the SCN, such depression-associated disturbances of 
internal rhythms and sleep-wake cycle may at least partly arise from changes in the 
cholinergic system. In fact, impaired cholinergic transmission has recently been 
linked to disruptions in melatonin production, sleep-wake cycle and other circadian 
rhythms in Alzheimer’s disease (Klaffke and Staedt, 2006). Cholinergic regulation of 
the SCN has also been implicated in cognitive processes (Van der Zee et al., 2004). 
As depression often accompanies or even precedes the Alzheimer’s disease, similar 
changes may underlie both pathologies (Starkstein et al., 2008). Recognition that 
desynchronization of circadian rhythms also plays an important role in depression 
has led to the development of the first melatonergic antidepressant, agomelatine 
(Tuma et al., 2005; Lam, 2008; Popoli, 2009). Besides being a potent agonist of the 
melatonergic (MT1/MT2) receptors, agomelatine also acts as an antagonist of the 
serotonergic (5-HT2C) receptors (Audinot et al., 2003; Millan et al., 2003). This novel 
drug combines antidepressant efficacy with beneficial effect on sleep quality, 
achieved via synergy between the melatonergic and 5-HT2C receptors, highly 
expressed in the SCN and limbic brain areas (Popoli, 2009). Preclinical studies have 
already demonstrated a variety of agomelatine-mediated changes on neural 
plasticity (Banasr et al., 2006; Conboy et al., 2009; Soumier et al., 2009), including 
its beneficial action in the stress-compromised brain (Dagyte et al., 2010d). However, 
the effects of agomelatine on the cholinergic transmission are not yet known and 




CONCLUSION AND FUTURE DIRECTIONS 
Dysfunctions in the cholinergic system alone do not fully explain the etio-
pathophysiology of major depressive disorder, but they represent likely contributors 
to its wide spectra of associated symptoms, particularly those involving cognition. 
Acetylcholine plays an important role in regulation of hippocampal neurogenesis, 
believed to be involved in the pathophysiology and treatment of depressive disorder. 
Alterations in the central cholinergic system may thus affect adult neurogenesis and 
hippocampal function, leading in turn to the cognitive deficits observed in 
depression. Besides the hippocampus, cholinergic neurons from the basal forebrain 
also project to other brain structures implicated in depressive disorder. Therefore, 
cholinergic changes may also account for depression-associated circadian rhythm 
desynchronization as well as cognitive symptoms related to the functions of such 
structures as the prefrontal cortex and amygdala. Future research is needed to 
elucidate more precise cholinergic changes that underlie depression, but as 
cholinergic drugs continue to modify cognitive deficits characteristic of this disorder, 
application of these neuropharmacological findings may provide a new therapeutic 
niche while yielding valuable insight into the pathophysiology of this complex 
illness.  
In conclusion, the cholinergic system plays a considerable, albeit poorly 
recognized, role in major depression-associated cognitive dysfunctions (see figure 
6.1). Yet, the cholinergic system represents merely one of many players involved in 
this severe illness. The complex interaction of multiple factors and neurobiological 
systems is thought to underlie the intricate changes associated with depressive 
disorder, in a variety of brain areas. Future research can thus greatly benefit from 
an integrated approach in attempts to elucidate the interaction among diverse 
factors of depression, rather than focusing on changes of one neurobiological system. 
Such cohesive knowledge might not only shed light on the more poorly understood 
aspects of this disorder but also pave the way to development of novel multifaceted 
therapies against it. 
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“The important thing in science is not so much to obtain new facts 
as to discover new ways of thinking about them” 
 




The previous chapters of this thesis provided experimental evidence for the existence 
of neurobiological changes associated with stress, depression and the novel 
antidepressant agomelatine. The aim of this final chapter is to give an overall 
interpretation and integration of the results. At first, the caveats concerning stress 
research are discussed. Second, chronic stress models used in this thesis are reviewed, 
in an attempt to place the present data within the greater framework of our 
knowledge regarding the pathophysiology of stress and related disorders. Also, 
potential neurobiological changes underlying the mechanism of action of the anti-
depressant agomelatine are discussed. At last, the future perspectives concerning this 




WHAT IS STRESS? 
“Everybody knows what stress is and nobody knows what it is” (Selye, 1973). 
 
The concept of stress, reviewed in chapter 1, has been a subject of scientific debate 
ever since its introduction. In particular, the definition of stress in terms of threat to 
homeostasis has been criticized as too broad and almost meaningless since virtually 
all actions of an organism are involved in maintaining a homeostatic equilibrium 
(Day, 2005; Koolhaas et al., 2010). Although the complexity of this issue has been 
addressed, yet, there is no universal definition of stress with operationally defined 
terms that can be applied equally to rodents and humans (Kim and Diamond, 2002). 
Not surprisingly, this hampers the interpretation of results coming from stress 
research. 
 
Stress is relative 
The term stress is often generalized implying that exposure to any kind of stressor 
evokes similar changes in physiology and behavior. In addition, it is intuitively 
believed that the stressor with a higher intensity has more severe effects. However, 
this is not entirely true. First, the “non-specific” stress response, as postulated by 
Selye, is followed by changes specific to each stressor (Selye, 1955). Although most 
stressors lead to similar neurochemical alterations, it is important to note that not 
all stressors in general have the same effects (Anisman and Matheson, 2005). 
Second, the intensity of a stressor is not so much related to the physical nature of 
the stimulus, but rather to the degree to which it challenges adaptive defense 
mechanisms (Koolhaas et al., 2006). Thus, a seemingly very aversive stressor (e.g. 
footshock) may have rather mild effects, as discussed in the following sections. 
Moreover, it is uncertain what role should be addressed to anticipatory processes in 
chronic stress paradigms since it is unknown whether anticipating an adverse event 
is stressful for rodents as it is for most humans (Anisman and Matheson, 2005). 
Finally, stress occurrence is determined by how an organism perceives and reacts to 
the stimulus (Kim and Diamond, 2002). Hence, stress pathology occurs due to 
psychological appraisal of the stressor, not due to its physical characteristics 
(Koolhaas et al., 2006). 
Another caveat in stress research is the absence of unique physiological 
measures that are stress specific. Although the elevation of glucocorticoid levels 
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often serves as a measure of a stress response, it is not a definitive indicator of a 
stress state (Koolhaas et al., 2010). In fact, increased glucocorticoid levels are also 
associated with pleasurable activities, such as exercise, feeding and sex (Bronson 
and Desjardins, 1982; Rosmond et al., 2000; Kanaley et al., 2001; Kim and Diamond, 
2002).  
 
Acute versus chronic stress 
The acute stress response is initiated immediately after the exposure to a 
challenging stimulus and terminated when the stressful experience is over. In case 
of chronic stress, however, this response is commenced repeatedly and may persist if 
exposure to a stressful situation endures. Yet, the effects of chronic stress are not 
simply an extrapolation of the effects of acute stress, as complex adaptive and 
maladaptive phenomena must be taken into account in the long run.  
In chapter 2 of the present thesis, this notion is elaborated by investigating 
whether repeated footshock stress leads to changes that are not seen after exposure 
to a single footshock session. Hippocampal neurogenesis, and cell proliferation in 
particular, served as the main readout in these experiments. Although both acute 
and repeated exposure to footshock stress led to strong activation of the HPA axis, 
only the latter caused suppression in hippocampal cell proliferation. This study thus 
demonstrated that repeated stress is necessary for the induction of this specific 
change in the brain. Since the effect of chronic stress on new cell generation was 
temporary (the rate of cell proliferation recovered within 24 hours), the present 
study also emphasized that timing of animal sacrifice is an important consideration 
in stress research (Dagyte et al., 2009).  
 
CHRONIC STRESS PARADIGMS AS PUTATIVE 
ANIMAL MODELS OF STRESS-RELATED 
DISORDERS 
“No perfect animal model exists for any aspects of any CNS disorder, as implied by 
the term modeling” (Mogil, 2009). 
 
In this thesis, animal models of chronic stress were used in order to elucidate 




brain prone to psychopathology. Induction of a stress-vulnerable state in the brain 
was also a prerequisite in the studies aimed at unraveling the working mechanism of 
the antidepressant agomelatine. As stated in the introductory chapter, however, no 
experimental paradigm in animals can fully mimic depressive disorder in humans. 
With this in mind, I will review the chronic footshock stress model which was 
employed in the majority of experiments described in the present thesis (chapter 2, 
3, and 5).  
 
The chronic footshock stress model: review 
Footshock is a frequently used stimulus in stress and learning paradigms. The focus 
of this section, however, is only on the chronic footshock stress model, established to 
investigate effects of prolonged stress and their implication for psychopathology 
(Trentani et al., 2002; Kuipers et al., 2003; Trentani et al., 2003). Previous studies 
using this stress model illustrated a variety of gender-related dimorphisms, 
emphasizing different responses to stress in male and female individuals. Although 
undoubtedly interesting and important, these gender differences will not be 
discussed in more detail, since experiments described in the current thesis involved 
only male rats.  
An important methodological difference of the present thesis as compared to the 
above mentioned studies is the timing of animal sacrifice in relation to the last 
footshock exposure. Whereas the earlier studies investigated changes 2 hours post-
stress exposure, the current thesis first examined the time-dependency of chronic 
footshock-associated effects (2 / 24 hours post-stress; chapter 2) and employed the 24 
hours post-stress sacrifice schedule in the following experiments (chapter 3 and 5). 
This was done with the intention to avoid confounding effects of the acute stress 
response as well as with an attempt to focus on lasting effects of chronic stress.  
 
Effects on physiological and endocrine measures 
The chronic footshock stress model has been associated with changes at multiple 
levels. At the systemic level, this stress paradigm was shown to affect several 
physiological and endocrine measurements. Exposure to repeated footshock reduced 
food intake (this thesis) and decreased body weight gain (this thesis and previous 
studies) (Trentani et al., 2002; Kuipers et al., 2003; Westenbroek et al., 2003a). 
Moreover, this type of stress enhanced plasma adrenaline levels (previous studies) 
and induced a robust HPA axis response as reflected by elevated ACTH and CORT 
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concentrations (this thesis and previous studies) (Trentani et al., 2002). These 
changes in stress hormone levels were observed after exposure to repeated footshock; 
yet, they were measured 2 hours after the last stress session at the latest, and may 
therefore rather represent the acute stress response than long-lasting alterations in 
endocrine regulation. In agreement, the data described in this thesis revealed no 
differences in baseline levels of ACTH and CORT, measured after 3 weeks of daily 
footshock exposure (chapter 2). Nevertheless, the previous studies reported an 
increase in adrenal weight following this chronic stress paradigm (Trentani et al., 
2002; Westenbroek et al., 2005), although these effects were not always significant 
(Westenbroek et al., 2003a), like in the present thesis (unpublished data).  
 
Effects on behavior 
At the behavioral level, exposure to footshock stress induced massive ultrasonic 
vocalization (this thesis). Surprisingly, however, this chronic stress model was 
associated with rather mild changes in various other behavioral tests, or was even 
devoid of effects therein. Westenbroek and coworkers using this stress paradigm 
reported significantly increased locomotor activity in the open field test following 
exposure to repeated footshock (Westenbroek et al., 2003b); however, this finding 
was not confirmed in the current thesis (figure 7.1A). Differences in experimental 
design (reversed light-dark cycle and repeated testing in the study of Westenbroek 
and coworkers) might explain this discrepancy. The present thesis attempted to 
further characterize behavioral correlates of this stress model. In turn, several 
experiments were performed where chronically stressed rats were tested in various 
behavioral paradigms, including elevated plus maze and sucrose preference tests. 
Notably, none of these behavioral paradigms detected significant changes following 
chronic footshock stress (figure 7.1B and 7.1C). One explanation for the lack of 
effects could be the timing of the stress exposure in relation to behavioral testing. In 
the studies described in this thesis, rats were generally tested about 20 hours after 
the previous footshock session, right before the stress session of that day, in order to 
assess the chronic effects of stress on behavior. One possibility might thus be that 
chronic footshock did induce short-lasting changes in behavior that went unnoticed 
in these experiments. Studying the time-dependency of stress effects on behavior 
might clarify this issue; however, it was beyond the scope of this thesis. Another 
possibility is that despite a wide array of behavioral paradigms used, these were not 
sensitive enough to detect chronic footshock-induced changes. Moreover, behavioral 
parameters are associated with high individual variation that may hamper obtaining 
significant results, unless high numbers of animals per group are used. Additional 




Figure 7.1 Effects of chronic footshock stress 
(CFS) on rat behavior in open field test (A), 
elevated plus maze (B) and sucrose preference test 
(C). All the testing was performed at the end of the 
chronic stress period and no significant changes 
were found in any parameters measured. Chronic 
footshock stress did not affect rat locomotor 
activity in the open field as measured by the mean 
distance moved per minute (A). Although chro-
nically stressed rats spent less time on open arms 
of the elevated plus maze, this effect was not 
significant (B). Both control and stressed rats 
showed high preference to 1% sucrose solution (C). 
















shock stress-evoked effects on behavior. Furthermore, rats might be able to cope 
with daily stress of this type, despite the lack of adaptation in terms of ultrasonic 
vocalization and the peak HPA axis response. Faster recovery of the CORT response 
at the end of the chronic footshock period (chapter 2) suggests that animals partly 
habituate to this type of stress at the endocrine level. In turn, they might also adapt 




A variety of chronic footshock effects have been described in the brain at the cellular 
and molecular levels. Figure 7.2 attempts an integration of these findings, discussed 
in detail in the following text.  
 
Effects on neuronal activity 
An in-depth analysis of neuronal activity was carried out using c-Fos as a marker 
(Trentani et al., 2002; Kuipers et al., 2003; Westenbroek et al., 2003a). These studies 
revealed that 2 hours after the last stress exposure, when c-Fos expression is at peak 
levels, there were pronounced region-specific changes in neuronal activity. In 
particular, rats showed increased c-Fos immunoreactivity in stress-related brain 
areas, including medial prefrontal cortex (mPFC), amygdala, paraventricular 
nucleus (PVN) of the hypothalamus, and raphe nuclei, demonstrating enhanced 
activity in this neural circuit after repeated footshock (Trentani et al., 2003). 
Interestingly, however, reduced c-Fos expression was found in the hippocampal 
dentate gyrus, suggesting that chronic stress decreased neuronal activity in this 
limbic region (Trentani et al., 2003). The latter observation was further investigated 
in the current thesis which largely focused on stress-induced changes in the 
hippocampus. As described in chapter 3, repeated footshock stress also down-
regulated basal c-Fos expression (24 hours after the last stress exposure) in the 
dentate gyrus and showed a similar tendency towards decrease in the CA1 and CA3 
areas of the hippocampus (Dagyte et al., 2010b). Interestingly, however, chronic 
stress did not alter basal c-Fos immunoreactivity in the PVN (unpublished results). 
These data suggest that repeated footshock stress leads to region-specific changes in 
basal c-Fos expression. The induction of c-Fos reflects the activity of the neurons 
(Kovacs, 1998). Thus, decrease in c-Fos expression in the dentate gyrus and CA 
areas may indicate reduced neural activity and suppressed hippocampal function in 







Figure 7.2 Overview of the neurobiological effects observed in the chronic footshock stress model. This 
figure is based on several studies, including the present thesis, which are discussed in the main text.  
AMYG – amygdala, BrdU – bromodeoxyuridine, CREB – cAMP response element binding protein, DCX – 
doublecortin, ERK1/2 – extracellular signal-regulated kinase 1/2, HIPP – hippocampus, PFC – prefrontal 





Effects on hippocampal neurogenesis 
In this thesis, adult hippocampal neurogenesis was used as one of the main readouts 
of stress effects on the brain. Impact of chronic footshock stress on different stages of 
the neurogenesis process was investigated in chapter 2. These experiments revealed 
that exposure to chronic footshock transiently suppressed hippocampal cell pro-
liferation: whereas the number of dividing progenitors decreased 2 hours after the 
last stress exposure, it returned to control levels within the next 24 hours. Similar 
dynamics of stress effects on new cell production was reported in a social defeat 
model in mice (Lagace et al., 2010). As described above, the present study also 
assessed changes in cell proliferation after acute footshock, but no significant effects 
were found. Thus, negligible impact of a single footshock session became evident 
after repeated stress. Such gradually developing changes in the production of new 
cells in the course of chronic stress might have consequences in the long run. The 
present study showed that chronic footshock stress decreased the number of newly-
born immature neurons in the dentate gyrus. Although several processes might 
account for changes in this neuronal population, the transient reduction in the 
generation of new cells by the end of the chronic stress period is a likely cause since 
fewer cells born after stress may yield fewer young neurons (Dagyte et al., 2009). 
Repeated footshock had no effect on survival of hippocampal cells that were born 
several days before the start of the chronic stress protocol (a single BrdU labeling on 
day –4) (Dagyte et al., 2009). Notably, a previous report using the same stress model 
showed that repeated footshock decreased survival of cells born early during the 
chronic stress period (daily BrdU injections on days 4–8) (Westenbroek et al., 2004). 
However, when proliferating cells were labeled in the second half of the chronic 
footshock stress period (daily BrdU injections on days 13–16), only a non-significant 
trend towards a decrease in cell survival was found (Kuipers, 2004). Given such 
BrdU labeling schedules in the latter two studies, they were unable to isolate effects 
of stress on cell proliferation per se from the mere impact on cell survival that occurs 
later. Nevertheless, these data together suggest that hippocampal cell survival is 
regulated dynamically by chronic footshock stress. Thus, the final outcome of each 
study might very much depend on the timing of BrdU labeling as well as on other 
factors known to influence adult neurogenesis. Literature suggests that similar 
dynamics of stress impact on hippocampal cell survival also occurs in response to 
other forms of stress. For instance, a recent study reported that chronic restraint 
stress increased the survival of 14-day old cells, but did not affect survival of 21-day 
old cells (Snyder et al., 2009). In sum, this shows that subtle changes in the study 




The overall impact of chronic stress on hippocampal neurogenesis in this stress 
model was rather mild. Yet, exposure to footshock repeatedly and strongly activated 
the HPA axis. Together, these findings point to a limited role of glucocorticoids in 
regulating neurogenesis. Although an increase in CORT levels has been suggested as 
a prerequisite for negative effects of stress on neurogenesis, it alone is, however, not 
sufficient and does not strictly correlate with the effect on newly-generated cells as 
discussed in detail in chapter 2 of this thesis.  
 
Effects on neuronal plasticity 
Previously, multiple changes in cellular signaling cascades regulating neuronal 
plasticity were reported using the chronic footshock stress model. Repeated 
footshock was shown to target the ERK1/2–CREB cascade; specifically, it increased 
ERK1/2 phosphorylation in dendrites of the mPFC and reduced CREB 
phosphorylation in neurons of various cortical regions (mPFC, cingulate and 
perirhinal cortex) as well as subcortical areas (hippocampal dentate gyrus, lateral 
and basolateral amygdala, and paraventricular thalamic nucleus) (Kuipers et al., 
2003; Trentani et al., 2003; Kuipers, 2004). In addition, chronic footshock was 
reported to decrease the expression of calcineurin (PP2B) in the cingulate cortex and 
hippocampus (Kuipers et al., 2003; Kuipers, 2004). 
 
Effects on synaptic plasticity 
The chronic footshock stress model was also associated with changes in the 
expression of several synaptic proteins. Specifically, repeated stress was shown to 
increase mRNA levels of synaptotagmin, synaptophysin and synapsin in both the 
mPFC and hippocampus (Kuipers, 2004). This thesis further investigated chronic 
footshock-induced effects on synapsin I (SynI) expression and its phosphorylation 
pattern in several stress-related brain regions. These immunohistochemical findings 
are described in detail in chapter 5. In brief, chronic stress induced region-specific 
changes in total and phosphorylated SynI. Repeated footshock increased expression 
of total SynI protein but decreased the fraction of its phosphorylated form in the 
mPFC. Yet, chronic stress did not affect total SynI in the hippocampal subregions 
but selectively decreased the fraction of phosphorylated SynI in the outer and middle 
molecular layers of the hippocampal dentate gyrus. Given the function of SynI in 
synaptic transmission and plasticity, these data suggest alterations in synaptic 




Validity of the model 
The previous paragraphs described a variety of effects reported in the chronic 
footshock stress model. Yet, it is important to ask to what extent these findings 
represent changes in the human situation.  
Animal models for any human disorder are assessed by their construct validity 
(theoretical rationale of the model), face validity (phenomenological similarities 
between the model and the disorder), and predictive validity (correspondence of drug 
action in the model to that in the clinic). The construct validity of the chronic 
footshock stress model is based on the notion that stress, especially when severe and 
prolonged, might predispose to affective disorders, including major depression. 
However, this model has shortcomings with respect to face validity. Minor 
behavioral changes observed so far are difficult to compare to the clinical symptoms 
of patients suffering from major depressive disorder. Although loss of appetite and 
body weight are often associated with major depression, their occurrence alone is not 
sufficient to diagnose this disorder. A strong induction of the HPA axis in response to 
footshock confirms the aversive nature of this stressor. Nonetheless, this model does 
not seem to produce long-term endocrine changes that are often observed in 
depressed patients. Chronic footshock stress induces a variety of effects on neuronal 
and synaptic plasticity, which are proposed to underlie the pathophysiology of major 
depressive disorder. At present, it is not clear whether these changes are cause or 
consequence of depression, as clinical research on this topic is hampered by technical 
limitations. Yet, since chronic stress-induced alterations are, at least partly, rever-
sed by antidepressant drugs, this model shows predictive validity.  
In conclusion, albeit limited in effects at the behavioral level, the chronic 
footshock stress model is associated with changes at the cellular and molecular level. 
Although these alterations are rather mild, yet, they may indicate impaired brain 
plasticity and increased vulnerability to stress-related pathology.  
 
The chronic mild stress model:  
effects on hippocampal neurogenesis 
Another stress model used in this thesis is the chronic mild stress (CMS) paradigm 
(chapter 4). This model has been reviewed extensively (Willner, 1997, Willner, 2005); 
therefore, the current text will focus on specific effects obtained in the present study. 
The primary goal of this experiment was to further characterize the actions of the 
antidepressant agomelatine in the stress-compromised brain. Nevertheless, here I 




Although this experiment was not designed to study differences between two stress 
paradigms (chronic footshock and CMS), their neurobiological effects will be 
indirectly compared.  
As described in chapter 4, exposure to a five-week CMS paradigm did not change 
the rate of hippocampal cell proliferation. Nevertheless, it decreased the survival of 
hippocampal cells, born before the stress period. Moreover, CMS was associated with 
a reduction in the expression of DCX, a protein present mainly in the newborn 
immature neurons. These data suggest that distinct aspects of the neurogenesis 
process might be differentially regulated by stressful stimuli. Chapter 4 provides an 
overview of other studies supporting this notion as well as discusses possible 
mechanisms underlying such distinct effects. Here, I will focus on the lack of 
changes in hippocampal cell proliferation following CMS. 
As indicated previously, timing is an important issue in this type of research. 
The temporal dynamics of footshock stress-associated changes in cell proliferation is 
described in chapter 2. In brief, chronic footshock stress had a short-term effect on 
new cell production, which was detected 2 hours post-stress but gone 24 hours later. 
The sacrifice of animals in the CMS experiment was carried out 4–6 hours after the 
last stress session. At present, this looks like a methodological flaw, when viewed 
from the perspective of above described results. However, the results of chapter 2 
were not yet completely analyzed when the CMS experiment was designed. Anyhow, 
I do not expect that CMS would have inhibited cell proliferation, even if rats were 
sacrificed 2 hours after the last stress session. The present data do not indicate even 
a slightest tendency towards a decrease in new cell production. Therefore, it is 
rather hard to comprehend that the rate of cell proliferation recovered completely 
within a couple of hours. Hence, there must be an alternative explanation for the 
lack of effect on newborn cell generation. The last stressor in the current CMS 
paradigm was exposure to predator sounds. Being a rarely used stressor, its effects 
are unknown. Therefore, another possibility is that animals were not sufficiently 
stressed right before they were sacrificed. Hippocampal neurogenesis, and cell 
proliferation in particular, is a highly dynamic process, heterogeneously regulated by 
various factors that act in concert to shape the final overall effect. Thus, it might be 
that other procedures performed in this experiment, e.g. behavioral testing, also 
influenced the rate of cell proliferation, and thereby masked the stress effect. Of 




Different stress models:  
distinct effects on hippocampal neurogenesis 
Interestingly, the present findings in the CMS paradigm partly contrast with those 
observed in the chronic footshock stress model. Whereas both paradigms induced 
changes in DCX-positive hippocampal neuron population, yet, they had distinct 
effects on cell proliferation and survival. The different outcomes obtained in two 
stress models cannot be compared directly. For instance, it is not clear whether the 
CMS-induced decrease in cell survival is a result of specific stressors used or a longer 
duration of an overall stress period, or some other factors. Notably, newborn cells 
were labeled before the stress period in both experiments (BrdU injection on day –4); 
however, their survival was assessed at different time points after chronic stress 
(five weeks versus three weeks). Thus, this may again reflect the importance of 
timing in studying effects of stress on the dynamic process of hippocampal 
neurogenesis.  
 
TARGETING NEURAL AND SYNAPTIC 
PLASTICITY BY AGOMELATINE 
The action of agomelatine in the brain has been shown to involve changes in 
hippocampal neurogenesis and neuroplasticity in general (chapter 1). This 
information was obtained from experiments using unchallenged laboratory animals. 
However, antidepressant drugs are meant to treat pathological conditions and their 
effects might differ in disturbed versus intact systems (Berton and Nestler, 2006). 
Therefore, the present thesis investigated actions of agomelatine in the brain 
exposed to chronic stress as a risk factor for mood disorders.  
Agomelatine-induced changes in the stress-compromised brain were the focus of 
the experiments described in chapter 3, 4, and 5. As mentioned previously, two 
stress models, namely chronic footshock and CMS, were used in order to characterize 
the actions of agomelatine under conditions of prolonged stress. Despite differences 
in stress paradigms and their evoked effects on the brain, here I will attempt an 
overall synthesis of the findings on agomelatine. Hence, I will refer to “the action of 
agomelatine in the stressed brain”, and will not specify the type of stress involved.  
The present data suggest that agomelatine acts by normalizing stress-affected 
hippocampal neuronal activity (chapter 3). Moreover, this antidepressant enhances 




and/or reverses stress-induced changes therein (chapter 3 and 4). Furthermore, 
agomelatine counteracts, at least partly, the stress-associated decline of DCX 
expression in the hippocampal dentate gyrus. Interestingly, in control conditions 
agomelatine itself reduces the expression of DCX, which may depend on its ability to 
speed up the maturation of newborn cells (Soumier et al., 2009) and shortening in 
the time window of the expression of this marker (Banasr et al., 2006). Finally, 
agomelatine treatment is associated with region-specific changes in SynI, a 
presynaptic protein involved in the regulation of synaptic transmission and 
plasticity (chapter 5). Importantly, this antidepressant prevents some of the stress 
effects on SynI in the mPFC and reverses stress-induced alterations in the 
hippocampal dentate gyrus. Altogether, this indicates that modulation of neural and 




Figure 7.3 The figure depicts the multiple targets by which agomelatine may increase brain plasticity and 
cellular resilience. This model is based on several studies, including the present thesis, which are discussed in 
the main text. The targets that have been shown to participate in the action mechanism of agomelatine are 
framed; the others represent putative players.  
5-HT – serotonin, Akt – protein kinase B, BDNF – brain-derived neurotrophic factor, CREB – cAMP response 
element binding protein, DA – dopamine, ERK1/2 – extracellular signal-regulated kinase 1/2, GSK3ß – 
glycogen synthase kinase 3ß, MEK – mitogen-activated protein kinase kinase, MT – melatonin, NE – 




As described in chapter 1, agomelatine is an agonist of the melatonergic 
MT1/MT2 receptors, and also a serotonergic 5-HT2C receptor antagonist. 
Neurobiological effects of agomelatine may, at least in part, depend on its synergistic 
action through these receptor sites (Soumier et al., 2009; de Bodinat et al., 2010; 
Tardito et al., 2010). The downstream signaling of agomelatine, depicted in figure 
7.3, is proposed to involve multiple molecules implicated in brain plasticity and 
cellular resilience. Treatment with agomelatine was associated with increased 
BDNF expression in the hippocampus; this effect involved synergy between 
melatonergic and 5-HT2C receptor-dependent pathways (Soumier et al., 2009). 
Moreover, agomelatine was reported to increase the phosphorylation of ERK1/2, Akt 
and GSK3ß, intracellular signals known to convey the effects of antidepressants and 
mood stabilizers on hippocampal neurogenesis and cell survival (Jiang et al., 2005; 
Silva et al., 2008; Wexler et al., 2008). Importantly, inhibition of GSK3ß by 
phosphorylation was suggested to exert antiapoptotic effects (Jope and Bijur, 2002) 
as well as to produce antidepressant-like behavioral changes in rodents (Gould et al., 
2004). Phosphorylation of ERK1/2 activates the transcription factor, CREB, 
implicated in the regulation of neuroplasticity, neurogenesis and survival through 
the downstream gene, e.g. BDNF, transcription. ERK1/2 also induces phos-
phorylation of SynI, a synaptic vesicle-associated protein involved in 
neurotransmitter release. In turn, modulation of synaptic transmission by SynI 
might contribute to cellular resilience. Furthermore, treatment with agomelatine 
was shown to enhance noradrenergic and dopaminergic transmission; this effect was 
achieved through 5-HT2C receptor blockage (Millan et al., 2003; Millan et al., 2005). 
Increase in noradrenaline and dopamine might also ultimately lead to activation of 
CREB and thereby contribute to its associated effects on brain plasticity and cellular 
resilience.  
Overall, the cascades targeted by agomelatine are similar to those involved in 
the mechanism of action of other antidepressants and mood stabilizers (Malberg and 
Blendy, 2005; Tardito et al., 2006; Schloesser et al., 2008). This notion thus 
highlights the possibility that drugs with diverse pharmacological profiles ultimately 
converge on the same signaling cascades. The following neuronal and synaptic 
changes might be required to attain an adaptive response of the brain underlying 
clinical recovery and/or prevention of psychopathological syndromes. If the 
neuroplasticity hypothesis of depression holds true, then such convergence in 
cellular signaling governing brain plasticity may also provide an explanation for a 
rather similar clinical efficacy of various antidepressant drugs. Diversity in their 
targeted receptor profile, however, may account for differences in tolerability and 




The innovation of agomelatine thus lays in its actions achieved through 
melatonergic receptors, in combination with the blockage of 5-HT2C receptors. 
Importantly, treatment with agomelatine does not modify extracellular levels of 
serotonin and does not down-regulate presynaptic and postsynaptic 5-HT1A 
receptors, contrary to the effects of the classical antidepressants, SSRIs.  
These data on agomelatine, however, has been gathered in the experiments 
using male animals only. Given the higher prevalence of depressive disorders in 
women and the existence of gender dimorphisms in the mechanisms underlying 
associated neuronal dysfunctions, the actions of agomelatine should also be 
evaluated in the female counterpart. 
 
TOWARDS AN INTEGRATED VIEW  
OF DEPRESSION 
Depression has been identified since antiquity but it is still conceptualized as a 
disorder without firmly established mechanism. As stated in chapter 1, many 
different theories have been postulated in an attempt to elucidate its etiology and 
pathophysiology. To this date, however, none of the proposed hypotheses alone could 
adequately explain the mechanisms underlying development and treatment of 
depression. Nonetheless, each and every theory has yielded valuable insights into 
specific aspects of this illness.  
An intriguing possibility holds that previously highlighted multiple hypotheses 
may act in concert to explain neuronal defects underlying major depressive disorder. 
For instance, changes in the HPA axis activity, neurotransmitter systems, 
neuroplasticity, proinflammatory cytokines and other factors implicated in 
depression together with individual genetic make-up may comprise vulnerable 
phenotypes prone to the development of this disorder (see figure 1.1 in the 
introductory chapter). Hence, an attempt to integrate actions of these diverse 
players may help to formulate a unifying hypothesis of depression. A true 
understanding of the pathophysiology of depressive disorder must, therefore, also 
encompass changes at different levels at which the disease manifests: molecular, 
cellular, systemic, and behavioral (figure 7.4). 
The multiple hypotheses of depression yield a variety of changes associated with 
this complex disorder. Despite conceptual differences, these theories do not exclude 
each other but rather complement one another or even overlap. For instance, the 





Figure 7.4 The figure illustrates multiple factors that encompass the pathophysiology of major depressive 
disorder at different levels. These levels are indicated in the central part of the figure. On the left, the findings 
of the current thesis are outlined. On the right, the literature data are summarized. Adapted from Schloesser 
et al., 2008.  
PFC – prefrontal cortex, BrdU – bromodeoxyuridine, DCX – doublecortin, HIPP – hippocampus, Mol – 
molecular level, NT – neurotransmitter, SynI – synapsin I. 
 
nisms (Chung et al., 2000; Hemrick-Luecke and Evans, 2002); vice versa, 
corticosteroids modulate 5-HT synthesis and turnover (Azmitia et al., 1993; Clark 
and Russo, 1997). Furthermore, the monoamine systems as well as glucocorticoids 
have been implicated in regulation of neuronal plasticity and hippocampal 
neurogenesis (Brezun and Daszuta, 1999; Gould, 1999; Huang and Herbert, 2005). 
Interestingly, whereas these processes are enhanced by antidepressants with 




Hen, 2006; Pittenger and Duman, 2008). Although the exact mechanisms underlying 
antidepressant- and stress-evoked changes in neuroplasticity are not yet fully 
understood, the current evidence suggests the convergence of their effects on 
common molecular pathways (Pittenger and Duman, 2008). Thus, depressive 
disorder may involve alterations in neuronal and synaptic plasticity, triggered by 
various intrinsic and extrinsic factors predisposing to psychoneuropathology. 
Chapter 6 of the present thesis provides yet another example of how several theories 
of depression may be integrated in an attempt to explain cognitive impairments 
associated with this illness.  
Hence, approaching depression from a broader perspective and acknowledging 
the role of different systems in its etiology and pathophysiology may yield a more 
complete picture on the nature of this disorder (see figure 1.1 in the introductory 
chapter). Naturally, the degree of influence conveyed by multiple factors will differ 
in individual cases of depression, thereby clarifying its symptom heterogeneity, 
highly variable course and differences in response to treatment. 
 
FUTURE VIEWS AND CONSIDERATIONS 
In view of future research, it would be of interest from a clinical perspective to 
further pursue the neurobiological substrates and neurochemical profiles underlying 
the states of chronic stress and depression in the human brain. Advances in the 
imaging techniques might one day allow us to directly assess the aforementioned 
processes of neuroplasticity in the living human brain, and to trace time-dependent 
changes in the course of disease and its treatment. The ongoing clinical 
investigations of the role of inflammation in depression hold promise for better 
understanding of the etiopathogenesis of this disorder. Further genetic analyses are 
necessary to reliably determine the impact of genetic make-up in depression, as the 
findings of previous association studies have often been inconsistent and difficult to 
replicate (Lopez-Leon et al., 2008; Bosker et al., 2010). Altogether, research on 
depression would benefit from longitudinal clinical studies followed up by 
postmortem investigation of the brain. Despite the emerging prospects for examining 
the disease mechanisms in humans, scientific advances in this research field will 
also depend on preclinical investigations using animal models.  
Several issues should be considered when translating the preclinical findings in 
laboratory animals to the human situation. First, as already discussed in the present 
thesis, no experimental paradigm in animals can fully mimic depressive disorder in 
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humans. This is unfortunate because complex illnesses, such as depression, are at 
present unlikely to be fully unraveled without animal models; yet, a good 
experimental paradigm requires thorough knowledge of the mechanisms of the 
disease, thereby creating a catch-22 situation. Second, depression occurs more than 
twice as often in women than in men. Yet, most preclinical studies, including the 
current thesis, focus on changes in males. Since findings associated with one gender 
cannot be automatically extrapolated to the other, future research should pursue the 
neurobiological substrates underlying development and treatment of depression in 
both genders. Third, the rodent and primate brain differ structurally and 
functionally; therefore, effects of stress in rat and/or mouse brain might not 
adequately correspond to depression-associated changes in human brain, especially 
in its highly developed cortical areas. This could be illustrated by an example of the 
PFC, which is not only subdivided differently in rodent and primate brain but also 
partly contrasts in the functional characteristics of its subregions (box 7.1). 
Literature suggests that the infralimbic cortex (IL) of the rat is homologous to the 
ventromedial PFC (VMPFC) in humans, and that the rat prelimbic cortex (PL) 
corresponds to the dorsolateral sector (DLPFC) of the human PFC (Vertes, 2006). 
Functionally, both the IL and VMPFC are involved in visceromotor control of 
emotion, although VMPFC is also ascribed “affective” functions. The dorsal sector of 
the PFC, mainly implicated in “affective” and “cognitive” activities in rat brain (PL), 
however, is primarily associated with “cognitive” or “executive” functions in human 
brain (DLPFC) (Vertes, 2006; Koenigs and Grafman, 2009). This illustrates that 
comparisons between certain PFC regions in rodent and primate brain should be 
exercised with caution. Interestingly, the majority of studies on depression in 
humans report alterations in the DLPFC, whereas preclinical research using rodents 
usually investigates changes in the entire mPFC and only occasionally mentions its 
subregions. Given the disparate functionality of the mPFC areas, the work described 
in this thesis intentionally focused on the changes in the PL, proposed to most 
closely relate to the human DLPFC. 
Besides the PFC, multiple other brain regions show functional impairments in 
major depressive disorder. Nevertheless, recent research has mainly focused on the 
hippocampal formation. Although this brain region is important in regulating the 
HPA axis and orchestrating other limbic structures involved in affection, yet, the 
main function of the hippocampus remains contextual learning and memory. In view 
of this, the specific structural and functional alterations in the hippocampus may 
underlie the cognitive symptoms of depression. This issue is covered in chapter 6 of 
the present thesis. The hippocampal formation is subdivided into dorsal and ventral 
parts, and the latter is suggested to play a role in the affective symptoms of 





Subregions of the PFC: nomenclature and function 
The PFC in both humans and rodents is organized in a topo-
graphical manner, such that regions regulating emotions are 
situated ventrally and medially, and regions regulating thought and 
action are located more dorsally and laterally (Arnsten, 2009). In 
humans, the PFC is generally divided into the ventromedial 
(VMPFC) and dorsolateral (DLPFC) sectors (Koenigs and Grafman, 
2009). The VMPFC includes the ventral portion of the medial PFC 
and medial portion of the orbitofrontal cortex. The main function of 
the VMPFC is regulation of emotional responses, e.g. processing of 
fear and modulation of the visceral autonomic activity associated 
with emotion. The DLPFC includes portions of the middle and 
superior frontal gyri on the lateral surface of the frontal lobes, and 
plays a key role in regulating attention, thought and action 
(Arnsten, 2009; Koenigs and Grafman, 2009). The PFC in rats is 
divided into the orbital, medial and lateral sectors, however, a 
generally accepted nomenclature for the PFC subregions is still 
lacking (Uylings et al., 2003). According to the rat brain atlas 
consulted in the current thesis (Paxinos and Watson, 2007), the PFC 
is divided into the medial orbital (MO), infralimbic (IL), prelimbic 
(PL), anterior cingulate (AC or Cg1), and secondary motor (M2) 
areas. The AC, PL and IL together comprise the medial PFC 
(mPFC), suggested to functionally correspond to the primate PFC 
(Vertes, 2006). Whereas AC has been linked to various motor 
behaviors, ventral regions of the mPFC (IL and PL) have been 
associated with diverse emotional, cognitive, and mnemonic 
processes (Heidbreder and Groenewegen, 2003). More specifically, 
the IL of rats primarily controls visceromotor functions, and the PL 
is involved in limbic and cognitive activities (Vertes, 2006) 
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lar nuclei and the aforementioned subregions of the PFC, closely interact with the 
ventral hippocampus as well as with one another in regulating mood and emotions. 
Their function implies a more straightforward role in stress-related pathologies, and 
therefore urges future research to move beyond the hippocampus and pay more 
attention to other brain structures.  
The biased focus on the hippocampus in stress research could be explained by 
the discovery of dentate neurogenesis in adulthood and its linkage to depression. The 
majority of the experiments described in the present thesis also used hippocampal 
neurogenesis as the readout of stress and antidepressant effects on the brain. In 
order to understand the functional implications of these findings, it is crucial, 
however, to functionally decipher the process of adult neurogenesis. The present 
debate on the function of hippocampal neurogenesis has suggested its involvement in 
the processes of learning and memory as well as in the regulation of mood and 
emotion (Sahay and Hen, 2007; Deng et al., 2010). Consequently, suppressed dentate 
neurogenesis has been proposed as a final common pathway in many brain disorders 
associated with mood and cognitive dysfunction, such as geriatric depression and the 
depression-mild cognitive impairment-dementia complex (Maes, 2009). Nevertheless, 
the precise function of adult-born dentate granule cells in these processes remains 
elusive. There is no direct evidence that hippocampal neurogenesis is causally 
implicated in the development of depressive disorder, although it might mediate the 
behavioral effects of antidepressant drugs under certain (Santarelli et al., 2003; 
Surget et al., 2008; David et al., 2009) but not all conditions (Bessa et al., 2009; 
David et al., 2009). Therefore, the aim of future research on this topic is to elucidate 
the function of adult neurogenesis, in order to adequately interpret addition and 
removal of new neurons to the hippocampal circuit. From a broader perspective, it 
would be helpful to better understand the role of the dentate gyrus in hippocampal 
functioning as it might explain how changes in information processing by this 
circuitry relate to depression.  
 
CONCLUDING REMARKS 
Stress and its related disorders pose a considerable threat to health in modern 
societies. Much attention in research has been devoted to deciphering mechanisms 
underlying maladaptation to stress and development of associated psycho-
pathologies, including major depression. Although many drugs have been developed 
to treat this pathological condition, their therapeutic effects are suboptimal and the 




physiology of stress, a risk factor of depressive disorder, may therefore clarify 
fundamental changes in the brain predisposing to psychopathology, and enable the 
development of novel therapeutic strategies. These and related issues were at the 
core of the present thesis, which largely focused on investigation of the neuro-
biological effects associated with chronic stress and antidepressant treatment in 
adult rats.  
Taken together, the work presented in this thesis supports the notion that 
prolonged stress is accompanied by neuronal and synaptic changes in the brain. 
Nonetheless, the extent of these effects is highly dependent on the timing of their 
investigation as well as on the type and duration of stress procedure. The current 
thesis also suggests that the processes of neuronal and synaptic plasticity may 
underlie the action mechanism of agomelatine, the antidepressant with an 
innovative pharmacological profile. Further characterization of cellular signaling 
cascades targeted by agomelatine is necessary to more thoroughly understand the 
molecular pathways governing its therapeutic actions. This information might also 
yield more general insight into mechanisms underlying the recovery from affective 
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5-HT  Serotonin 
AChE  Acetylcholinesterase  
ACTH  Adrenocorticotropic hormone 
Ago   Agomelatine 
Akt   Protein kinase B 
AS   Acute stress 
AVP  Arginine-vasopressin  
BDNF  Brain-derived neurotrophic factor 
BLA  Basolateral nucleus of the amygdala 
BNST  Bed nucleus of stria terminalis 
BrdU  Bromodeoxyuridine 
cAMP  Cyclic adenosine monophosphate  
CeA  Central nucleus of the amygdala 
CMS  Chronic mild stress 
COD  Corrected optical density 
CORT  Cortisol / corticosterone 
CREB  cAMP responsive element binding protein  
CS   Chronic stress 
CRH  Corticotropin-releasing hormone 
CTR  Control group 
DA   Dopamine  
DCX  Doublecortin  
DG   Dentate gyrus 
ERK1/2  Extracellular signal-regulated kinase 1/2 
GABA  γ-aminobutyric acid 
GAS  General adaptation syndrome 
GCL  Granular cell layer 
GR   Glucocorticoid receptor 
GR-i mice Glucocorticoid receptor-impaired mice 
GSK3ß  Glycogen synthase kinase 3ß  
HEC  Hydroxyethylcellulose  
HPA axis Hypothalamic-pituitary-adrenal axis 
IDO  Indoleamine 2,3-dioxygenase  
IL   Infralimbic cortex 
IML  Inner molecular layer 
ir   Immunoreactivity 
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LPMR  Mediorostral part of the lateral posterior thalamic nucleus  
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MT   Melatonin 
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NF-κB  Nuclear factor kappa B 
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NT   Neurotransmitter 
OD   Optical density 
OML  Outer molecular layer 
PI3K  Phosphoinositide-3-kinase 
PFC  Prefrontal cortex 
PKA  Protein kinase A 
PL   Prelimbic cortex 
POMC  Proopiomelanocortin  
PVN  Paraventricular nucleus 
ROI  Region of interest 
SCN  Suprachiasmatic nucleus 
SGZ  Subgranular zone 
SO   Stratum oriens 
SL   Stratum lucidum 
SLM  Stratum lacunosum-moleculare 
SNP  Single nucleotide polymorphism 
SNRI  Serotonin and noradrenaline reuptake inhibitor 
SP   Sucrose preference 
SPT  Sucrose preference test 
SR   Stratum radiatum 
SSRI  Selective serotonin reuptake inhibitor 
STR  Stressed group 
SynI  Synapsin I 
TCA  Tricyclic antidepressant 






The rationale of this research 
Stress and its related disorders pose a considerable threat to health in modern 
societies. Stressful life events promote alterations in the brain that may lead to 
psychopathology, such as major depression. Preclinical research studies substantiate 
this causal association and chronically stressed animals show multiple changes that 
mimic those observed in depressed humans. Therefore, chronic stress models in 
laboratory animals are widely used to investigate fundamental changes in the brain 
that might predispose to psychopathology in humans. A better understanding of  
“the stressed brain” thus may decipher mechanisms underlying affective disorders 
and enable the development of novel therapeutic strategies. Despite advances in 
treatment of major depression, therapeutic effects of the currently available 
antidepressant drugs are suboptimal and their mechanisms of action remain 
obscure. This urges elucidation of the specific neurobiological processes underlying 
recovery from depressive disorder and necessitates investigation of antidepressant-
induced effects on the brain.  
This thesis aims to dissect neurobiological changes associated with stress, 
depression and novel antidepressant treatment. The experimental approach is based 
on two animal stress models (the chronic footshock stress and chronic mild stress), 
employed to study stress-induced alterations in neuroplasticity and adult 
hippocampal neurogenesis, implicated in the pathophysiology of depression. 
Moreover, this thesis investigates neurobiological effects of a new antidepressant, 
agomelatine. 
 
Effects of chronic stress on the brain 
The experimental work presented in this thesis reveals that chronic stress is 
accompanied by neuronal and synaptic changes in the brain (chapter 2–5). Among 
them are decreases in generation, survival, and maturation of new neurons (the 
process called adult neurogenesis) in the hippocampus, the brain region involved in 
regulation of mood and memory. According to a recent hypothesis, changes in adult 
hippocampal neurogenesis underlie depressive disorder and its treatment. Whereas 
stress, a risk factor for depression, inhibits the rate of hippocampal neurogenesis, 
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various antidepressant treatments increase it and/or prevent the effects of stress. 
The current thesis, however, reveals that the above noted hypothesis is not as 
straightforward as it may suggest. Importantly, the effects of stress on hippocampal 
neurogenesis have specific temporal dynamics and depend on type and duration of 
the stress experience (chapter 2 and 4). Our experiments in rats showed that 
repeated footshock stress induces alterations in hippocampal cell proliferation that 
are not seen after exposure to a single footshock session. Thus, the negative impact 
of stress on hippocampal neurogenesis may be subtle and only appear after chronic 
exposure to the stressor. Nonetheless, some effects of chronic footshock stress on 
adult neurogenesis are temporary and recover shortly after the stressful experience 
is over (chapter 2). Furthermore, the type of stress matters. Exposure of rats to 
another experimental paradigm, the chronic mild stress model, did not influence the 
rate of hippocampal cell proliferation, yet suppressed cell survival and neuronal 
maturation (chapter 4). Other stress-induced alterations, as revealed by experiments 
described in this thesis, include decreased neuronal activity in the hippocampus 
(chapter 3) and brain-region specific changes in the expression of synapsin I, a key 
regulator of signal transmission between neurons (chapter 5). Taken together, these 
data show that chronic stress induces a variety of effects on neuronal and synaptic 
plasticity. These alterations may indicate impaired brain plasticity and signal 
transmission, and increase vulnerability to stress-related pathology.  
 
Effects of the novel antidepressant agomelatine on the brain 
Search for new targets in treatment of depression has led to the development of the 
first melatonergic antidepressant, agomelatine. This novel antidepressant acts as an 
agonist of melatonin receptors as well as an antagonist of serotonergic 5-HT2C 
receptors, and its therapeutic effects are proposed to derive from the synergy 
between these receptor sites. The current thesis investigated the action of 
agomelatine in the brain exposed to chronic stress as a risk factor for mood disorders 
(chapter 3–5). Our experiments revealed that agomelatine normalizes stress-affected 
neuronal activity in the hippocampus (chapter 3). Moreover, this antidepressant 
enhances adult hippocampal neurogenesis under conditions of chronic stress  
and/or reverses stress-induced changes therein (chapter 3–4). Furthermore, 
agomelatine treatment prevents some of the stress effects on synapsin I, a key 
regulator of synaptic transmission (chapter 5). Altogether, these data indicate that 
modulation of neural and synaptic plasticity underlies the action mechanism of 





View on depression 
Depression has been identified since antiquity but it is still conceptualized as a 
disorder without firmly established mechanism. This thesis provides a brief overview 
of different theories of depression, postulated in an attempt to better understand its 
development, course and treatment. In particular, we discuss the involvement of the 
cholinergic system in depressive disorder and associated cognitive impairments 
(chapter 6). Literature review suggests that cholinergic changes contribute to certain 
aspects of depression, especially its cognitive symptoms. In view of this, we outline a 
potential link between the cholinergic system, hippocampal neurogenesis and 
cognitive dysfunction in depression. 
 
Conclusions and future perspectives 
Overall, this thesis provides evidence for the existence of neurobiological changes 
associated with stress, depression and novel antidepressant agomelatine. Specific 
neuronal and synaptic alterations develop in response to prolonged stress and might 
increase brain susceptibility to psychopathology. They could be, however, reversed 
by treatment with agomelatine and might underlie its antidepressant action. 
Further characterization of cellular signaling cascades targeted by agomelatine is 
necessary to better understand the molecular pathways governing its therapeutic 
action. Such knowledge may yield valuable insight into mechanisms underlying 
recovery from affective disorders while opening up novel prospects for their 









Achtergrond van dit onderzoek 
Stress en de gevolgen ervan vormen een aanzienlijke bedreiging voor de geestelijke 
gezondheid in de hedendaagse samenleving. Stressvolle gebeurtenissen veroorzaken 
veranderingen in de hersenen, die aanleiding kunnen geven tot psychiatrische 
ziekteprocessen zoals depressie. Experimenteel onderzoek onderbouwt deze oorzaken 
van depressie, en proefdieren blootgesteld aan langdurige stress vertonen verande-
ringen in hersenen en gedrag die erg lijken op depressie bij de mens. Om die reden 
wordt chronische stress in proefdieren veel toegepast in het laboratorium om de 
veranderingen te kunnen begrijpen die mensen ondergaan bij het ontwikkelen van 
depressie. Een beter begrip van „het gestresste brein“ kan dus de mechanismen aan 
het licht brengen die leiden tot depressie en de mogelijkheden aangeven voor 
ontwikkeling van behandelstrategieën. Ondanks de toename van onze kennis van 
behandelmethoden voor depressie is het therapeutisch effect van beschikbare 
medicijnen verre van optimaal en zijn de onderliggende mechanismen nog steeds 
niet goed bekend. Dit is de aanleiding om meer specifieke aspecten van hersen-
processen van depressie nader te onderzoeken en het effect daarop van nieuw 
ontwikkelde antidepressiva. 
Dit vormt dan ook het doel van dit promotieonderzoek: de ontrafeling van de 
veranderingen in de hersenen ten gevolge van stress, depressie en het effect van 
antidepressiva. Het experimentele onderzoek is gebaseerd op een tweetal stress-
modellen: chronische voetschokstress, en chronische milde stress, en de gevolgen 
hiervan op aanpassingscapaciteit van de hersenen, en op neurogenese in de 
hippocampus, die beide een rol spelen in de veroorzaking van depressie. Voorts 
hebben we de effecten op deze aanpassingsprocessen onderzocht van een nieuw 
ontwikkeld antidepressivum agomelatine. 
 
Effecten van chronische stress op de hersenen 
De experimenten die in dit proefschrift zijn beschreven laten zien dat chronische 
stress aanleiding geeft tot neuronale en synaptische veranderingen (hoofdstuk 2–5). 
Onder andere veranderingen is het ontstaan, overleving en rijping van nieuwe 
zenuwcellen (een proces aangeduid met de term neurogenese) in de hippocampus, 
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een hersengebied dat essentieel is voor geheugenfuncties en stemmingen. Volgens 
een recente hypothese vormen veranderingen in de hippocampus een grondslag voor 
het ontstaan van depressie. Terwijl stress als risicofactor voor depressie het proces 
van neurogenese in de hippocampus onderdrukt, wordt neurogenese door het 
gebruik van antidepressiva juist bevorderd. Ons eigen onderzoek echter laat zien dat 
deze bovengenoemde hypothese niet zo eenvoudig is als vaak gedacht en dat de 
gevolgen van stress voor neurogenese afhankelijk zijn van de duur van de stress en 
de soort stress (hoofdstuk 2 en 4). Onze rattenexperimenten tonen aan dat herhaalde 
voetschokstress veranderingen in de neurogenese laten zien, die niet optraden na 
een enkelvoudige stresservaring. Deze negatieve gevolgen van stress zijn dus subtiel 
en treden alleen op na langdurige blootstelling aan stress. Daarnaast zijn sommige 
effecten van langdurige stress slechts tijdelijk en herstelt het hersenweefsel snel na 
het beëindigen van de stresservaring (hoofdstuk 2). Verder is de aard van de stress 
van belang. Blootsteling van ratten aan een geheel ander stressprotocol, de zg. 
chronische milde stress, had geen gevolgen voor het ontstaan van nieuwe 
zenuwcellen, maar onderdrukte wel de overleving en de rijping van nieuwe 
zenuwcellen (hoofdstuk 4). Andere verandering veroorzaakt door stress die wij 
hebben waargenomen, hadden betrekking op de activiteit van de hippocampus 
(hoofdstuk 3) en dan met name in de lokale verandering in de activiteit van 
synapsine I, een eiwit dat betrokken is bij de afgifte van neurotransmitters 
(hoofdstuk 5). Deze bevindingen tonen aan dat stress een veelheid van 
veranderingen teweegbrengt. Ook maken deze gegevens aannemelijk dat het 
aanpassingsvermogen en de signaaloverdracht van de hersenen in negatieve zin 
wordt aangetast door stress en de gevoeligheid voor het ontstaan van pathologie 
bevordert. 
 
Effecten van het nieuwe antidepressivum agomelatine  
op de hersenen 
De zoektocht naar nieuwe medicijnen voor de behandeling van depressie heeft geleid 
tot de ontwikkeling van het eerste antidepressivum dat is gericht op het melatonine 
systeem van de hersenen: agomelatine. Dit nieuwe antidepressivum werkt als een 
agonist (activator) van de melatonine receptoren, zowel als antagonist (remmer) van 
de serotonine 5-HT2C receptor, en men denkt dan ook dat het therapeutisch effect 
van agomelatine berust op de samenwerkende gevolgen op beide receptorsoorten. In 
dit proefschrift werd het effect van agomelatine onderzocht op de gevolgen van de 
door stress veroorzaakte veranderingen in de hersenen als risicofactor voor het 




de veranderde activiteit in de hippocampus ten gevolge van stress compenseert en 
terugbrengt naar normale waarden (hoofdstuk 3). Tevens verhoogt dit nieuwe 
antidepressivum neurogenese in de hippocampus bij chronische stress en keert het 
de door stress veroorzaakte veranderingen om in het neurogenese proces (hoofdstuk 
3–4). Voorts voorkomt agomelatine de stress effecten op synapsine I, een eiwit  
dat een sleutelrol speelt in de afgifte van neurotransmitters (hoofdstuk 5). 
Samenvattend tonen deze gegevens aan dat het werkingsmechanisme van 
agomelatine berust op het moduleren van neuronale en synaptische aanpassings-
processen, en erop gericht is om de communicatie tussen zenuwcellen onder 
stressvolle condities te verbeteren.  
 
Cognitie en depressie 
Depressie is al bekend sedert de oudheid, maar het is nog steeds een ziektebeeld 
waar het onderliggende mechanisme niet goed van bekend is. Dit proefschrift geeft 
een kort overzicht van de verschillende theorieën over depressie met het doel een 
beter begrip te krijgen van ontwikkeling, verloop en behandeling. In het bijzonder 
hebben we aandacht besteed aan de rol van het acetylcholine systeem van de 
voorhersenen bij depressie en de daarmee samenhangende cognitieve symptomen 
(hoofdstuk 6). Een overzicht van de beschikbare literatuur geeft aan dat verande-
ringen in dit acetylcholine systeem bijdragen aan bepaalde aspecten van depressie, 
in het bijzonder aan de cognitieve verschijnselen die met depressie samenhangen. In 
dit verband hebben we speciaal aandacht besteed aan de relatie tussen het 
acetylcholine systeem, de vorming van nieuwe neuronen in de hippocampus, en 
cognitieve stoornissen bij depressie.  
 
Conclusies en toekomstperspectieven 
Dit proefschrift beschrijft een reeks bevindingen over neurobiologische 
veranderingen die samenhangen met chronische stress, depressie en behandeling 
met het nieuwe antidepressivum agomelatine. Specifieke neuronale en synaptische 
veranderingen traden als gevolg van langdurige blootstelling aan stress die de 
hersenen gevoelig maken voor het ontwikkelen van psychopathologische 
verschijnselen. Deze veranderingen konden worden gecompenseerd door toepassing 
van agomelatine wat mogelijk het antidepressieve werkingsmechanisme verklaart. 
Voortgaande karakterisering van de moleculaire en cellulaire processen  
van signaaloverdracht is noodzakelijk om het therapeutisch mechanisme van 
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agomelatine beter te kunnen begrijpen. Dergelijke kennis zal het inzicht verder 
vergroten in de processen die de grondslag vormen voor het herstel van affectieve 
stoornissen en de weg banen voor nieuwe en betere behandeling van deze veel 
voorkomende psychiatrische ziektebeelden. 
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SANTRAUKA LIETUVIŲ KALBA 
 
Tyrimo problema ir prielaidos 
Šiuolaikinėje visuomenėje stresas ir su juo susijusios ligos kelia didelį pavojų 
sveikatai. Nuolatinė įtampa ir stresas palieka pokyčius smegenyse, kurie gali 
paskatinti psichinių ligų, pavyzdžiui, depresijos atsiradimą. Moksliniai tyrimai, 
atliekami su laboratoriniais gyvūnais, ir depresija sergančių ligonių stebėjimas 
patvirtina šį priežastinį ryšį: lėtinis stresas ir depresija sukelia panašius 
neurofiziologinius pokyčius. Todėl laboratorinių gyvūnų lėtinio streso modeliai 
taikomi tyrinėjant fundamentalius pakitimus smegenyse, įtakojančius depresijos 
vystymąsi. Nuodugnios žinios apie „streso paveiktas smegenis“ galėtų padėti 
nustatyti nuotaikos sutrikimų priežastis ir eigą, pagerinti jų gydymą. Nors depresija 
jau sėkmingiau gydoma, visgi šiuo metu naudojamų antidepresantų veiksmin- 
gumas dar nepakankamas ir jų veikimo principai tebėra neaiškūs. Visa tai skatina 
visapusiškai nagrinėti neurobiologinius procesus, vykstančius smegenyse sveikstant 
nuo depresijos, ir sąlygoja antidepresantų sukeltų pokyčių smegenyse tyrimus.  
Šios disertacijos tikslas – streso, depresijos ir naujojo antidepresanto 
agomelatino sukeltų neurobiologinių pokyčių analizė. Atlikti ir aprašyti 
eksperimentai taikant du laboratorinių gyvūnų streso – elektrinio pėdos šoko ir 
lėtinio silpnojo streso – modelius, ištirtas streso poveikis smegenų plastiškumui, 
galintis įtakoti depresijos išsivystymą. Šioje disertacijoje nagrinėjami ir naujojo 
antidepresanto agomelatino sąlygojami pokyčiai smegenyse.  
 
Lėtinio streso poveikis smegenims 
Šioje disertacijoje pateikti eksperimentai įrodo, kad lėtinis stresas sukelia įvairių 
neuroninių ir sinapsinių pakitimų smegenyse (2–5 skyr.). Vienas iš tokių pokyčių – 
tai neuronų dauginimosi proceso (vadinamojo neurogeneze) spartos mažėjimas 
hipokampe, smegenų srityje, atsakingoje už nuotaikos ir atminties reguliavimą. 
Viena iš šiuolaikinių depresijos hipotezių teigia, kad neurogenezės pakitimai 
smegenų hipokampe gali būti depresijos atsiradimo priežastimi, kita vertus, 
pasitarnauti šios ligos gydymui. Moksliniai eksperimentai patvirtina, kad stresas, 
kaip depresijos vystymosi rizikos veiksnys, slopina neurogenezę hipokampe, tuo 
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tarpu įvairūs antidepresantai skatina šį procesą ir užkerta kelią streso sukeltiems 
pokyčiams.  
Šioje disertacijoje pateikti rezultatai atskleidžia, kad minėtoji hipotezė visgi 
nėra pakankama ir turi būti patikslinta kai kuriais naujai ištirtais veiksniais. Streso 
padariniai hipokampo neurogenezei pasižymi tam tikra laiko dinamika ir priklauso 
nuo streso rūšies bei jo trukmės (2 ir 4 skyr.). Mūsų eksperimentai su žiurkėmis 
parodė, kad, skirtingai nuo ūmaus streso, pakartotinio elektrinio pėdos šoko 
išprovokuotas lėtinis stresas sukelia hipokampo neuronų dauginimosi pokyčius. 
Vadinasi, neigiamas streso poveikis hipokampo neurogenezei gali būti vos 
pastebimas ir pasireikšti tik esant lėtiniam stresui. Nepaisant to, kai kurie lėtinio 
streso sukelti neurogenezės pakitimai tėra laikini ir greitai išnykstantys (2 skyr.). 
Turi reikšmės ir streso rūšis. Buvo nustatyta, kad kitokia streso procedūra, t. y. 
lėtinis silpnojo streso modelis, neįtakojo neuronų dauginimosi hipokampe spartos, 
bet pristabdė jų gyvybingumą ir brendimą (4 skyr.). Disertacijoje aprašytais 
eksperimentais nustatyta, kad lėtinis stresas išprovokuoja ir daugiau pokyčių 
smegenyse, pavyzdžiui, susilpnina hipokampo neuronų aktyvumą (3 skyr.) bei 
sukelia baltymo sinapsino I, svarbaus signalui tarp neuronų perduoti, ekspresijos 
pakitimų (5 skyr.). Kartu paėmus, atliktieji tyrimai rodo, kad lėtinis stresas įtakoja 
neuronų ir sinapsių plastiškumą. Sukeldamas šiuos pokyčius, stresas gali pakenkti 
informacijos perdavimui ir apdorojimui smegenyse bei paskatinti psichikos ligų 
vystymąsi.  
 
Naujojo antidepresanto agomelatino poveikis smegenims 
Beieškant naujų vaistų depresijai gydyti buvo sukurtas pirmasis melatonerginis 
antidepresantas, pavadintas agomelatinu. Šis naujasis antidepresantas stimuliuoja 
melatonino receptorius ir slopina serotonino 5-HT2C receptorius. Manoma, kad šių 
receptorių grupių sąveika yra agomelatino gydomojo poveikio pagrindas, tačiau šio 
antidepresanto veikimo principai dar nėra gerai perprasti.  
Disertacijoje nagrinėjama, kaip agomelatinas veikia smegenis esant lėtiniam 
stresui (3–5 skyr.). Mūsų eksperimentai atskleidė, kad agomelatinas atstato streso 
susilpnintą neuronų aktyvumą hipokampe (3 skyr.). Be to, šis antidepresantas 
teigiamai įtakoja hipokampo neurogenezę streso paveiktose smegenyse (3–4 skyr.). 
Nustatyta, kad gydymas agomelatinu taip pat užkerta kelią tam tikriems streso 




Apibendrinus gautus rezultatus, galima teigti, kad agomelatino veikimo 
mechanizmui svarbi neuronų ir sinapsių moduliacija, kuri pagerina informacijos 
perdavimą streso paveiktose smegenyse. 
  
Pažiūra į depresiją 
Depresijos simptomai atpažįstami nuo antikos laikų, tačiau šios ligos raidos 
mechanizmas dar nėra iki galo išaiškintas. Depresijos vystymuisi, eigai ir gydymui 
paaiškinti sukurta įvairių teorijų, jos trumpai apžvelgtos disertacijoje. Kiek 
išsamiau aptariama cholinerginės sistemos sąsaja su depresija, ypač – su šios ligos 
kognityviniais simptomais (6 skyr.). Remiantis išnagrinėtais moksliniais darbais, 
galima teigti, kad cholinerginiai pakitimai smegenyse prisideda prie depresijos 
vystymosi ir gali sukelti kognityvinių sutrikimų. Turint tai omenyje, šiame 
disertacijos skyriuje aptariama galima sąveika tarp cholinerginės sistemos ir 
hipokampo neurogenezės pakitimų bei depresijai būdingų kognityvinių funkcijų 
sutrikimo. 
 
Bendrosios išvados ir ateities perspektyvos 
Atlikta streso, depresijos ir naujojo antidepresanto agomelatino sukeltų neuro-
biologinių pokyčių smegenyse analizė, gauti rezultatai publikuoti moksliniuose 
straipsniuose ir aprašyti disertacijoje. Sukaupti duomenys patvirtina, kad stresas, 
depresija ir naujasis antidepresantas agomelatinas sukelia neurobiologinių pokyčių 
smegenyse. Lėtinis stresas išprovokuoja neuronų ir sinapsių plastiškumo pakitimus, 
kurie sudaro palankią terpę psichikos ligoms vystytis. Šie streso padariniai visgi 
išnyksta ar bent sušvelnėja gydant agomelatinu. Taigi šio naujojo antidepresanto 
veikimo mechanizmui svarbi neuronų ir sinapsių moduliacija. Norint iš esmės 
perprasti molekulinius procesus, įtakojančius agomelatino gydomąsias savybes, 
reikėtų nuodugniau tirti ląstelinių signalų perdavimo kaskadas. Ši informacija 
papildytų turimas žinias apie depresijos gydymą įtakojančius veiksnius ir tuo pačiu 




























“A little consideration, a little thought for others, makes all the difference” 




The start of my PhD project in Groningen coincided with a lab outing. This event 
was typically Dutch, called Wadlopen, which translates as “mudflat hiking” and 
means walking on the muddy bottom of the sea during low tide. Literally! I joined 
this outing with great enthusiasm, driven by my adventurous nature and curiosity. 
Likewise, I started my PhD project, excited about new venture and determined to 
find my way through it. Like in the Wadlopen, some parts of the PhD path were 
difficult to cross; detours were even made at times. Like in the Wadlopen, other parts 
of the PhD trip were exciting and fulfilling. Now, at the end of this four-year voyage, 
I view it as a very special period of my life, which served my thirst for knowledge and 
granted me invaluable experience. 
Along the way, I met a lot of good-willing people, who enriched this venture with 
their insight and wisdom. A number of them contributed their skills and knowledge 
to my everyday work; a few of the very special ones granted me their friendship and 
love. Here, I express my sincere gratitude to all of you. 
First of all, I would like to acknowledge my promotores, Hans den Boer, Paul 
Luiten, and Eddy van der Zee, working with whom has been a great pleasure for me. 
Hans, I am grateful for the opportunity to pursue this project and freedom to change 
its course. Your optimism has been of encouragement to me. Paul, thank you so 
much for welcoming me into your group. Your continual support, both of my PhD 
work as well as of my future goals, has made it all possible. Eddy, despite the busy 
agenda, you always had time for extensive data discussions and brainstorming 
sessions that I have very much enjoyed. Your scientific insight has no boundaries. I 
truly appreciate your help and input, and I have learned a lot from it! 
Besides the promotores, this thesis was shaped by several other people, involved 
in different parts of the project. I would like to acknowledge the contribution of the 
Servier team, especially Cecilia Gabriel, Elisabeth Mocaër, and Laure Seguin, who 
provided financial support as well as scientific input regarding research on 
agomelatine. Cecilia, we exchanged hundreds of e-mails while planning experiments 
and discussing the data. Thanks for your patience and eagerness to brainstorm. 
Elisabeth and Laure, I am grateful for your input too. Furthermore, I would like to 
acknowledge Peter Meerlo, who guided me in the beginning of this project. Peter, 
thank you for all your help, critical remarks on experiments and manuscripts, and 
our scientific discussions. I appreciate your time and effort. Also, I am grateful to 
Andrea Trentani, who paved the way for this project by obtaining a grant from 
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Servier. Andrea, thank you (and Sjoukje, in whose footsteps I seem to follow) for 
bringing me to Groningen! Both of you supported me in choosing and pursuing the 
PhD project, and I am happy to see you at its defense too. Last but not least, I would 
like to express my gratitude to Jaap Koolhaas for our collaborations and intriguing 
discussions. Jaap, I enjoyed learning from your insights in the stress field and 
appreciate your willingness to evaluate my thesis. 
I am also thankful to the other two members of the reading committee, Brigitte 
Kudielka and Ben Westerink, for time they have invested in reviewing the thesis.   
This work would not have been done in a four-year period without the skillful 
help of our technicians. Folkert, jij hebt mij altijd en in alles gesteund, en mij heel 
veel geholpen. Door jou werd ook mijn Nederlands elke dag beter. Hartelijk bedankt 
voor alles! Jan K., your troubleshooting skills are legendary. Thanks a lot for all your 
help, from lab bench to PC! Jan B., I am grateful for your skilled hormone analysis – 
always so quick and neatly presented. Wanda and Bert – thanks for your support 
too. It goes without saying that this work would not have been possible without our 
animal caretakers. Linda, Jaap en Auke, bedankt voor jullie hulp (ook voor de 
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